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ABSTRACT 
Transcriptional regulatory complexes control gene expression patterns and permit 
cellular responses to stimuli. Deregulation of complex components upsets target gene 
expression and can lead to disease. This dissertation examines proteins involved in two 
distinct regulatory complexes: C-terminal binding protein (CtBP) 1 and 2, and Interferon 
Regulatory Factors (IRF) 3 and 5. Although critical in developmental processes and 
injury response, CtBP transcriptional repression of cell adhesion proteins, pro-apoptotic 
factors, and tumor suppressors has been linked to the pathogenesis of multiple forms of 
cancer. IRFs function in the immune system and have been implicated in autoimmune 
disorders.  
Understanding IRF activation is critical to treating pathogens that target IRF 
function or for future autoimmune disease therapies. We attempted to determine crystal 
structures that would provide the details of IRF activation, allowing insight into 
mechanisms of pathogen immune evasion and autoimmune disorders. Although no new 
structures were solved, we have optimized expression of C-terminal IRF-3 / co-activator 
complexes, as well as full-length IRF3 and IRF5 constructs. Modifying the constructs 
coupled with new crystal screening will soon result in structures which detail IRF 
activation, advancing understanding of the roles of IRF family members in disease. 
Through structural and biochemical characterization we sought to identify and 
develop inhibitors of CtBP transcriptional regulatory functions. High concentrations of 
CtBP substrate, 4-Methylthio 2-oxobutyric acid (MTOB), have been shown in different 
cancer models to interfere with CtBP transcriptional regulation. We began the process of 
 vii 
structure based drug design by solving crystal structures of both CtBP family members 
bound to MTOB. The resulting models identified critical ligand contacts and unique 
active site features, which were utilized in inhibitor design. Potential CtBP inhibitors 
were identified and co-crystallized with CtBP1. One such compound binds to CtBP more 
than 1000 times more tightly than does MTOB, as a result of our structure-based 
inclusion of a phenyl ring and a novel pattern of hydrogen bonding. This molecule 
provides a starting point for the development of compounds that will both bind more 
tightly and interfere with transcriptional signaling as we progress towards 
pharmacologically targeting CtBP as a therapy for specific cancers. 
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PREFACE 
 The results presented in Chapter III have been formatted as a manuscript and will 
be submitted to ACS Chemical Biology. The results presented in Chapter IV will be 
submitted for publication upon completion of key experiments. 
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CHAPTER I 
Introduction 
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Transcriptional Regulatory Complexes 
Regulation of Gene Expression 
 Transcriptional regulatory complexes often use chromatin modification to 
modulate gene expression. In response to stimuli, transcriptional activators or repressors 
and chromatin modifying enzymes form large multi-subunit complexes to activate or 
repress specific gene expression. The chromatin modifying enzymes lend fine control to 
the complex by tailoring specific effects with different types of covalent modifications. 
The specific regulatory complex members recruited to DNA controls modifications 
including histone phosphorylation, acetylation, methylation, and ubiquitination, 
permitting control of gene transcription (1). These modifications of DNA-binding 
histones alter chromatin architecture by changing histone-histone and DNA-histone 
interactions and by recruiting activator or repressor proteins to histone moieties. The 
diversity of chromatin modification function in concert with ubiquitous and specific 
transcriptional complex subunits to tightly control transcription of both individual and 
groups of genes, maintaining homeostasis. By tightly controlling gene expression 
patterns, transcriptional regulation allows cells to respond to millions of stimuli. 
However, improper gene regulation disturbs cell function, possibly contributing to 
disease states. 
 This thesis focuses on C-terminal Binding Proteins (CtBP) and Interferon 
Regulatory Factors (IRF): repressor and activator proteins involved in independent 
transcriptional complexes. CtBP proteins are co-transcriptional regulatory factors that 
associate with specific transcriptional factors to impact expression of a large number of 
 3 
genes. Our interest in the CtBP family stems from the apparent roles these proteins have 
in the development and progression of cancer. Targeting CtBP appears to relieve 
transcriptional repression of proteins involved in apoptosis, tumor suppression, and cell 
adhesion. IRFs are specific transcriptional factors that function in the immune response, 
immune cell development, and tumor suppression. Critical for activating interferon (IFN) 
transcription, the IRFs are frequently targeted for inhibition by pathogens, whereas 
elevated IRF activity can lead to autoimmune disorders. Understanding IRF inhibition 
and activation are therefore critical to treat various infections and autoimmune disorders. 
This thesis therefore focused on elucidating mechanisms of activation and inhibition of 
both the CtBP and IRF families through structural and biochemical studies in order to 
develop future treatments for human disease.  
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The CtBP Family 
CtBP Genes and Isoforms 
C-terminal Binding Protein 1 (CtBP1) (441 amino acids) was discovered for the 
ability to bind the C-terminus of the Adenovirus E1A protein and repress oncogenic 
transformation (2, 3). Unlike invertebrates, which possess only a single CtBP locus (4), 
the vertebrate genome contains a second CtBP gene, CtBP2 (445 amino acids), which 
shares 83% amino acid similarity to CtBP1 (5). Both vertebrate loci each code for 
multiple CtBP isoforms, which include long (CtBP-L) and short (CtBP-S) RNA splice 
variants. The CtBP1-S truncation lacks the first 13 N-terminal amino acids present in 
CtBP1-L (6), while CtBP2-S lacks the first 25 N-terminal amino acids present in CtBP2-
L (7, 8). (Figure 1.1) Additionally, a tissue specific promoter in ribbon synapses 
expresses an additional related protein, RIBEYE, composed of an N-terminal domain 
fused to CtBP2 (20-445) (9). 
 
CtBP Domain Arrangement 
 The CtBP proteins share high homology with the D-isomer specific 2-Hydroxy 
Acid Dehydrogenase (D2-HDH) family in both sequence and structure (2, 10). The core 
dehydrogenase domain possesses a common dinucleotide or Rossman fold typical of 
many NAD(H) dependent dehydrogenases (11). This dehydrogenase domain, consisting 
approximately of residues 30-350, can be subdivided into two domains: a substrate  
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Figure 1.1: CtBP1 and CtBP2 domain arrangement. The CtBP-L isoforms possess an 
the full CtBP sequence, whereas the CtBP-S isoforms possess an N-terminal truncation 
(purple). In CtBP2-S, the loss of the first 25 amino acids eliminates a NLS, shifting 
localization to the cytoplasm. The D2-HDH domain consists of a substrate binding 
domain (green) and a coenzyme binding domain (yellow) connected by small hinges. In 
addition to the NAD(H) binding site, the conenzyme binding domain contains the 
catalytic residues R, E, H. Both domains contain binding sites utilized in complex 
formation. The substrate binding domain has the PXDLS binding site, whereas the 
coenzyme binding domain contains the RRT binding site. 
 6 
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binding domain and coenzyme binding domain (Figure 1.1). The two globular domains 
connect via a hinge region, forming a cleft at their convergence (10). The CtBP family 
dehydrogenase domain retains the catalytic residues present in other D2-HDHs (2). The 
C-terminal ~90 amino acids after the dehydrogenase domain are unstructured (12). 
 
Localization 
 The CtBP isoforms localize to the cytoplasm or the nucleus based on a 
combination of protein sequence and post-translational modifications. CtBP2-L, 
possessing an NLS sequence in the N-terminal 25 amino acids, localizes to the nucleus 
(7, 13). The CtBP2-S isoform, however, lacks this NLS, localizing instead to the 
cytoplasm (7). The CtBP2 isoform, RIBEYE, also localizes to the cytoplasm, aggregating 
in large protein complexes at the active zone of the ribbon synapse (9, 14). Interestingly, 
CtBP2-L dimer interface mutants localize to cytoplasm, suggesting factors other than the 
N-terminal NLS contribute to localization (15).  
Signals dictating CtBP1 localization are less defined and as such vary throughout 
the literature. Verger et al. observed CtBP1-L and CtBP1-S in both the nucleus and 
cytoplasm (7), consistent with the general observations of CtBP1 function in both the 
cytoplasm and nucleus. Conflicting reports from studies may be due to the effects of 
post-translational modification on CtBP1 localization. For example, phosphorylation of 
S158 in the dehydrogenase domain redistributes CtBP1 into the cytoplasm (16). 
Conversely, SUMOylation of the extreme C-terminus at K428 may maintain CtBP1 in 
the nucleus (17), although these results were not reproduced (18). Inhibiting CtBP1 
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dimerization appears to impair nuclear accumulation, suggesting oligomerization may 
play a role in localization (18). It is also possible that CtBP1 imports into the nucleus via 
binding partners, including CtBP2, which possess an NLS (7). 
 
Oligomerization 
 Typical of the D2-HDH family, CtBP forms dimers. Oligomerization exists in all 
the structures solved for different D2-HDH members, including both bacterial and human 
enzymes. Structural data for bacterial members includes, but is not limited to, two distinct 
D-Lactate Dehydrogenases (D-LDH) (19, 20), Hydroxyisocaproate Dehydrogenase (D-
HicDH) (21), Formate Dehydrogenase (FDH) (22), and D-Glycerate Dehydrogenase 
(DGDH) (23). Although fewer related human proteins exist, the two most highly related 
dehydrogenases have also been crystallized. Structures of Glyoxylate 
Reductase/Hydroxypyruvate Reductase (GRHPR) (24) and D-3 Phosphoglycerate 
Dehydrogenase (PHGDH) (25) were both solved by X-ray crystallography. Roughly 90% 
of the dimer interface exists between the well conserved coenzyme binding domains of 
each monomer (21). The variable substrate binding domain therefore minimally 
contributes to the interface, suggesting dimerization is evolutionarily conserved in this 
family. 
By preferentially binding different redox states of NADH, CtBP acts as a redox 
sensor, modulating its activity in response to metabolic changes. CtBP possesses a 100 
fold higher affinity for NADH than for NAD+ (26), making CtBP sensitive to 
perturbations in the NADH/NAD+ ratio. Binding of either NADH or NAD+ induces CtBP 
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dimerization (27), a structural change necessary for full CtBP activity (15, 28-30). 
Stimuli that increase cellular NADH, such as hypoxia and high extracellular glucose, 
induce higher CtBP activity. These observations suggest the level of coenzyme binding, 
dependent on the NADH/NAD+ ratio, modulates CtBP oligomerization and formation of 
competent transcriptional regulatory complexes.  
 Dimerization provides a stable platform for other transcriptional complex 
members to bind. Each CtBP monomer contains a PXDLS domain that possesses a 
common binding site utilized by critical CtBP binding partners; dimerization increases 
the available PXDLS sites (15). Evidence suggests having only a single monomer 
available results in competition for binding between different complex members, 
disrupting transcriptional regulation (15). Only rarely will monomeric CtBP be required 
in specific regulatory complexes, indicating the context of the transcriptional regulation 
may determine CtBP oligomeric state (31). Overall, oligomerization appears critical for 
CtBP to properly recruit the necessary transcriptional regulatory machinery. 
 
Nuclear Functions 
 Studies in the last 15 years have focused on CtBP transcriptional roles in 
development as well as in cancer. The role in regards to development will be discussed 
here, while CtBP’s function in cancer is discussed below. Hildebrand et al. demonstrated 
that CtBP activity is critical in murine development. Mutation in Ctbp2 results in 
embryonic lethality; E10.5 embryos exhibit defects in heart and neural development (32). 
Although viable, Ctbp1-null mice are smaller in size than littermates containing one or 
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two functional copies of Ctbp1. The Ctbp1-null mice exhibit a 23% mortality rate within 
20 days of birth (32). Reducing the dosage of Ctbp1 in a Ctbp2-null background, and vice 
versa, severely impedes development in the embryo, demonstrating the overlapping roles 
of CtBP proteins (32). Additional roles in development were revealed through studies of 
CtBP in D. melanogaster. The single CtBP gene possesses regulatory roles in wing (33), 
eye (34, 35), sensory organ (36), as well as more generalized roles in development (37, 
38). The role CtBP in each of these developmental processes is related to CtBP’s function 
in transcriptional regulation.  
CtBP achieves transcriptional regulation through formation of large DNA-bound 
chromatin remodeling complexes (Figure 1.2). DNA binding proteins recruit CtBP by 
binding the PXDLS domain, discovered from the interaction with the adenovirus E1A 
protein (2). The PXDLS domain exists in the unique Substrate Binding Domain of the N-
terminus of CtBP (39). Many DNA-binding proteins, including the most commonly cited 
DNA-binding CtBP partners, zinc finger proteins ZEB 1/2, act as the bridge between 
promoters and the CtBP PXDLS domain (4, 15, 40-43). An additional RRT binding motif 
(RRTGXPPXL) discovered in the CtBP coenzyme binding domain also binds cofactors 
involved in repression (44). DNA-binding transcription factor, Znf217, binds CtBP 
utilizing not only the PXDLS motif, but also the RRT motif (18, 45). Interestingly, 
structural data demonstrate that the RRT binding site on one CtBP dimeric subunit rests 
on the same face as the PXDLS site of the second dimeric subunit, suggesting that 
proteins possessing both an RRT and PXDLS binding motifs bind both dimeric subunits 
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simultaneously (44), reinforcing the idea that oligomerization is critical for CtBP 
function.  
Analyses of the CtBP transcriptional complexes revealed multiple types of 
chromatin modifying proteins. Class I histone deacetylases (HDAC 1/2) associate with 
the CtBP complex (18, 46) and yeast two-hybrid screens suggest Class II HDAC proteins 
may also interact with CtBP (47). Histone methyltransferases (HMT), G9A and GLP 
(EuHMTase I), and a lysine demethylase (LSD-1) also bind the CtBP complex (18, 46). 
The variation among chromatin modifying proteins is indicative of CtBP’s role at 
different promoter regions, each requiring a specific set of transcriptional regulatory 
machinery. 
Histone-modifying proteins bind to CtBP either directly or through adapter 
proteins. Members of the HDAC1/2 family have the ability to bind directly to CtBP, as 
does a corepressor, CoREST; these proteins utilize non-PXDLS interactions (18, 46). 
CoREST not only recruits HDAC1/2, but also demethylase LSD-1 to CtBP (48, 49). 
Unlike CoREST, corepressor LCoR exploits the CtBP PXDLS motif to tether HDAC1/2 
to CtBP (50). DNA binding proteins that partner with CtBP can also recruit chromatin-
modifying proteins, demonstrating yet another means of forming a chromatin-modifying 
complex that contains CtBP. In particular Znf217 binds CoREST, which in turn recruits 
HDAC1/2 and LSD1 (45). Another zinc finger protein, Wiz, binds directly to the 
G9A/GLP histone methyltransferases and CtBP when forming a regulatory complex (51). 
These observations again suggest that histone-modifying proteins are recruited through 
different DNA-binding proteins and adapters between various CtBP  
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Figure 1.2:  CtBP binding proteins use common binding motifs to form histone-
modifying complexes. (A) DNA-binding proteins (orange), such as Zeb1, TGIF (52), 
and Evi-1 (53), bind a CtBP dimeric subunit through a PXDLS motif. Other DNA-
binding proteins (purple), such as ZNF217, utilize both the PXDLS and RRT motifs to 
interact with CtBP. (B) DNA-binding proteins can directly recruit histone 
deacetylation/demethylation complexes, such as the CoREST/HDAC/LSD1 complex, or 
methyltransferase complexes, such as G9A/GLP. (C) Some corepressors that recruit 
histone-modifying enzymes (yellow), such as LCoR1, utilize a PXDLS motif to bind 
CtBP. Alternatively CtBP can directly bind histone-modifying enzymes that utilize non-
PXDLS interaction, such as HDAC1/2 and Co-REST/LSD1. CtBP binds a specific 
combination of DNA binding proteins, adapters, and histone modifying enzymes to target 
individual genes. 
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regulatory complexes depending on the context, forming distinct chromatin-remodeling 
complexes to tailor transcriptional regulation (15) (Figure 1.2). 
Cytoplasmic Functions 
 In addition to roles in the nucleus, CtBP also functions in the cytoplasm. CtBP1-S 
induces tubule constriction and fissioning at the Golgi (54), dependent upon CtBP 
binding long-chain acyl-coenzyme A (acyl-CoA) molecules. CtBP1-S also appears to 
possess acyl-transferase activity targeting lysophosphatidic acid (LPA), thereby altering 
the membrane properties to induce tubule constriction and fission (55, 56). However, the 
enzymatic role of CtBP1 remains controversial as other studies demonstrated CtBP1 
either lacks acyl-transferase activity (57) or does not require acyl-transferase activity to 
induce fission (58). Complicating the issue, recent reports reveal that RIBEYE, or at least 
the CtBP2 domain of RIBEYE, also displays acyl-transferase activity (59) and functions 
in vesicle formation at ribbon synapses (9, 14, 59). Regardless of the exact mechanism, 
CtBP1 and CtBP2 have important roles in vesicle formation (58), Golgi partitioning 
during mitosis (60), and synapse signaling (14, 59).  
 
CtBP Dehydrogenase Activity 
 Discovery of the sequence similarity of CtBP to other D2-HDHs resulted in 
studies attempting to determine if CtBP enzymatic activity existed and, if so, the identity 
of a potential substrate. D2-HDH catalysis involves hydride transfer to substrate during 
NADH oxidation, converting an α-keto acid 2-C carbonyl to the D-isomer hydroxyl  
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Figure 1.3: The D-2-hydroxyacid dehydrogenase enzymatic reaction. NADH and the 
α-keto acid substrate bind the active site. The substrate carbonyl and carboxylate oxygen 
are stabilized by a conserved arginine. An acidic residue, typically Glutamate, raises the 
pKa of an adjacent histidine, stabilizing protonation. The histidine proton hydrogen bonds 
with and polarizes the substrate carbonyl. A hydride then transfers from the nicotinamide 
C4 carbon to the partial positive C2 substrate carbon. The carbonyl abstracts the histidine 
proton, and the D-isomer hydroxyacid product is released.  
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group (21, 61, 62) (Figure 1.3). Evidence of CtBP enzymatic activity was first 
discovered for the ability to convert pyruvate to lactic acid through oxidation of NADH 
(10, 27). A more thorough search of potential substrates yielded the discovery that 4-
methylthio-2-oxobutyric acid (MTOB) was an 80-fold better substrate for CtBP1 than 
pyruvate (63). Interestingly, substituting the MTOB sulfur for a methylene group, as in 2-
oxohexanoic acid, reduced the enzymatic activity eight-fold relative to MTOB, 
suggesting the sulfur confers specificity (63). MTOB was identified as the final 
intermediate in the methionine salvage pathway, in which transamination of MTOB 
results in formation of methionine (64). Dietary supplements for livestock even employ 
MTOB to increase methionine levels (65). CtBP mediated transcriptional regulation does 
not appear to require enzymatic activity, suggesting that the NADH binding function has 
been conserved for the purpose of regulating CtBP transcriptional functions, not for 
catalytic turnover (66). 
Despite the higher catalytic turnover relative to pyruvate, MTOB remains a fairly 
poor substrate when compared to the catalytic efficiencies of related D2-HDH family 
members. For example, D2-HDH family member rat PHGDH catalyzes substrate 400 
times more efficiently, while E. coli DGDH processes substrate more than 2600 times 
more efficiently than MTOB is catalyzed by CtBP (63, 67, 68).  
 
Roles in Cancer 
Evidence continues to grow linking CtBP transcriptional regulatory function to 
development of cancer, especially in the context of the epithelial-to-mesenchymal 
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transition (EMT). EMT is a transdifferentiation process necessary in a multitude of 
developmental processes, in which non-motile epithelial cells lose polarity and cell 
adhesion, acquiring instead migratory and invasive characteristics (69). Although 
necessary in development and wound healing, EMT increases the metastatic potential of 
malignant tumors as well as resistance to apoptosis (70). 
CtBP represses expression of certain cell adhesion molecules, cell-cell junction 
proteins, cytoskeletal elements, pro-apoptotic factors (66), and tumor suppressors (71), 
linking CtBP function to cell reprogramming associated with EMT. CtBP represses 
transcription of E-cadherin, a cell adhesion molecule whose loss is a key indicator of 
EMT (66). The apparent influence of CtBP across such varied targets is not surprising 
given recent data demonstrating CtBP binding throughout the mammalian genome at 
greater than 1,800 promoters (72). Given the pro-oncogenic nature of CtBP targets, 
research focuses on CtBP function in multiple types of cancer. Although limited evidence 
suggests roles for CtBP in progression of melanoma (73), pituitary tumors (74), and 
prostate cancer (75), larger studies implicate CtBP function in progression and severity of 
colon (76-81) and breast cancer (8, 72, 82-84).  
Loss of the ability of tumor suppressors to target CtBP leads to formation and 
progression of colon cancer. Adenomatous polyposis coli (APC) possesses a tumor 
suppressor function that targets CtBP1 for degradation (76). Mutation of APC is a well 
established mechanism for development of colorectal tumors (85). The loss of APC 
tumor suppression results in elevated CtBP expression, an early event in cancer initiation 
(76, 77). A second tumor suppressor, p14arf (ARF), also targets CtBP for proteosomal 
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degradation. Direct ARF-CtBP interaction results in p53-dependent apoptosis (78). 
Further investigation revealed CtBP represses Bik, a pro-apoptotic factor, and that this 
was relieved through CtBP interaction with ARF (79). Bik serves to bind anti-apoptotic 
factors, antagonizing their function and sensitizing cells to apoptotic signals (86). CtBP 
therefore inhibits apoptosis directly through targeting Bik (81). Therefore, the loss of 
both APC and ARF tumor suppression increases CtBP activity and contributes to 
tumorigenesis. 
Although CtBP is not known to directly target ARF, there is an inverse correlation 
between the expression levels of CtBP and ARF. Colon cancer tissue samples exhibited 
elevated levels of CtBP with simultaneous diminished expression of ARF. Adjacent 
healthy tissue exhibited inverse expression, displaying low expression of CtBP and 
normal expression of ARF (81). Additional evidence for the CtBP-ARF relationship in 
colon cancer arose by studying cell migration. Several studies demonstrate that the 
hypoxia-induced elevation in NADH levels increased cell migration in different colon 
cancer cell lines (28, 80), again suggesting NADH-mediated dimerization plays a role in 
CtBP function in cancer. Whereas loss of ARF resulted in higher rates of cell migration 
in a lung carcinoma cell line, introduction of exogenous ARF into an ARF-null colon 
adenocarcinoma cell line reduced cell migration under both normoxic and hypoxic 
conditions (80). Presumably, ARF antagonizes CtBP function, allowing Bik-mediated 
apoptosis, even under elevated NADH conditions. In colon adenocarcinomas, decreased 
ARF expression and increased CtBP levels result in cell survival and increased migration. 
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Deregulation of CtBP through loss of ARF, APC, or both proteins appears to 
significantly contribute to the development, survival, and progression of colon cancer. 
The role of CtBP activity in breast cancer was examined across a representative 
group of various cell lines and tumor samples. Results indicate elevated CtBP activity 
allows cell survival and metastasis, whereas CtBP depletion arrests cell growth. CtBP1 
displays elevated expression levels in invasive ductal carcinoma tissue, relative to normal 
breast tissue (82), and can even serve as a n indicator in median survival estimates in 
patients with basal-like triple negative breast cancer (72). Much like colon cancer, breast 
cancer tissue also exhibits the loss of E-cadherin expression. In addition, there is an 
inverse correlation between CtBP and the early-onset breast cancer gene, BRCA1, 
expression levels. Mutations in BRCA1, a DNA-repair protein, are typically associated 
with increased risk of developing breast cancer. CtBP1 knockdown restores normal E-
cadherin and BRCA1 levels; further linking CtBP function to tumorigenesis (82). 
Additional evidence demonstrates BRCA1 levels increase with a reduction of the 
NADH/NAD+ ratio, causing removal of HDAC1 from the promoter (83). These results 
suggest a decrease in NADH levels negatively impacts CtBP ability to dimerize and form 
a competent transcriptional repressor complex, causing the loss in CtBP repressor 
activity. This observation potentially links elevated CtBP transcriptional activity with the 
Warburg effect (87), in which elevated glycolysis raises NADH levels in malignancies 
(88). Knockdown of CtBP appears to sensitize breast cancer cells to chemotherapeutics, 
such as cisplatin, as well as reduces cell proliferation (8). Overall, CtBP influences breast 
cancer through transcriptional repression of typical EMT related targets such as E-
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cadherin, as well as cancer specific targets, such as BRCA1. The effects of CtBP 
repression may also explain why some breast cancer patients show a loss of BRCA1 
expression despite the absence of mutation in the BRCA1 (83). 
 
Targeting CtBP to Treat Cancer 
 Attempts to pharmacologically target CtBP in cancer models reveal that 
millimolar (mM) levels of the substrate MTOB shows anti-tumor effects in both colon 
and breast cancer models. Studies previously identified MTOB as a growth inhibitor and 
apoptosis-inducing agent for multiple transformed cell lines, although the targets of 
MTOB remained unclear (89). Later testing revealed MTOB displayed p53-independent 
cytotoxicity to colon adenocarcinoma HCT116 cells. However, the concentration 
required for high cytotoxicity were 4 mM or greater (81). MTOB treatment displaces 
CtBP from the Bik promoter, relieving Bik repression and leading to increased Bik 
expression relative to untreated cells. Either exogenous CtBP2 expression or silencing of 
Bik negated MTOB’s effects, linking MTOB-induced apoptosis to CtBP repression of Bik 
(81). MTOB treatment of nude mice injected with p53-null HCT116 cells increased 
median survival slightly and dramatically decreased tumor burden relative to control 
mice (81). Finally, MTOB seems to target only malignant cells, as no cytotoxicity was 
observed in healthy tissue from mice injected with MTOB (81). Therefore, CtBP activity 
specific to colon cancer was safely inhibited by large quantities of MTOB, suggesting 
that CtBP is a viable target for cancer therapy. 
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 MTOB’s anti-cancer effect mediated through CtBP was corroborated in a second 
study examining the response in different breast cancer cell lines. Treatment of MCF-7 
and MDA-MD231 cells with 10 mM MTOB evicted CtBP from a substantial number of 
promoters and attenuated repression of genes associated with genome stability, EMT, and 
stem cell pathways (72). Furthermore, markers for epithelial and mesenchymal 
phenotypes indicated a shift away from a mesenchymal phenotype towards an epithelial 
phenotype upon MTOB treatment, suggesting partial reversal of EMT (72). These data 
further support the idea of pharmacologically targeting CtBP in a number of different 
cancers. X-ray crystal structures of CtBP1 and CtBP2, solved prior to discovering the 
role of MTOB as a substrate and anti-cancer agent, suggested CtBP would be a good 
candidate for structure based drug design in the endeavor to develop new cancer 
therapeutics. 
 
Scope of Thesis: CtBP and Structure Based Drug Design 
 The first portion of my research addresses the need for substrate bound CtBP 
structures to initiate development of rationally designed CtBP inhibitors.  CtBP appeared 
to be a good candidate for structure based drug design as binary structures of both CtBP1 
and CtBP2 in complex with NAD+ had previously been solved (10, 90). In this endeavor I 
succeeded in co-crystallizing MTOB bound in the active site of both CtBP1 and CtBP2. 
The position and orientation of MTOB mimics other ligand bound D2-HDH family 
members. These structures provided data on the similarity of the architecture between 
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MTOB bound and previously published MTOB-free CtBP1 and CtBP2, as well as 
revealing unique aspects of MTOB binding. 
Utilizing knowledge gained from the MTOB bound structures, the second part of 
this thesis focuses on identifying small molecules that tightly bind the CtBP active site. 
To this end, I identified multiple small molecules that inhibited CtBP enzymatic function. 
Co-crystallization was attempted with multiple compounds, the successes of which 
provided new details on ligand binding. At the suggestion of our collaborator, we 
explored the binding of 2-hydroxyimino-3-phenylpropionic acid, (HIPP) with CtBP1. My 
co-crystal structure of CtBP1 revealed that HIPP binding exploits the intended contacts 
with CtBP active site specificity determinants, while binding in an unexpected 
conformation. In addition, I found that HIPP shows a dramatic increase in affinity for 
CtBP of greater than 3 orders of magnitude compared with that of MTOB. With this 
novel co-crystal structure, new molecules can be synthesized to further enhance affinity 
and specificity. As new molecules are designed, insight into the mechanism behind small 
molecule inhibition of CtBP transcriptional regulatory activity can be deduced.  
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INTERFERON REGULATORY FACTORS 
 
The IRF Family and Domain Arrangement 
The Interferon Regulatory Factor (IRF) family consists of nine members (IRF1-
IRF9) in humans and mice (91, 92). This family of proteins possesses diverse functions 
relating to immunity, immune cell development, and tumor suppression. The scope of 
research in this thesis focuses on two members of the IRF family: IRF3 and IRF5 (variant 
4). Tamura et al. have reviewed the expression and function of the other IRF family 
members (92). 
Each IRF member possesses a conserved N-terminal DNA binding domain (DBD; 
~120 residues) that contains a tryptophan pentad and binds to a 5’-AAXXGAAA DNA 
sequence (91, 93, 94). Many interferon (IFN) stimulated genes, including IFN-α/β 
themselves, possess this sequence upstream of the transcriptional start site, often with 
multiple tandem repeats of the IRF binding consensus sequence above (95). IRF3 and 
IRF5 possess a DBD typical of the IRF family (Figure 1.4). 
The C-terminal domain of the IRF family members possesses much more 
diversity than the DBD. The C-terminal domain of most IRF family members, including 
IRF3 and IRF5, contains an IRF association domain (IAD) responsible for homo- and 
heteromeric associations (96, 97). Additionally, the IRF3 and IRF5 extreme C-terminus 
includes an autoinhibitory loop that prevents IAD associated activation (98, 99). The 
autoinhibitory region of IRF3 and IRF5 contains clusters of serine and threonine residues, 
which serve as phosphorylation targets. Phosphorylation activates the IRFs by triggering 
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oligomerization, localization to the nucleus, and transcriptional activation of target genes 
(Figure 1.4) (see IRF Activation below for details). 
A linker region of ~75 amino acids separates the DBD from the IAD. The exact 
function of the linker region remains unknown, however, evidence is mounting that the 
linker has more functions than to simply tether the DBD and IAD to one another. For 
example, IRF3 and IRF5 each possess a nuclear export sequence (NES) in the linker 
region, important for proper localization (100, 101). Reports suggest that the IRF3 linker 
may not be unfolded as previously thought (102). Gaining insight into the function of the 
linker region is paramount for understanding IRF function. 
 
The Distinct Functions of IRF3 and IRF5 
 IRF3 and IRF5 have related but distinct roles in innate immunity. Concerning 
cellular expression, IRF3 is expressed constitutively in all cell types (92, 103), whereas 
IRF5, expressed in immune cells only, exhibits constitutive or inducible expression. 
Specifically, different variants of IRF5 were detected in B- and T-cells, dendritic cells, 
monocytes, natural killer cells, and peripheral blood mononuclear cells (104). The 
different expression patterns and higher variation of isoforms in IRF5 tailor the unique 
functions of each protein within and across different cell types. The IRF5 variant 4 
sequence will be used for residue numbering throughout this dissertation. 
Host innate immunity is critical for the initial response to pathogen invasion. 
Germline encoded receptors exist as soluble pattern recognition receptors (PRRs) or 
membrane bound Toll-like receptors (TLRs) and recognize pathogen associated  
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Figure 1.4:  IRF domain arrangement. The IRF proteins consist of an N-terminal DNA 
Binding Domain (DBD; green), a linker region (grey), an IRF association domain (IAD; 
blue), and autoinhibitory region (yellow). The DBD contains a tryptophan pentad 
conserved throughout the IRF family, as well as NLS signals in both IRF3 and IRF5 (red 
bars). The linker region of both proteins also possesses an NES (blue bar). The C-
terminal IAD is responsible for homo- and heteromeric interactions after IRF activation, 
including CBP binding. The IRF5 IAD contains an NLS / ubiquitination site (red bar with 
star) necessary for activation and nuclear localization. The autoinhibitory region prevents 
co-activator association with the IAD by shielding the binding site. This region also 
contains putative phosphorylation sites (orange spheres) necessary for IRF activation and 
dimerization. 
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molecular patterns (PAMPs). TLRs are expressed mainly in antigen presenting cells 
(APCs), while soluble PRRs are expressed more ubiquitously across different cell types. 
When activated, both receptor classes induce expression of Type I IFNs and pro-
inflammatory cytokines (92). Human Type I IFNs consist of factors from 13 IFN-α genes 
and a single gene for IFN-β, -ε, -κ, and -ω each, which in turn generate multifaceted 
intra- and inter-cellular responses influencing hundreds of gene targets involved in the 
antiviral response, anti-proliferation, and immune signaling (105). 
Although both IRF3 and IRF5 regulate Type I IFN expression (92, 106, 107), 
each protein becomes activated through a distinct set of pattern recognition receptors 
(PRRs). For example, both soluble PRRs (RIG1/MDA5) and membrane bound PRRs 
(TLR3, TLR4) each begin a signal cascade that ultimately leads to IRF3 activation (108-
110).  IRF5, however, becomes activated in response to signals from membrane bound 
TLR7, TLR8, and TLR9 (111, 112). Other studies suggest the involvement of other TLRs 
in IRF5 activation, but results can be contradictory due to cell-specific expression of 
different IRF5 variants and activating pathways (113). IRF3 appears to have a larger role 
in the antiviral response, activating IFN expression across almost all cell types in 
response to viral infection. The IRF5 antiviral response is more limited as IRF5 is not 
ubiquitously expressed. 
In addition to antiviral activity, IRF5 functions as a tumor suppressor. Studies 
indicate defects in both DNA damage and virus-induced apoptosis in IRF5-null models 
(114). Additionally IRF5 overexpression sensitizes tumor cells to apoptosis, an event 
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linked with IRF5 phosphorylation and activation (115). Thus IRF5 appears to possess 
dual roles in innate immunity and tumor suppression.  
Innate Immunity: Activating Interferon Gene Transcription 
The IFN-β enhancer has been well studied and serves as a model for 
transcriptional activation in innate immunity. IFN-β gene regulation involves formation 
of an activating transcriptional complex termed the enhanceosome. The enhanceosome 
binds to the Interferon Stimulated Response Element (ISRE) located about -50 bp from 
the transcriptional start site (94). The ISRE is broken up into four Positive Regulatory 
Domains (PRDs I-IV), with each PRD nucleotide sequence binding cofactors as they 
assemble on the ISRE. “Architectural” protein HMG-I (116) recruits the NF-κB p50/p65 
heterodimer (PRD II) (117), ATF2/C-Jun heterodimer (PRD IV) (118), and IRF3 (119) or 
IRF-7 (120) (PRD III/I) to the ISRE, forming the enhanceosome.  
The enhanceosome sequentially recruits histone acetyltransferases (HATs) and 
chromatin remodeling complexes to facilitate IFN-β gene transcription (Figure 1.5). 
Although the ISRE remains nucleosome free, a nucleosome binds directly downstream of 
the TATA box, shielding the transcriptional start site of the IFN-β gene (121). In order to 
activate transcription, the enhanceosome assembly recruits two HATs: GCN5 and CBP, 
both of which are able to acetylate the nucleosome (121). Each of the ISRE binding 
factors contacts CREB Binding Protein (CBP) recruiting it to the enhancer region (122-
125). After acetylation, GCN5 releases from the complex, while CBP remains to recruit 
the Pol II holoenzyme and Swi/Snf chromatin remodeling complex (121). Chromatin 
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Figure 1.5:  The enhanceosome mediates transcriptional activation.  
(A) A nucleosome blocks the transcriptional start site of a target gene. The elements 
comprising the enhanceosome, including ATF/C-jun heterodimer, IRFs, and NF-κB, 
assemble on the ISRE. (B) The enhanceosome recruits CBP and GCN5, which acetylate 
the histone. (C) CBP then recruits the Pol II holoenzyme and Swi/Snf complex. The 
Swi/Snf complex binds the acetylated nucleosome and repositions it, exposing the 
transcriptional start site. (D) Transcription factors are recruited and transcription begins.
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 remodeling shifts the nucleosome position, allowing transcription of IFN-β. Similar 
events occur at other IFN stimulated genes that also possess ISREs. 
 
IRF3 Activation 
 Signals from a distinct set of PRRs result in IRF3 activation. Although these 
cascades may begin at different receptors, the separate pathways eventually converge, 
utilizing Tank Binding Kinase I (TBK-1) or IκB kinase ε (IKKε) to phosphorylate the C-
terminus and activate IRF3 (126, 127). The presence of an NLS in the DBD and an NES 
in the linker region results in IRF3 shuttling between the nucleus and cytoplasm. 
Retention in the nucleus however, requires phosphorylated (activated) IRF3 binding to 
CBP, while inactive IRF3 localizes exclusively to the cytoplasm (100).  
 The IRF3 C-terminal autoinhibitory region possesses two clusters of Ser/Thr 
residues that may be targeted for phosphorylation. Site I includes S385 and S386 while 
Site II is composed of S396, S398, S402, T404, S405 (92). Residues S386 and S398 were 
identified as being critical to IRF3 dimerization and association with co-activator CBP 
(128-130). TBK1 appears to target Site II residues S396 and S402 for phosphorylation, 
followed by phosphorylation at Site I residue S386, which induces dimerization (131, 
132). A study utilizing co-expression of the IRF3 IAD with IKKε revealed multiple 
distinct phosphorylated IRF3 species. Mass spectrometry identified phosphorylation 
patterns including mono-phosphorylation at S402, dual phosphorylation at S386/S402, 
and dual phosphorylation at S396/S402 (133). Only the dually phosphorylated S386/S402 
species formed dimers and associated with CBP. Although multiple phosphorylation sites 
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have been identified as important, controversy still exists as to the exact mechanism, 
order, and residues targeted in IRF3 phosphorylation. 
 
IRF5 Activation 
 IRF5 activation parallels the mechanism of activation of IRF3 despite responding 
to different PRRs and being expressed in only a subset of cells. Like IRF3, inactive IRF5 
shuttles between compartments, but localizes to the cytoplasm under basal conditions. 
IRF5 possesses two NLSs, one in the N- and C-terminal domains each (99), and a single, 
dominant NES (101). Lysine residues in the C-terminal NLS are directly targeted for K-
63 linked ubiquitination, a step necessary for nuclear translocation and IRF5 mediated 
transcriptional activation (134). 
 The exact pattern of phosphorylation for the IRF5 C-terminal serine cluster is less 
well understood than for IRF3. Initial experiments indicated that mutation of S425, S427, 
and S430 all impacted the ability of cells to respond to Newcastle Disease Virus (NDV) 
infection (99). Isothermal titration calorimetry (ITC) experiments tested phosphomimetic 
mutations (serine to aspartic acid) of the serine cluster for interaction with co-activator 
CBP. Results indicate S425D, S427D, S430D and S436D all induced tighter interactions 
with CBP, although the fold change in affinity between IRF5 and CBP was significantly 
lower compared to the parallel experiment in IRF3 (130, 135). The S430D mutation 
resulted not only in the strongest interaction with CBP, but also induced dimerization in 
the C-terminal IRF5 crystal structure (135). Recently, co-expression of IRF5 with 
different kinases or other activators resulted in phosphorylation of S425 and S436 (136). 
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Therefore, similar to IRF3, phosphorylation of a cluster of serine residues in the C-
terminus of IRF5 appears critical to phosphorylation and activation of the molecule. 
However, the exact targets and pattern of phosphorylation remains to be determined. 
 
IRFs and Disease 
 Pathogens frequently target IRF family members to evade the host immune 
response. In particular, many pathogens have evolved mechanisms to target IRF3 
function. This is no surprise given that IRF3 functions in almost all cells, serving as a 
universal factor in immunity. As such, pathogens, particularly viruses, have evolved 
mechanisms to target the IRF3 pathway, or directly inactivate IRF3 to evade or suppress 
the immune response. For example, multiple human herpes viruses including HSV-1, 
varicella-zoster, Epstein-Barr, and human cytomegalovirus target IRF3 or its activation 
pathway (137-141). Similarly, members of the coronaviridae family, including SARS 
virus, and the filoviridae family, including Ebola and Marburg virus, evade immune 
response and establish infection in part by targeting IRF3 function (142-145). 
Understanding the mechanisms of IRF3 function may in turn lead to future prevention or 
treatment of various infections. 
 Despite its limited cell specific expression, some viruses still target IRF5 activity 
to suppress the immune response. The limited expression pattern of IRF5 curtails the role 
it plays in response to viral infection and as such, fewer examples exist of viral evolution 
targeting IRF5. One exception is human herpes virus 8, or Kaposi’s Sarcoma-associated 
Herpes Virus (KSHV). KSHV infection can cause formation of small tumors, Kaposi’s 
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sarcoma (146), and two lymphoproliferative disorders; primary effusion lymphoma 
(PEL) (147, 148) and multicentric Castleman’s disease (149). During viral evolution 
KSHV acquired a viral homologue to the IRF family (vIRF), which produces four 
transcripts (vIRF1-4) (150). Of these vIRFs, vIRF3 blocks activation of both IRF5 and 
IRF7, blunting the IFN response (151, 152). Interestingly, PEL growth requires vIRF3 
(153), possibly due to repression of IRF5 tumor suppressor functions (152). Thus, KSHV 
appears to target the IRFs to establish infection, but the resulting suppression of IRF5 
function contributes to uncontrolled cell proliferation. 
 Although necessary for response to pathogens and tumor suppression, aberrant 
IRF5 activity is linked with the autoimmune disorder systemic lupus erythematosus 
(SLE). Although the cause of SLE is not completely understood, overactive immune 
cells, particularly B-cells, characterize the disease. This results in increased cytokines and 
autoantibody production (154). Various studies identified IRF5 polymorphisms as a 
marker for increased probability of developing SLE (155-158). The IRF5 polymorphisms 
are thought to upregulate expression (159, 160) or produce risk associated splice variants 
(156, 161). While other studies focused on the role of IFN production in SLE (162), two 
recent studies utilized SLE mouse models to demonstrate IRF5 expression is critical for 
SLE development independent of IFN expression (163, 164). These results suggest IRF5 
regulation of other cytokines leads to development of SLE. Therefore, pharmacologically 
targeting IRF5 function may be a viable future treatment for SLE.  
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IRF Structures 
  There are several IRF structures deposited in the Protein Data Bank that have 
advanced understanding of IRF function. The murine IRF1 and IRF2 DBD bound to 
DNA and both the free and DNA bound forms of the human IRF3 and IRF7 DBD, have 
been crystallized (93, 94, 165-167). No structures exist for an IRF containing the linker 
region between the DBD and IAD. 
Although there are fewer structures published for the IAD, the existing structures 
have significantly impacted understanding of IRF regulation, including dimerization and 
co-activator binding during activation. The first C-terminal IRF structures consisted of an 
autoinhibited IRF3 IAD (168, 169). The structure revealed that residues responsible for 
autoinhibition pack against helices 3 and 4, shielding them from solvent exposure. This 
same region contains the Ser/Thr phosphorylation targets described previously (168). 
Based on these observations, the Kai Lin laboratory predicted that phosphorylation would 
unfold the autoinhibitory region, exposing the helices. To test this hypothesis, and IRF3 
IAD lacking the autoinhibitory region was crystallized with the IRF binding domain of 
CBP, forming and IRF3 IAD/CBP complex (170). Removing the autoinhibitory region 
exposed the CBP binding site, allowing CBP to bind, suggesting that releasing 
autoinhibition through phosphorylation is critical for co-activator binding (170). 
Following the IRF3 IAD/CBP complex, a phosphomimetic IRF5 (S430D) IAD was also 
crystalized in an attempt to favor dimerization (135). Unlike the IRF3 IAD/CBP 
complex, the phosphomimetic IRF5 construct possessed its autoinhibitory region, which 
extended  
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Figure 1.6: Activation and dimerization in the IRF family. From the Kai Lin 
laboratory, adapted from Chen et al. (135) (A) The activated IRF-5 IAD S430D 
phosphomimetic mutant demonstrates that the autoinhibitory region (green) extends away 
from the globular domain (blue) exposing the cofactor binding site at helices 3 and 4. 
Putative phosphorylation sites are shown as orange spheres. (B) The IRF-3 IAD (blue) in 
the autoinhibited conformation. The C-terminal autoinhibitory region (green) shields 
helices 3 and 4.  (C) Removal of the autoinhibitory region and incubation with co-
activator CBP (yellow) reveals that activation through phosphorylation and subsequent 
displacement of the autoinhibitory loop exposes the CBP binding site. (D) The displaced 
autoinhibitory region, including helix 5, makes extensive contact along the IRF-5 IAD 
S430D dimer interface. The autoinhibitory region of one subunit (green) forms contacts 
near helix 2’ of the second subunit (grey). 
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away from the globular domain to form the dimeric interface between IRF5 subunits 
(135). Mutational analysis supports the crystallographically observed dimer as 
representative of an active conformation for both IRF5 and IRF3 (135). Thus, a model 
was formed in which phosphorylation displaces the autoinhibitory region, simultaneously 
exposing the co-activator binding site and forming extensive contacts with a neighboring 
IRF5 subunit, resulting in a fully activated IRF dimer (Figure 1.6). However, Takahasi et 
al. has challenged this model for IRF3 activation. They show a phosphorylated IRF3 
structure that does not dimerize; instead it aligns very closely with the unphosphorylated 
IRF3 IAD (171). Flaws in their approach to crystallizing phosphorylated IRF-3 (see 
below) may have led to a similar conformation as seen in the unphosphorylated form.  
 
Scope of The Thesis: Generating New IRF Structures to Understand IRF Function 
 Despite the large number of IRF structures, the model of IRF activation remains 
incomplete and unconfirmed. Takahasi et al. assert IRF3 does not dimerize in a manner 
similar to IRF5 based on their phosphorylated IRF3 structure (171). Instead of a model 
where the autoinhibitory region is displaced, they favor a model of direct interaction 
between the charged phosphate of one subunit with a charged surface of the second 
subunit. However, the structure of phosphorylated IRF3 does not demonstrate this direct 
interaction model, leaving their hypothesis unsupported. Despite this, they reason that 
IRF5 and IRF3 possess distinct activation mechanisms (171), ignoring the extensive 
sequence, structural and functional similarities between the two molecules.  
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 Current IRF structures lack the linker region between DBD and IAD. The 
functional significance of the linker in all IRFs underscores the necessity of 
understanding the linker region’s conformation. The lack of a structure that contains both 
a DBD and IAD also leaves a gap in the understanding of IRF function. The two domains 
may interact with one another through the influence of the linker. Recent data even 
suggests the domains may bind one another (172), adding the possibility of an additional 
layer of control over IRF activation. Similarly, a ~40 amino acid segment of a viral IRF 
homologue (vIRF3) binds portions of the N- and C-terminal domains of IRF5 and IRF7, 
despite a sequence gap of ~150 residues between the bound regions (151, 152). This 
suggests proximity of the DBD to the IAD, reinforcing the idea that IRF inter-domain 
interaction may have a role in protein function and inhibition. Through understanding the 
KSHV mediated inhibition of IRF5, future work could pharmacologically target IRF5 in 
specific autoimmune disorders. 
 In order to address the current gaps in understanding IRF activation, I sought to 
solve three different structures. The first structure, an IRF3 IAD/CBP construct that 
contains the autoinhibitory region, would address whether IRF3 dimerizes and, thus 
activates, in a mechanism analogous to IRF5. The IRF3 molecule would require 
phosphomimetic mutations to displace the autoinhibitory region analogous to the IRF5 
structure. The second structure contains the missing linker region and inter-domain 
interactions. A full length IRF3 molecule would answer questions regarding 
conformations and inter-domain contacts in a full length IRF, and their implications on 
activation. The third structure was the complex of Kaposi’s sarcoma associated Herpes 
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Virus (KSHV) protein vIRF3 bound to full length IRF5. Determining how vIRF3 
achieves IRF5 inhibition by binding separate IRF5 domains would provide clues 
concerning not only IRF activation, but also methods to inhibit IRF5 in the context of 
autoimmune disease. Although my efforts to solve these structures were not successful, 
my work provides a platform for future attempts to complete the structural 
characterization of IRF activation and function.  
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CHAPTER II 
Characterizing Interferon Regulatory Factor Activation 
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INTRODUCTION 
The nine members of the Interferon Regulatory Factor (IRF) family of proteins 
possess diverse functions in immune response, immune cell development, and tumor 
suppression (91, 92). This chapter will focus on two members, IRF3 and IRF5, and their 
roles as transcription factors. All members of the IRF family share a highly conserved 
DNA binding domain (DBD) (91, 93, 94). A linker region of ~75 amino acids connects 
the DBD to the less well-conserved C-terminal domain. Many IRFs, including IRF3 and 
IRF5, possess a C-terminal IRF association domain (IAD) responsible for homo- and 
heteromeric interactions (96, 97). The C-terminus also contains an autoinhibitory region, 
restricting IRF association when the protein is in an inactive form (98, 99).  
IRF3 and IRF5 possess similar functions, yet different expression patterns and 
unique activities set these two family members apart. Nearly ubiquitous expression of 
IRF3 across almost all cell types provides a generalized response to multiple types of 
infection (92, 103, 107, 109, 110). IRF5 however is expressed in a subset of immune 
cells, thereby limiting the role of IRF5 in antiviral responses (104). Despite its limited 
expression, IRF5 still participates in IFN activation upon infection (106). Unlike IRF3, 
IRF5 also functions in tumor suppression, with roles in both DNA-damage and virally 
induced apoptosis (114, 115). Understanding IRF5 activation is of particular interest, due 
to evidence that links IRF5 variants with autoimmune diseases, most strongly systemic 
lupus erythematosus (155-161, 163, 164). 
 IRF3 and IRF5 are activated upon signaling from germline encoded pattern 
recognition receptors (PRRs). These molecules recognize common pathogen associated 
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molecular patterns (PAMPs) such as LPS or viral nucleic acids. Cell soluble PRRs, such 
as RIG1 and MDA5, and membrane bound PRRs, including toll-like receptors (TLR) 
trigger signal transduction cascades upon PAMP binding. Although the participants in 
each PRR signaling differ, the cascades typically converge, triggering the IRFs to activate 
transcription of specific genes (92). Upon signal transduction, kinases phosphorylate 
IRF3 (126, 127, 133) and IRF5 (136) within serine/threonine rich regions of the 
autoinhibitory domain. Phosphorylation relieves autoinhibition; this leads to IRF 
oligomerization, nuclear translocation, and ultimately transcriptional activation (96, 97).  
 Upon localization to the nucleus, IRFs associate with other factors to bind DNA at 
enhancer regions and form a transcriptional activation complex termed the enhanceosome 
(94, 117-119). The interferon (IFN) β enhancer has been widely studied and is used as a 
model for IRF transcriptional activation. The IRFs and other factors assemble into the 
enhanceosome and recruit histone acetylation transferases (HAT), including CREB 
binding protein (CBP), which acetylate nucleosomes positioned to block transcription 
(121-125). Acetylation is followed by recruitment of chromatin remodeling complexes 
that move the nucleosome, allowing transcription to occur (121).  
 Multiple pathogens target IRF proteins to evade immune responses. Due to 
ubiquitous expression, viruses frequently target IRF3 activation pathways or IRF3 itself. 
These viruses include multiple herpes viruses, filoviruses (Ebola and Marburg viruses), 
as well as coronaviruses (including SARS) (137-145). Kaposi’s Sarcoma-associated 
Herpes Virus (KSHV), which encodes four viral IRF homologues (vIRF), inhibits IRF5; 
vIRF3 targets the activity of both IRF5 and IRF7 (150-152). Understanding the activation 
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of IRF family members may provide insight into the mechanisms used by pathogens to 
inhibit IRF functions. Moreover, understanding how the IRFs become deactivated may 
eventually lead to new therapies for autoimmune disorders. 
 Structural studies have already made significant progress into the mechanisms 
underlying IRF activation. Multiple IRF DBD structures have been solved, both free and 
bound to DNA, providing information on specific DNA induced changes and contacts 
(93, 94, 165-167). More importantly for understanding regulation, structures have been 
solved for the IAD of IRF3 and IRF5 (135, 168-171). The initial IRF3 structures included 
the IAD complete with the autoinhibitory region (168, 169). The autoinhibitory region 
contains the putative phosphorylation sites and packs against a surface formed by helices 
3 and 4, shielding them from solvent exposure. Based on this stereochemical 
arrangement, the laboratory of Kai Lin proposed that this surface could become exposed 
if phosphorylation triggers an unfolding of the autoinhibitory region. To test the 
hypothesis, the Lin laboratory determined a crystal structure of the IRF3 IAD without the 
C-terminal autoinhibitory region in complex with the IRF binding region of the co-
activator CBP (170). This structure demonstrated that the surface obscured by the C-
terminal autoinhibitory domain serves as a binding site for the co-activator CBP.  In order 
for CBP to bind, helices 3 and 4 must be exposed, supporting the hypothesis that 
activation by phosphorylation causes the autoinhibitory domain to unfold. These results 
were followed by the first IRF5 crystal structure with an intact autoinhibitory domain, in 
which a phosphomimetic mutation (S430D) was introduced to favor dimerization. In this 
IAD structure the C-terminal autoinhibitory region was displaced from the CBP binding 
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site, forming extensive contacts with a second subunit to form a dimer (135). Thus a 
model was developed for IRF activation in which phosphorylation, dimerization, and 
CBP binding are coupled through the disposition of the autoinhibitory region. The 
applicability of this model to IRF3 has recently been challenged by another group that did 
not observe structural changes in the autoinhibitory region upon crystallization of a 
dually phosphorylated IRF3 C-terminus (171). 
 Although the model for IRF activation has begun to take shape, questions persist 
regarding fine details of IRF activation. In order to address the similarity between IRF3 
and IRF5 activation, we attempted to solve the crystal structure of the dimeric IRF3 IAD, 
a construct that includes the autoinhibitory domain, in complex with CBP. Next, we 
endeavored to solve the structure of full-length IRF3 in an effort to determine if there are 
functionally important interactions between the DBD and IAD and to understand the role 
of the region linking these domains. This linker, absent in the existing IRF structures, 
may serve a role in IRF activation beyond simply tethering the domains together. The 
linker regions contain localization signals (100, 101) and may not be unfolded as 
previously thought (102). Finally, we sought to address how KSHV viral IRF homologue, 
vIRF3, achieves inhibition of IRF5. We addressed this issue by trying to solve the crystal 
structure of full-length IRF5 bound to vIRF3. Through structural studies, we intended to 
understand how vIRF3 inhibits IRF5 and IRF7 by simultaneously binding the N- and C-
terminal regions despite a sequence gap of ~150 amino acids. The inhibition observed as 
a result of vIRF3 binding to both the DBD and IAD further suggests that the 
conformation of these domains relative to one another may have a role in IRF activation, 
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dimerization or the ability to bind DNA. A complex of IRF5 and vIRF3 would not only 
address the mechanism of KSHV mediated inhibition, but would also demonstrate 
possible means of pharmacologically targeting IRF5 for inhibition in autoimmune 
disorders. 
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MATERIALS AND METHODS 
 
Constructs and Expression 
IRF3 5D /CBP Complex:  
The IRF3 phosphomimetic 5D construct (143-427) was cloned from the wild type 
C-terminal construct (168) in the pET28a vector (Novagen). The following 
phosphomimetic mutations were introduced through site directed mutagenesis: S386D, 
S396D, S402D, T404D, and S405D. A codon optimized CBP (2069-2113) was 
synthesized by Genescript and cloned into the pGEX6P-1 vector (GE). Both constructs 
were simultaneously transformed into HB101 cells and plated on agar containing 
Kanamycin (pET28a marker) and Ampicillin (pGEX6P-1 marker). Colonies were used to 
make starter cultures that were scaled up to six liters in tryptone-phosphate media (2% 
bacto-tryptone, 1.5% yeast extract, 0.2% dibasic sodium phosphate, 0.1% 
monopotassium phosphate, 0.8% sodium chloride). Cultures were grown at 25°C until 
induction with 0.05 mM IPTG at OD600= 0.5. Temperature was lowered to 20°C and cells 
were harvested 18-24 hours after induction. Cells were pelleted and resuspended in buffer 
containing Complete EDTA-Free protease inhibitors (Roche), 50 mM Tris (pH 7.3), 100 
mM sodium chloride, 0.2 mM EDTA and then flash frozen to be stored at -80°C.  
Full Length IRF3 2D:   
The full-length IRF3 2D (S386, 396D) phosphomimetic construct cloned into the 
pET28a vector was transformed into BL21-DE3 cells for expression. Culture growth, 
induction, and harvesting protocol were identical to above.  
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vIRF3:   
Various vIRF3 single and co-expression constructs were created in pet28a, 
pGEX6P-1, and pMNO vectors. Michael Omartian modified a multi-cassette vector 
utilized in bacterial expression of hemoglobin (173) to create the pMNO co-expression 
vector. Expression of vIRF3 alone consisted mostly of vIRF3 (235-327) in pGEX6P-1 
(N-terminal GST tag), with or without an additional C-terminal His6 tag, transformed into 
BL21-DE3 cells. Growth, induction, and harvesting were identical to above with the 
exception of induction at 18-20°C with 0.2 mM IPTG. Co-expression constructs 
consisted of vIRF3 (235-327) or (240-277) in one cassette and His6 tagged codon 
optimized synthetic (Genescript) IRF5 (1-467) or IRF5 (1-467) S430D in the second 
cassette of the pMNO vector. Constructs were transformed into E. coli Q cells 
(W3110lacIq L8) (174). Growth, induction and harvesting were identical to above with 
the exception of utilizing a higher IPTG (0.2 mM) concentration for culture induction. 
 
Purification: 
IRF3 5D /CBP Complex 
 Cells were lysed, cell debris pelleted, and lysate applied to nickel (NiNTA 
agarose) beads with the same protocol as purification of CtBP1 & CtBP2. After a 2-hour 
incubation, the nickel beads were applied to a column and washed with 100 mL buffer 
containing 100 mM sodium chloride, 50 mM Tris pH 7.3, 20 mM imidazole, and 1 mM 
DTT. 2-3 mL of wash was kept to cover the bed of beads for cleavage of the affinity tags. 
15 µL of Thrombin (Novagen) diluted in 500 µL dilution buffer and 100 µL Prescission 
 50 
protease (GE) were then added to the beads. After mixing the beads with a stir rod, the 
column and beads were incubated overnight at 14°C. The complex was eluted off the 
beads in eight 5 mL elutions with wash buffer. Complex elution was verified with 
samples of elutions and beads utilizing SDS-PAGE. Elutions containing the complex 
were pooled and dialyzed overnight into DEAE buffer (10 mM sodium chloride, 20 mM 
Tris pH 7.3, 1 mM DTT). The sample was loaded onto a pre-equilibrated DEAE 
sepharose column, and a 0-400 mM sodium chloride gradient was applied. The A280 was 
used to monitor elution. Elution samples were run on SDS-PAGE to determine purity and 
presence of both proteins. Elutions were concentrated to 28-66 mg/mL, and flash frozen 
for storage at -80°C. 
Full Length IRF3 2D 
 Full length IRF3 2D purification utilized the same protocol as IRF3 5D / CBP 
with the following differences:  The affinity (His6) tag was not cleaved from the protein. 
Instead, protein was eluted from the beads with 300 mM imidazole in wash buffer. 
Protein was dialyzed and run on a DEAE sepharose column with a 0-300 mM sodium 
chloride gradient. Protein was concentrated to 4.5 mg/mL and flash frozen for storage at -
80°C. Later crystallization trials demonstrated that in a lower salt buffer the protein could 
be concentrated as high as 12.7 mg/mL. (Note: Based on purification of full-length IRF5 
constructs, size exclusion may be more efficient than ion exchange in removing 
contaminants and proteolytic degradation products from full-length IRF3 constructs.) 
 
 
 51 
vIRF3 (235-327) pGEX6P-1 
 Cell lysis and cell debris removal were identical to above. Lysate was applied to 5 
mL of water washed GST beads and incubated 2 hours at 4°C. Beads were washed with 
150-200 mL of 100 mM sodium chloride, 50 mM Tris pH 7.3, 1 mM EDTA, and 1 mM 
DTT. 100 µL Prescission protease was added and protein was cleaved overnight at 4°C. 
Eight 5 mL elutions with the wash buffer were analyzed by SDS-PAGE. Elutions 
containing protein were pooled. Constructs with a C-terminal His6 tag were incubated 
with nickel bead and eluted with imidazole as above. Constructs without an additional 
affinity tag were subjected to ion exchange as above. 
vIRF3 (240-277) / Full Length IRF5 co-expression pMNO 
 Cell lysis and cell debris removal were identical to above. Lysate was applied to 
nickel beads (His6 present on accompanying IRF5 constructs). Cleavage off of the beads 
with Thrombin was attempted, but proves consistently problematic with any construct 
containing the N-terminal domain of IRF5. As such, proteins were eluted with 300 mM 
imidazole, and dialyzed into 300 mM sodium chloride, 50 mM Tris pH 7.3, 1 mM 
EDTA, and 1 mM DTT. Eluted protein was concentrated and applied to a Superdex 200 
size exclusion column. Fractions containing the protein were concentrated and flash 
frozen for storage at -80°C. (Note: This protocol, utilizing size exclusion, works well for 
purification of full-length IRF5 or IRF3 constructs expressed alone.) 
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Crystallization: 
IRF3 5D /CBP Complex 
 Initial crystallization screening led to formation of small crystals in two 
conditions: 30% PEG 400 and 100 mM CAPS pH 10.5 (Wizard I crystal screen, Emerald 
Biosystems) and in 1.7 M 1,6 hexanediol, 100 mM magnesium chloride, and 50 mM Tris 
pH 8.5 (Hampton II crystal screen diluted 50%, Hampton Research). Protein (15 and 19 
mg/mL in screens respectively) was mixed 1:1 with buffer. Crystals appeared in 2-4 
weeks. Conditions were optimized and crystals used for diffraction were grown in 
hanging drops with 10-30 mg/mL protein grown in 1.8-2.4 M 1,6 hexanediol, 100 mM 
magnesium chloride, and 50 mM CHES pH 10.0 at a ratio of 3:2 buffer to protein. 
Optimized conditions resulted in crystal growth from 1-5 days. 
Full Length IRF3 2D 
Initial crystal screening resulted in crystallization of full-length IRF- 2D in 200 
mM sodium or potassium citrate with 20% (w/v) PEG 3350 (PEG/Ion screen, Hampton 
Research). Conditions were optimized to grow crystals for diffraction in hanging drops 
with 12-16% PEG 3350, 100 mM potassium citrate, and 50 mM imidazole pH 7.8 at a 
1:1 ratio with full-length IRF-3 2D (1.5-12.5 mg/mL). 
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RESULTS 
 Dimeric IRF-3 IAD / CBP complex 
Solubility and crystallization 
IRF3 5D (173-427) / CBP (2069-2113) co-expression produces a stable complex 
that can be readily purified. The IRF3 5D construct was designed to be similar to 
constitutively active, dimeric IRF3 phosphomimetics utilized in previous studies (175, 
176). Initial IRF3 5D (173-427) purification resulted in a relatively low yield (0.5-0.75 
mg/L culture) of protein with low maximum solubility (2 mg/mL). Co-expression of the 
CBP IRF binding domain (2069-2113) on a separate plasmid resulted in stable complex 
formation with vastly improved yield (5 mg/L) and solubility (66 mg/mL). The large 
increase in solubility and stability suggests the hydrophobic CBP binding site was solvent 
exposed, resulting in low solubility unless shielded by CBP. Interestingly, IRF5 S430D is 
stable as a dimer and was crystallized without CBP, highlighting stereochemical 
differences between IRF3 and IRF5 upon phosphomimetic activation. Although the exact 
cause of the difference remains unclear, partial covering of the exposed CBP binding site 
by the extreme IRF5 N-terminus, observed in the phosphomimetic dimer, shields a small 
portion of the hydrophobic surface from the solvent. IRF3 may be unable to achieve this 
partial coverage of the exposed CBP site as a result of sequence variation and construct 
differences, potentially explaining the loss of solubility and stability in the 
phosphomimetic IRF3 mutant. 
The purified IRF3 5D / CBP complex was subjected to different crystallization 
screens, resulting in crystal growth in two different conditions. The crystals grew in a 
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Figure 2.1:  IRF3 5D / CBP crystallization. (A) The initial IRF3 5D / CBP crystal 
screen hit in 30% PEG 400 and 0.1 M CAPS pH 10.5 (protein concentration 15 mg/mL). 
Crystals grew slowly over many weeks. (B) A second screening hit with similar 
morphology in 1.7 M 1,6 hexanediol, 100 mM MgCl2, and 50 mM Tris pH 8.5 (protein 
concentration 19 mg/mL). (C) With the elevated pH level of condition in (A) and the salt 
and precipitant of the condition in (B), crystals grew in less than a week (1.8-2.4 M 1,6 
hexanediol, 100 mM magnesium chloride, and 50 mM CHES pH 10.0 at a ratio of 3:2 
buffer to protein). Protein concentrations ranged from 10-30 mg/mL. The length of the 
bunch of needles is roughly 600 µm. Individual needle widths were never larger than 15-
20 µm. (D) At high protein concentrations a thick skin formed around the edge of the 
hanging drop. Crystals frequently grew at the edge and became completely embedded in 
the skin. 
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small “starbursts” of needles nucleating from a central point in both conditions, 3-4 
weeks after hanging drops were set up (Figure 2.1A-B). Focused screening resulted in 
optimized conditions combining the precipitant and salt of one initial condition (1,6 
hexanediol and magnesium chloride) with the elevated pH of the second initial condition 
(pH 10.5). The combination resulted in more rapid formation and increased crystal size, 
although crystals still grew as needles from a central nucleation point (Figure 2.1C). The 
number of needles ranged from half a dozen to hundreds. At higher protein 
concentrations, crystals formed embedded within a thick “skin” that formed on the edge 
of the droplets (Figure 2.1D). 
 
Diffraction 
IRF3 5D / CBP crystals do not diffract well. Crystals were harvested for 
diffraction on the GM/CA CAT minibeam at APS. Large individual needles (100-200 
µM length, 15-20 µM width) were collected as well as full clusters of needles. Crystals 
were frozen in various different cryogenic conditions or simply frozen in crystallization 
buffer. Despite the incredibly small width of the crystals, diffraction was observed 
(Figure 2.2). However, the diffraction pattern was low resolution and resembled that of 
fiber diffraction. No dataset was successfully collected. 
Attempts to modify the IRF3 construct to improve crystallization were met with 
severely reduced levels of expression. The IRF3 5D construct was truncated further on 
both the N- and C-termini. The N-terminus was modified to match the sequence of the 
phosphorylated IRF3 construct (171), which corresponds roughly to the first ordered 
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residue observed in all the IRF3 IAD structures. The C-terminal truncation was an 
attempt to remove residues not involved in secondary structures. However, it appears to 
destabilize the protein, causing the reduced expression and a noticeable increase in 
degradation. One option for optimization would be to leave the His-tag uncleaved on 
either the N- or C-terminus. Different expression protocols may also be able to address 
the current drawbacks of C-terminal truncation. Alternatively, surface entropy reduction, 
by means of mutation of large surface residues to alanine or serine, may facilitate new 
interface contacts and induce crystallization.  In the meantime, work with an unmodified 
C-terminus is ongoing. 
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Figure 2.2: IRF3 5D / CBP fiber diffraction. The diffraction pattern from IRF3 5D / 
CBP crystals resembles a fiber pattern. Modification of the construct may induce 
formation of crystals instead of fibers, yielding the desired diffraction pattern. 
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Full-length IRF3 
Crystallization 
Full length IRF3 2D (S386, 396D) was purified and crystallized. Although the 
construct is not constitutively active, as is the IRF3 5D mutant, the construct was 
amenable to purification and thus utilized for crystal trials. Initial screening resulted in 
high nucleation and growth of small single crystal rods that reached a maximum size of 
50 x 20 x 20 µm (Figure 2.3A-B). Conditions were optimized and trials performed to 
minimize nucleation in an attempt to increase crystal size. Crystal growth increased, with 
maximum dimensions reaching 150 µm in length and 30-40 µm in width (Figure 2.3 C-
D). 
 
Diffraction 
 Attempts to collect a full-length IRF3 2D dataset resulted in limited quality 
diffraction. Full length IRF3 2D crystals were harvested and flash frozen with glycerol or 
ethylene glycol as a cryoprotectant. Crystals were exposed to the same microbeam x-ray 
source as the IRF3 5D / CBP complex. Diffraction was rarely observed, however, two 
separate crystals showed medium-high resolution diffraction between 2.0 and 2.5 Å 
(Figure 2.4 A,B). The diffraction spots were severely smeared, making data processing 
impossible. It remains unclear whether intrinsic disorder in the crystal or effects of the 
cryosolution were responsible for the smearing. Although no dataset was collected, the 
diffraction demonstrates the potential for solving a full-length IRF3 2D structure in the 
future. 
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Figure 2.3:  Full-length IRF3 2D crystals. (A) and (B) Typical crystals grown before 
optimization. High nucleation and small crystal size (maximum 50 x 20 x 20 µm) 
plagued the first trials. The initial buffer conditions were 200 mM sodium or potassium 
citrate with 20% (w/v) PEG 3350.  (C) and (D) After optimizing conditions there were 
fewer nucleation events, leading to larger crystal growth. Crystals eventually reached a 
maximum of 150 µm in length, with a maximum 30-40 µm in width. 
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Figure 2.4:  Full-length IRF3 2D crystal diffraction. High and low contrast composite 
picture of the diffraction pattern from full-length IRF3 2D crystals. The data were unable 
to be processed due to the smearing of the diffraction spots. Despite the poor quality data, 
diffraction was observed to about 2.0 Å, suggesting slight changes in crystallization 
might allow the full-length IRF3 2D structure to be solved. 
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vIRF3 and IRF5 
Design and expression 
 The initial vIRF3 construct was designed to include the IRF5 / IRF7 binding 
domain (240-280) as well as adjacent regions predicted to be folded, for the purposes of 
increasing solubility and proper folding for crystallization. A protein folding prediction 
program, FoldIndex (177), indicated that in addition to the IRF binding residues, the ~50 
amino acids C-terminal to the IRF binding residues also have a propensity to fold into 
secondary structures. Thus, the long vIRF3 construct was designed with residues 235-327 
to include the IRF binding residues and the adjacent folded region or domain. However, 
expression of this region resulted in an unstable vIRF3 protein prone to proteolytic 
degradation. 
 For the purposes of co-expression with IRF5, we utilized both the long vIRF3 
construct (235-327) and short vIRF3 construct possessing the minimum residues 
identified as responsible for IRF binding (240-277). vIRF3 residues 240-277 are 
predicted to form two helices. IRF5 expression was poor when utilizing the full-length 
protein (1-488), but greatly increased when unstructured residues were removed from the 
C-terminus, matching the previously crystallized IRF5 IAD construct. Co-expression of 
both constructs was attempted with IRF5 residues 1-467 hereon referred to as “full-
length”. Unfortunately, neither vIRF3 construct was observed in the soluble fraction of 
co-expression trials with either the wild-type or the S430D phosphomimetic full-length 
IRF5. 
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Purification 
 Attempts to purify the long vIRF3 construct alone resulted in proteolytic 
degradation or tight binding to an E. coli protein contaminant (Figure 2.5 A). Initial 
attempts to purify an N-terminal GST tagged 235-327 construct were met with 
inconsistent expression and continuous degradation throughout purification. Adding a C-
terminal His6 tag appeared to stabilize the protein, increasing the intensity of the largest 
band on Coomassie stained gels. The C-terminal tag also allowed selection of full-length 
construct over degraded vIRF3. However, expression remained inconsistent, often with 
no protein observed. When the protein was successfully expressed, a contaminating E. 
coli protein remained tightly bound to vIRF3. High salt and detergent washes, in addition 
to affinity tag and ion exchange purification steps, did not remove the contaminant. In the 
event that this protein was an E. coli chaperone, purified complex was incubated with 
ATP and magnesium. The contaminant, however, remained tightly bound. The low 
vIRF3 yield and contaminating protein led to abandoning this course of purification. 
 Co-expression of vIRF3 with IRF5 did not result in the desired effects of 
stabilizing vIRF3 expression, but did result in good expression of both the full-length 
IRF5 wild type and S430D mutant. Neither vIRF3 construct was observed at any point 
during or after purification on SDS-PAGE gels. The affinity tag purification followed by 
size exclusion however, purified large quantities of IRF5 (Figure 2.5B). Wild type IRF5 
was then expressed without any vIRF3 ensuring only pure IRF5 was recovered (Figure 
2.5C). The purified protein was concentrated to 8 mg/mL and utilized for crystal 
screening without success (Figure 2.5D). However, the ordered precipitate observed in 
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the IRF5 crystal trials resembles that observed during full-length IRF3 2D crystallization 
(Figure 2.5E). The similarities between ordered precipitates imply that like IRF3 2D, 
IRF5 may indeed be able to be crystallized. Overall, size exclusion appears to function 
better as a second step in full-length IRF purification than ion exchange.  
The S430D mutant proved more difficult to purify than wild type IRF5. Size 
exclusion did not remove contaminating degradation products common to full-length IRF 
expression. Detergent washes followed by subsequent size exclusion with detergent 
present resulted in removal of contaminating degradation products. Unfortunately, the 
detergent (Triton-X 100) binds so tightly to IRF5 S430D that extensive dialysis and 
buffer exchanges failed to remove the detergent. Different detergents, more amenable to 
crystallization, will be utilized in subsequent IRF5 S430D 1-467 purification. The 
detergent may be binding the CBP binding site, suggesting co-expression with CBP could 
prevent detergent or proteolytic cleavage product binding to IRF5 S430D. The 
chromatogram indicated the S430D mutant might be in monomer-dimer equilibrium. At 
least three peaks containing IRF5 S430D existed between the expected monomer/dimer 
elution volumes. The unexpected number of peaks and the lack of resolution between 
peaks prevented drawing any firm conclusions about the oligomeric state. 
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Figure 2.5: vIRF3 and IRF5 expression. (A) The dual affinity tagged vIRF3 235-327 
expressed inconsistently, and co-purified with an E. coli contaminant. The contaminant 
and residual free GST are present along with vIRF3 on a Coommassie stained SDS-
PAGE gel. Detergent and high salt conditions did not remove the contaminant. (B) Co-
expression of vIRF3 constructs and IRF5 1-467 showed expression of IRF5 only. 
Proteolytic cleavage products, which failed to separate from full-length protein during ion 
exchange, eluted separately using size exclusion. (C) Arrows from the Superdex 200 size 
exclusion elutions indicate the corresponding peaks on the chromatogram. vIRF3 was 
removed from constructs for expression of full-length IRF5 to be used in crystal trials. 
IRF5 expression was confirmed by western blot (data not shown). (D) Crystal screening 
for full-length IRF5 resulted in ordered precipitate but no crystallization. Drops 
commonly contained phase separation and what appeared to be translucent, spherical 
precipitate. Individual spheres (blue arrow) commonly bunched forming chains (red 
arrow). (E) Similar ordered precipitate was observed during full-length IRF3 2D 
screening. 
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DISCUSSION 
 Although no new IRF structures were determined, future crystallization and 
biochemistry will benefit from our current results. In the case of determining a dimeric 
IRF3 / CBP complex, important information was learned about the IRF3 – CBP 
interaction. Past ITC measurements demonstrated that CBP bound roughly 10 times more 
tightly to IRF3 phosphomimetic S386/396D than IRF5 phosphomimetic S430D (130, 
135). The tighter interaction may help explain why the IRF3 5D construct solubility and 
yield increased roughly 30 and 10 fold, respectively, with CBP co-expression. The 
difference in binding again implies stereochemical differences between the C-terminal 
IRF3 and IRF5 phosphomimetic constructs. The increase in solubility and tight CBP 
binding suggest that the IRF3 autoinhibitory region may require CBP binding to adopt 
the extended conformation observed in IRF5 S430D. Additionally the IRF5 S430D 
structure has partial covering of the CBP binding site by the extreme N-terminal residues, 
a conformation IRF3 may not be able to achieve. CBP induced stability and solubility are 
perhaps why Takahasi et al. (171) failed to observe dimerization, either by our model or 
their model, in their phosphorylated IRF3 structure. The energetic costs of exposing the 
CBP binding surface may simply be greater than the destabilization introduced by 
phosphorylation, requiring CBP to lower the energy barrier, shifting equilibrium towards 
the extended autoinhibitory region conformation. Requiring CBP would also account for 
why Takahasi et al. did not detect evidence of their direct interaction model in their 
structure, but observed dimerization in the presence of CBP (171). 
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 Ongoing work with the IRF3 5D IAD and CBP complex involves truncation of 
the N-terminus without the destabilizing truncation of the C-terminus. Expression levels 
remain elevated and degradation is minimal when purifying the modified construct 
complex. The newly purified complex will be subjected to more recently developed 
crystal screens (MCSG, etc.) with a wider variety of conditions. We are confident that the 
combination of subtle construct design changes with more varied crystallization 
conditions will result in diffraction quality crystals that do not exhibit the fiber pattern 
previously observed. More drastic construct alterations, such as surface entropy 
reduction, may be required if IRF3 5D / CBP continues to form fibers. 
 Suitable crystals for a full-length IRF3 structure may be obtained through 
modification of the full-length IRF3 2D construct or redesign of the phosphomimetic 
pattern. The IRF3 2D crystals grown to date were small and most did not diffract. 
Although the two crystals that did diffract displayed unacceptably high mosaicity, 
diffraction was observed near 2.0 Å. Minor truncations may be made at the N-terminus, 
but such truncations were not necessary for suitable crystallization of free and DNA 
bound IRF3 DBD. Truncation at the C-terminus will be avoided due to the problems 
observed in IRF3 5D construct degradation. Alternatively, the IRF3 2D construct may be 
swapped for a full-length 5D construct. The full-length IRF3 5D construct expressed very 
well, but remained contaminated with proteolytic cleavage products after two-step 
affinity tag and ion exchange purification. Utilizing size exclusion in place of the ion 
exchange proved vital to removing proteolytic cleavage products during full-length wild 
type IRF5 purification and may be applied here to full-length IRF3 5D, or any other full-
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length IRF to remove degradation products. The 5D mutant should be more active than 
the 2D mutant, possibly inducing dimerization. The higher expression levels in the 
absence of CBP indicate the full-length IRF3 5D protein may not require CBP to 
dimerize. 
Modification of full-length IRF5 constructs may also yield the elusive full-length 
IRF structure. IRF5 1-467 has yet to crystallize in any of the current screens. Modifying 
the IRF5 1-467 N-terminus may be more beneficial for crystallization than modification 
of the IRF3 N-terminus. The N-terminus of IRF5 possesses ~10 extra residues relative to 
IRF3. These residues do not align with the initial IRF3 residues, and are predicted not to 
be involved in any secondary structure. Removal of these residues may create a construct 
suitable for crystallization. An IRF5 structure with the DBD, linker, and IAD would not 
only provide the first IRF5 DBD structure, but also answer questions regarding linker 
conformation and inter-domain binding.  
 The issue of inter-domain binding may also be approached through small angle x-
ray scattering (SAXS) techniques. SAXS analysis avoids the need to crystallize the 
protein, making it ideal for the difficult to crystallize full-length IRF constructs. SAXS 
typically results in low-resolution information on domain arrangements. However, 
existing DBD and IAD structures should make fitting domains into SAXS results easier. 
The analysis could be used to compare inactive versus active constructs, identifying any 
large-scale movement of domains. If successful, SAXS could be applied toward other 
structural questions involving co-activator binding, DNA binding, and dimerization 
mutants. 
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 Finally, the KSHV vIRF3 / IRF5 complex may be solved by re-design of the 
constructs. In order to stably express the IRF binding region of vIRF3, constructs were 
designed by Dr. William Royer and Dr. Tara Kashav to tether vIRF3 residues 240-280 to 
the IRF5 N-terminus. Exact construct design and purification specifics are still being 
explored. At least one fusion construct has been purified and verified by western blot to 
be IRF5, presumably with a tethered N-terminal affinity tag followed by vIRF3 240-280. 
Continued work on this and the other IRF constructs will eventually yield our goals of 
understanding IRF structure and function. 
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 CHAPTER III  
Crystal Structures of Human CtBP in Complex with Substrate 
MTOB Reveal Active Site Features Useful for Inhibitor Design 
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INTRODUCTION 
C-terminal Binding Protein (CtBP) 1 and 2 are critical modulators of multiple 
cellular processes. Discovered first for the ability of CtBP1 to bind adenovirus E1A 
protein and repress oncogenic transformation (2, 3) these two proteins have functional 
roles in the cytoplasm and nucleus. Although CtBP1 cytoplasmic functions such as 
trafficking and membrane fission (9, 56) are significant, both CtBP1 and CtBP2 (hereon 
referred to as CtBP) have been studied in the last 15 years primarily for their crucial role 
in transcriptional regulation.  
CtBP functions as a transcriptional regulator by tethering chromatin remodeling 
proteins, such as histone deacetylases (HDAC), histone methyl transferases (HMT), and 
histone demethylases, to DNA bound transcription factors (18, 71). Intriguingly however, 
the amino acid sequence of CtBP clearly positions it as a member of a family of enzymes 
not known for transcriptional regulation (Figure 3.1). Members of this enzyme family, 
D-isomer specific 2-hydroxyacid dehydrogenases (D2-HDH), reduce or oxidize 
substrates utilizing coenzyme NAD+/NADH or NADP/NADPH (2, 4). This family 
includes human proteins Glyoxylate Reductase / Hydroxypyruvate Reducatse (GRHPR) 
and phosphoglycerate dehydrogenase (PHGDH), as well as bacterial specific members 
such as D-Lactate Dehydrogenase (D-LDH) and D-Hydroxyisocaproate Dehydrogenase 
(D-HicDH) (19, 21, 24, 25).  
Dimerization, induced through binding NAD+ or NADH (27), is critical for CtBP 
function. Dimerization modulates CtBP repressor activity by providing two available 
PXLDS binding motifs, one per subunit, to be utilized by multiple CtBP partners (15).  
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Figure 3.1: Sequence alignment of CtBP1 and 2 with Various D-isomer specific 2-
hydroxyacid dehydrogenases (D2-HDH). Sequence alignment was carried out with the 
program Geneious (www.Geneious.com) (178). Residue numbers for CtBP1/CtBP2 are 
shown above the sequences. Red circles above the sequences designate conserved 
catalytic residues; the green diamond identifies Trp318/324, which provides a unique 
aromatic surface in the CtBP active site; blue asterisks designates small residues critical 
to formation of a hydrophilic cavity of CtBP; the orange square identifies Arg97/103, 
which exhibits conformational variability in CtBP1. 
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Additional evidence shows dimerization is necessary to form a stable platform for non-
PXDLS factor binding (15). The requirements of coenzyme binding and dimerization on 
transcriptional regulatory activity provide a rationale for evolutionary conservation of the 
enzymatic function of NADH binding. With a 100 fold higher affinity for NADH than 
NAD+ (26), CtBP is able to sense the redox state of the cell through small changes in 
NADH concentration, increasing transcriptional regulatory function when stimuli, such 
as hypoxia and high extracellular glucose levels, increase the NADH/NAD+ ratio (28-30). 
 Mounting evidence implicates CtBP repressor function in human cancer. CtBP 
co-repression targets pro-apoptotic factors (Bik, Noxa), cell adhesion molecules (Keratin-
8, E-cadherin) (66), and tumor suppressors (p16INK4a, p15INK4b) (71), facilitating the 
Epithelial-to-Mesenchymal Transition (EMT), conferring resistance to apoptosis and 
promoting metastasis (179). Although repressing these genes is necessary during 
development, this activity of CtBP can also promote oncogenesis. CtBP itself is targeted 
by multiple tumor suppressors including HIPK2 (180), JNK1 (181), and ARF (79). 
Consistent with these cellular effects of CtBP are studies directly linking aberrant CtBP 
activity to colon, prostate, ovarian, and breast cancer (8, 72, 75, 81, 182).  
A substrate for CtBP catalysis, 4-methylthio 2-oxobutyric acid (MTOB) 
antagonizes CtBP transcriptional regulation (72, 81, 89). MTOB, the final compound in 
methionine salvage, was established as a superior substrate for enzyme catalysis when 
compared to other common 2-keto acids, possibly linking methionine salvage and 
transcriptional modulation (63). MTOB induced apoptosis through displacement of 
CtBP2 from the Bik promoter in HCT116 colon cancer cells, a cell line displaying 
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elevated CtBP2 levels (81). Administering MTOB in mouse xenograft models resulted in 
decreased tumor burden and prolonged survival for MTOB treated mice versus untreated 
(81). Additionally, MTOB evicted CtBP from target promoters in breast cancer cell lines, 
shifting phenotypic indicators (E-cadherin/Vimentin) from mesenchymal to a more 
epithelial phenotype (72). These studies indicate that because CtBP enzyme activity is 
coupled to corepressor activity, modulating enzyme activity with a small molecule may 
inhibit corepressor function, inducing apoptosis. Although high MTOB concentrations 
(mM) are required for inhibition of CtBP, its clear effect on cancer cells provides proof of 
principle that small molecules could be developed to effectively treat cancers specifically 
regulated by CtBP activity.  
 Crystal structures of both CtBP1 and CtBP2 have been reported (10, 39, 44, 90), 
but none in complex with putative substrates. Given the ability of MTOB to inhibit the 
carcinogenic action of CtBP, we determined crystal structures of both CtBP1 and CtBP2 
in complex with MTOB in order to provide a structural basis for the design of synthetic 
inhibitors. MTOB has similar but distinct binding modes in CtBP1 and CtBP2. The 
interactions of active site residues with the ligand suggest potential MTOB specificity 
determinants as well as stereochemical characteristics to exploit in future drug design. 
The structures reveal unique aspects of the CtBP active site size and shape that can be 
exploited to avoid cross reactivity of potential inhibitors with other members of the D2-
HDH family. Thus, this work provides a starting point for the development of inhibitors 
that exclusively target CtBP1 and CtBP2 that could lead to a future CtBP targeted cancer 
treatment.  
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This chapter summarizes the crystal structures and binding of MTOB to both 
CtBP1 and CtBP2, as well as how the structures will provide a framework for future 
inhibitor development. The overall structures were examined to determine if a 
conformational change links enzymatic function to corepressor activity. The focus then 
moved to ligand binding through assessment of specific types of molecular interactions 
between MTOB and each protein. This was followed by identifying important individual 
residue contributions to MTOB binding. Finally, distinct CtBP active site characteristics 
were examined, providing insight into gaining specificity for future inhibitor design. The 
structural analysis of the complexes served as the starting point to design tighter binding, 
CtBP specific molecules. Future inhibitor designs will be tested for their ability to block 
CtBP transcriptional activity, helping elucidate the mechanism linking active site binding 
to transcriptional regulatory function.  
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MATERIALS AND METHODS 
CtBP1 and 2 genes and protein expression 
The full-length human CtBP1 and CtBP2 genes were generously provided by Dr. 
Steven Grossman. Residues 31-364 of CtBP2 (UniProtKB/Swiss-Prot accession: 
P56545.1) were cloned in the pET28a vector (Novagen) using the BamHI and XhoI 
restriction sites. Residues 28-353 of CtBP1 (UniProtKB/Swiss-Prot accession Q13363.2) 
were cloned into the pET28a vector using the NdeI and SacI restriction sites. Constructs 
were transformed into BL21-CodonPlus®(DE3)-RIL competent cells (Stratagene). 25 
mL of starter cultures grown overnight at 37°C in LB were utilized to inoculate six 1 liter 
cultures, which in turn were grown at 37°C in tryptone-phosphate media (2% bacto-
tryptone, 1.5% yeast extract, 0.2% dibasic sodium phosphate, 0.1% monopotassium 
phosphate, 0.8% sodium chloride). Cultures were induced at an OD600 of 0.5-0.6 by 
addition of 0.2 mM IPTG and the temperature was reduced to 30°C. Cells were harvested 
4 hours after induction, pelleted and resuspended in 30 mL of buffer containing Complete 
EDTA-Free protease inhibitors (Roche), 50 mM Tris (pH 7.3), 100 mM sodium chloride, 
0.2 mM EDTA. Total volume was divided equally into two tubes and cells were flash 
frozen in liquid nitrogen and stored at -80°C. 
Recombinant CtBP2 purification 
Cells were thawed and lysed in a cell disruptor at 80 psi. Lysate was 
supplemented with 10 mM magnesium chloride and 200 µM calcium chloride and 35 mg 
DNaseI (per 100 mL). The lysate was then stirred at 4°C for 30 min and the insoluble 
fraction was pelleted. The soluble fraction was collected and incubated with 5 mL of 
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nickel beads (Qiagen) with gentle stirring at 4°C for 90 minutes. The lysate and beads 
were applied to a column, and the lysate allowed to flow through. Beads were washed 
with 25 mL of wash buffer (50 mM Tris pH 7.3, 300 mM sodium chloride, 0.2 mM 
EDTA, 1 mM DTT, 40 mM imidazole) followed by 25 mL of wash buffer supplemented 
with 250 mM sodium pyruvate. Beads were washed with an additional 25 mL of wash 
buffer. Four 5 mL elutions were performed with wash buffer supplemented with 250 mM 
imidazole. Elutions 1 and 2 were diluted with an equal amount of dialysis buffer (50 mM 
Tris pH 7.3, 300 mM sodium chloride, 2 mM DTT, 1 mM EDTA) to prevent 
precipitation. All washes and elutions were carried out at 4°C. Samples were taken from 
each elution for analysis with SDS-PAGE. The His6 affinity tag was cleaved with 15 µL 
Thrombin (Novagen) diluted in 500 µL Novagen Dilution Buffer that was added to the 
four pooled elution fractions. Fractions were dialyzed  (6-8K MWCO) overnight into 2 
liters of dialysis buffer at 4°C. Protein was either flash frozen and stored at -80°C, or 
concentrated for immediate loading on a Superdex 75 column. Size exclusion was 
performed in dialysis buffer. Elutions off of the column were analyzed by SDS-PAGE for 
purity before being pooled and concentrated. Protein was flash frozen and stored at -
80°C. 
Recombinant CtBP1 purification 
The same protocol above was used for CtBP1 purification with the following 
differences:  Protein bound to nickel beads was washed with 25 mL wash buffer, 50 mL 
wash buffer supplemented with 0.5% Triton-X 100, followed by 50 mL wash buffer 
supplemented with 2.0 M sodium chloride. 10 mL wash buffer supplemented with 250 
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mM sodium pyruvate was incubated for 5 minutes on the column at 4°C. Sodium 
pyruvate incubation was repeated 5 times. Beads were washed with final 25 mL of wash 
buffer. The His-tag was not cleaved off of the protein after elution. Eluted protein was 
dialyzed into dialysis buffer supplemented with 10% glycerol. Recombinant protein was 
then concentrated, flash frozen and stored at -80°C. 
Crystallization of ternary CtBP2/NAD+/MTOB complex 
Protein (20-25 mg/mL) was incubated with a 25 or 50 molar excess of MTOB, 
and with or without an additional 10 molar excess of NADH. Protein, NADH, and 
MTOB were incubated overnight at 4°C. Concentrated protein was mixed in a 2:1 ratio 
with buffer and hanging drop vapor diffusion trays were setup in 24 well VDX plates. 
Crystal screening efforts resulted in diffraction quality crystals grown in buffers with 
combinations of different salts (potassium thiocyanate, potassium iodide, potassium 
nitrate) and PEGs (3350 and 8000). The highest quality diffraction was observed with 
crystals incubated with a 50 molar excess of MTOB and no supplemental NADH in a 
buffer containing 200 mM potassium nitrate, 15-20% PEG 3350, and 100 mM bis tris 
propane pH 7.0. Crystals typically grew as multiple joined plates. Seeding drops resulted 
in large single plates suitable for diffraction. Seed solutions were made by crushing 
crystals in 300 µL of mother liquor followed by further 3 fold dilution into mother liquor. 
Crystals were cryoprotected by submersion in mother liquor supplemented with 20% 
ethylene glycol for 5-10 s and then flash frozen in liquid nitrogen. 
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Crystallization of CtBP1/NAD+/MTOB complex 
Protein (~10 mg/mL) was mixed with a 25-50 molar excess of MTOB 
immediately before hanging drops were setup. Bipyramidal crystals grew overnight at 
room temperature in 200-300 mM magnesium chloride, 0-140 mM sodium formate, 100 
mM Hepes pH 7.5, and 2.5 mM NAD+. Crystals were cryoprotected by adding well 
buffer solution supplemented with increasing amounts of glycerol. Once the drop 
containing the crystal reached 20% v/v glycerol, the crystal was moved to 30% glycerol 
for 5 seconds and flash frozen in liquid nitrogen.  
Data collection and structure solution 
Diffraction data for the CtBP1/NAD+/MTOB and CtBP2/NAD+/MTOB 
complexes were collected on the BioCARS 14-BM-C beamline at the Advanced Photon 
Source of Argonne National Laboratory. The CCP4 suite was utilized for solving the 
CtBP1/NAD+/MTOB ternary complex (183). The initial model was solved by molecular 
replacement with PhaserMR (184). The CtBP1 binary complex (pdb code 1MX3) (10) 
and individual domains of a monomer in the CtBP2 binary complex (90) were used as 
search models for CtBP1 and CtBP2 respectively. Waters were automatically generated 
by Arp/Warp (185), and the structure was refined with RefMac5 (186). All other 
structures were refined through PHENIX (187). Model building between rounds of 
refinement was performed with Coot (188). 
Hydrogen bond determination 
Liganded CtBP structures were imported to the Schrödinger software suite. The 
Protein Prepwizard (189, 190) was utilized to add hydrogens, followed by minimization 
 85 
with heavy atoms restrained. Hydrogen bonds were then determined using a maximum 
2.5 Å hydrogen to acceptor (H-A) distance, 120° minimum donor-hydrogen-acceptor (D-
H-A) angle, and 90° hydrogen-acceptor-acceptor antecedent (H-A-AA) angle. Hydrogen 
bond figures were generated in pymol (191). 
Distance difference plot matrix 
 Distance difference plot matrices were generated as performed by Prabu-
Jeyabalan et al. (192). Briefly, a distance matrix was created for the distance between 
every Cα pair with each structure. One matrix is then subtracted from the other 
generating a distance difference matrix. The resulting changes in Cα pair distances are 
displayed as a heat map. A crystallographic symmetry mate was generated for the CtBP1 
asymmetric unit monomer to generate the physiological dimer. The CtBP2 asymmetric 
unit contains four dimers, thus generating symmetry mates was unnecessary.  
van der Waals analysis 
Van der Waals contact data were computed using a simplified Lennard-Jones potential as 
previously described (193). The Lennard-Jones potential, Vr, was calculated using the 
interatomic distance (r), depth of the well potential (ε), and the collision diameter (σ) 
with the following equation: 
Vr = 4ε [ (σ/r)12 – (σ/r)6 ] 
Energies were calculated for each ligand/protein atom pair with r ≤ 5 Å, and potentials 
for non-bonded atom pairs separated by less than the distance at the minimum potential 
were equated to –ε. 
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RESULTS 
CtBP1 and CtBP2 MTOB co-crystal structures 
CtBP crystal structure determination 
Both human CtBP1 (28-353) and CtBP2 (33-364) minimal dehydrogenase 
domains were each crystallized in ternary complexes with coenzyme NAD+ and ligand 
MTOB. Molecular replacement utilizing the monomer from the CtBP1 binary structure 
(CtBP1/NAD+, pdb code 1MX3) (10) as a search molecule provided the initial CtBP1 
ternary complex phases. As with the CtBP1 binary complex, the ternary complex consists 
of a single monomer per asymmetric unit with the molecular dyad of the physiological 
dimer coincident with a two fold crystallographic axis in the P6422 space group. The 
CtBP2 ternary complex molecular replacement employed separate substrate binding and 
coenzyme binding domains of a CtBP2 binary complex (CtBP2/NAD+, pdb code 2OME) 
(90) as search molecules. The CtBP2 asymmetric unit contains eight monomers, arranged 
as four dimeric pairs (Figure 3.2A). Molecular replacement located a solution for all 
eight coenzyme binding domains, but only six of eight substrate binding domains. The 
two remaining substrate binding domains were built manually during refinement. For full 
crystallographic statistics, see Table 3.1. 
The CtBP binary and ternary complexes have similar conformations 
The overall CtBP/NAD+/MTOB ternary structures closely resemble the 
previously published binary complexes with bound coenzyme. A discontinuous substrate 
binding domain (28-120 and 327-353) and coenzyme binding domain (125-319) form an 
active site cleft where both NAD+ and MTOB bind (Figure 3.2B). The effects of MTOB  
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Figure 3.2: Architecture of the CtBP ternary complexes. (A) Twofold symmetric 
CtBP1 dimer with one monomer in blue and one in red (black oval denotes 
crystallographic 2-fold operating relating to the subunits). Each monomer possesses an 
active site cleft where coenzyme and substrate bind. (B) CtBP1 monomer with the 
substrate (orange) and coenzyme binding domains (green) connected by a small hinge 
region (grey). MTOB (cyan) and NAD+ (yellow) bind the CtBP1 active site cleft. A 
dimerization loop forms contacts with the other subunit of the dimeric complex. (C) A 
distance difference matrix plot (DDMP) compares the binary CtBP1 dimer to the ternary 
dimer. A distance matrix is created for each structure by calculating the distance between 
every Cα pair. The matrices are subtracted from one another, generating a distance 
difference matrix comparing the structures in which Cα pairwise differences are reported 
through a heat map (Å). For clarity, dashed lines mark the boundary between dimeric 
subunits. The lower left quadrant compares Subunit 1 and 1’, and the upper right 
quadrant compares Subunit 2 and 2’. The upper left quadrant (Subunit 1’ and 2) and 
lower right quadrant (Subunit 1 and 2’) reveal any differences in dimeric subunit 
positions. The CtBP1 monomers show no tertiary or quaternary variations upon MTOB 
binding. 
 
 
 
 
 89 
 
 90 
binding on enzyme structure were investigated by a distance difference matrix plot 
comparing binary and ternary complex dimers (Figure 3.2C). Only minor differences in 
Cα positions between dimeric CtBP1 binary (pdb code 1MX3) (10) and ternary 
complexes are apparent indicating no significant ligand-induced conformational changes 
in the overall tertiary or quaternary structure. 
Analysis of the eight crystallographically unique CtBP2 monomers indicates that 
MTOB also does not induce any large conformational changes upon binding to CtBP2 
(Appendix, Figure A.1, A.3).  As distance difference matrix plots for the eight 
crystallographically unique CtBP2 binary monomers (pdb 2OME) (90) display almost no 
Cα positional differences (Appendix, Figure A.2), probably due to strong non-
crystallographic (NCS) restraints, our comparison between the binary and ternary 
complex employed only a single CtBP2 binary complex monomer.  Differences observed 
between binary and ternary dimers (Appendix Figure A.3) closely correlate with 
differences observed between the crystallographically unique subunits of the ternary 
complex, which occur primarily at lattice interactions (Appendix A.4). The subtle, 
inconsistent differences appear driven by asymmetry among the ternary complex 
monomers. The minor differences in MTOB bound versus MTOB free CtBP1 and CtBP2 
are reflected in the rms deviations, 0.2-0.3 Å for monomers and 0.2-0.4 Å for dimers, 
suggesting the differences are purely crystallographic. 
Consistent with the very high degree of homology (89% sequence identity 
between the CtBP1 and CtBP2 constructs, Figure 3.1), limited differences exist between 
MTOB bound CtBP1 and CtBP2 monomers.  Not surprisingly, the small differences 
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observed occur at sequence variations, particularly those that impact lattice contacts.  
These include CtBP2 Gln214 (CtBP1 Ser208), CtBP2 Arg354 (CtBP1 Lys348), CtBP2 
residues 48 and 54-55 (Appendix Figure A.5A, B). An additional region of small 
differences between CtBP1 and CtBP2 results from the variability of the dimerization 
loop in CtBP2 monomers (Appendix Figure A.5C). Overall, no large consistent 
differences occur between the CtBP1 and CtBP2 complexes, allowing for direct 
comparison of MTOB binding between the structures.   
The above comparisons show that MTOB binding does not substantially alter the 
overall CtBP conformation. Additionally, the MTOB bound CtBP1 and CtBP2 structures 
are also nearly identical to one another, containing only small variations explained by 
crystal contacts, sequence variation, and backbone flexibility unrelated to MTOB 
binding. The lack of large structural changes upon binding argues against ligand-linked 
conformational changes driving transcriptional modulation by MTOB.  
MTOB placement 
MTOB is positioned in the active site similarly to ligands in other members of the 
D2-HDH protein family of proteins (Figure 3.3A) (20, 21, 24). Both the NAD+ 
coenzyme and MTOB bind in the cleft between the substrate binding domain and 
coenzyme binding domain (Figure 3.3B). MTOB binds between an active site loop from 
the substrate binding domain and catalytically conserved residues Arg and His of the 
coenzyme binding domain, while simultaneously positioned adjacent to the NAD+ 
nicotinamide ring (Figure 3.7B). The MTOB atom-labeling scheme utilized for 
discussion in this chapter derives from the PDB atom names (Figure 3.3C). 
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Figure 3.3: The binding location of MTOB relative to other D2-HDH substrates. (A) 
Product D-glycerate (green) positioned in the active site of D2-HDH family member 
Glyoxylate Reductase / Hydroxypyruvate Reductase (GRHPR) (24). D-glycerate rests 
between catalytic residues Arg245 and His293 from the coenzyme binding domain and 
active site loop residues Val83 and Gly84 from the substrate binding domain. Two final 
contacts, from Ser296 and a crystallographic water (red), stabilize the ligand. (B) MTOB 
(cyan) positioned in the CtBP1 active site analogous to D-glycerate. MTOB sits in the 
cleft separating the coenzyme binding domain (green) and substrate binding domain 
(orange), also contacting the NAD+ nicotinamide ring (yellow). Residues involved in 
MTOB binding from the coenzyme binding domain include catalytic residues Arg266 
and His315. Active site loop residues Ser100 and Gly101 from the substrate binding 
domain stabilize the MTOB carboxylate. (C) MTOB atom labels, derived from the PDB, 
utilized in descriptions of MTOB atom positioning in both CtBP1 and CtBP2. 
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CtBP1 MTOB placement 
Given the medium to low resolution of the crystallographic analysis (CtBP1 2.38 
Å, CtBP2 2.86 Å), particular care was taken in modeling MTOB. To minimize bias, 
water molecules were first refined into the active site Fobs-Fcalc (Fo-Fc) density for initial 
refinement. MTOB was then positioned into the active site utilizing the 2Fobs-Fcalc (2Fo-
Fc) density and subjected to further rounds of refinement. The electron density is highest 
at the MTOB sulfur (S8) and along the C2-C4 bond in the α-keto acid moiety. The 
MTOB O3 and C9 atoms did not fit fully into the density, when contoured at 1σ (Figure 
3.4A). Positions of these atoms were chosen based on the Fo-Fc map and refined B-factor 
analysis. The Fo-Fc map indicated C9 likely occupies two different positions; one oriented 
away from the Arg97 guanidinium, and the other toward Arg97 (Figure 3.4B-D). Water 
molecules in the binary CtBP1 structure occupy these positions and are displaced by 
MTOB (Figure 3.5A). Given the moderate resolution of the analysis, only one C9 
conformation of MTOB was chosen to satisfy the Fo-Fc map, retain optimal B-Factors, 
and avoid steric clashes, particularly with Arg97. The less favored position, which is 
predominant in CtBP2, appears to be disfavored by steric clashes in CtBP1. The MTOB 
O3 was positioned to minimize its B-factor and avoid negative Fo-Fc density, finalizing 
the ligand position in the active site.  
The Fo-Fc map, contoured to 3σ, and refined B-factors indicate that MTOB does 
not fully occupy all the active sites in the CtBP1 crystal. MTOB occupancy was set at 
67% based on the Fo-Fc map and local atomic B-factors. Fo-Fc density suggests another 
molecule may co-occupy a portion of the active site adjacent to the MTOB C7 atom  
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Figure 3.4: MTOB placement and conformations in the CtBP1 active site. 
(A) MTOB positioned in the 2Fo-Fc density (blue) contoured at 1σ (0.20 e-/Å3). MTOB 
atoms O3 and C9 protrude from the density. (B) The Fo-Fc density map (green), 
contoured to 3σ (0.10 e-/Å3), indicates that multiple MTOB conformations may exist 
around atoms C7 to C9. (C) A possible second conformation of MTOB is modeled 
(orange) in which the C9’ atom (alternate C9 position) occupies the positive Fo-Fc density 
from refinement in the original C9 position. (D) The Fo-Fc map of the original MTOB 
conformation is replaced with a Fo-Fc map (0.10 e-/Å3) of MTOB refined in the alternate 
conformation. The 2Fo-Fc map (not shown) is identical in the alternate conformation. 
Positive density now appears in the original C9 atom position, confirming MTOB can 
exist in both conformations. Poor B-factors and steric clashing with the Arg97 
guanidinium prevent C9’ modeling. Positive density still remains around the MTOB C7 
atom, suggesting mutually exclusive occupancy of the active site by another molecule. 
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Figure 3.5: Occupants of the CtBP1 active site. The active sites of other CtBP1 
structures were aligned with CtBP1 ternary complex. The MTOB structure Fo-Fc density 
(green) is included. (A) The CtBP1 binary complex active site contains an acetate ion 
(orange) and three water molecules (red). Two waters overlap with the MTOB C9 and 
C9’ alternate positions. The third water rests adjacent to the MTOB carboxylate. Two rat 
CtBP1 structures, (B) (1HKU) (39) and (C) (2HU2) (44) contain formate ions (orange) 
that partially occupy the positive Fo-Fc density. Employed for CtBP1 ternary complex 
crystallization, formate may occupy the active site mutually exclusive to MTOB. Low 
occupancy or ambiguity caused by MTOB C9 motion resulted in failure of formate or 
water co-occupancy modeling. (D) NAD+ modeled in two distinct conformations. The 
lower occupancy conformation (33%; green) has a large steric clash (red disks) with the 
MTOB carboxylate. The higher occupancy conformation (67%; yellow) does not have a 
severe clash with MTOB. 
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(Figure 3.4C,D). In addition to waters, binary structures of CtBP1/NAD(H) (pdb code 
1MX3) (10) and rat CtB1/NAD(H) (pdb codes 1HKU and 2HU2) (39, 44) have acetate or 
formate ions in the active site (Figure 3.5A-C). The CtBP1 ternary structure Fo-Fc map 
suggests a formate ion, employed in crystallization, or alternatively a water molecule, 
exhibits mutually exclusive occupation of the active site adjacent to Arg97 and MTOB 
atoms C7-C9. Attempts to model these atoms failed due to low occupancy and ambiguity 
caused by the adjacent MTOB density and movement of the MTOB C9 atom. NAD+ also  
exists in two distinct conformations (Figure 3.5D). In one form, the nicotinamide ribose 
ring sterically clashes with the MTOB carboxylate. This conformer, whose occupancy 
was refined at 33%, is apparently predominant in the absence of MTOB. The second 
NAD+ conformation, refined at 67%, does not clash with the carboxylate. Both NAD+ 
conformations appear similar to existing NAD+ conformations previously observed in 
other related structures (10, 21, 25, 39). 
CTBP2 MTOB placement 
MTOB was positioned in the CtBP2 active site similarly to CtBP1. Density from 
the 2Fo-Fc map and an Fo-Fc omit map guided ligand placement. The quality of the 2Fo-Fc 
density varies across the eight monomers, ranging from excellent to poor. Even in the 
poorest quality monomers, density was still present for the MTOB sulfur atom (S8) and 
at least some of the α-keto acid moiety. Omit Fo-Fc density maps confirm correct MTOB 
placement, yielding high confidence of MTOB conformation in monomers A, C and H. 
An NCS averaged 2Fo-Fc map (average 2Fo-Fc density from all monomers in the 
asymmetric unit) however, indicates the catalytic Arg272 guanidinium group of 
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monomer H occupies a different position than the other monomers (Figure 3.6A). Thus 
monomers A and C, where ligand and peptide fit best in all the considered maps, were 
utilized to ensure valid MTOB binding analysis (Figure 3.6 B, C). See appendix for the 
fit of MTOB in the remaining six monomers (Appendix Figure A.6, 7). As in the CtBP1 
ternary structure, MTOB does not fully occupy the CtBP2 active sites. The occupancies 
of MTOB were refined in PHENIX to 79% in monomers A and C. 
CtBP-MTOB interactions 
CtBP2 hydrogen bond network 
As the network of hydrogen bonds between the MTOB α-keto acid moiety and 
CtBP2 closely resembles that of other D2-HDHs (Figure 3.7A), we discuss it first, before 
considering the small differences observed with CtBP1 MTOB binding. Detailed 
discussion of the hydrogen bond network is restricted to monomers A and C, which show 
the clearest electron density maps – see above). The catalytically conserved Arg272 and 
His321 from the coenzyme binding domain provide half of the hydrogen donor atoms. 
The amide backbone and side chains of a flexible loop in the substrate binding domain 
provide the other three donors, helping bridge the active site cleft. Hydrogen bonds will 
be discussed with regards to distance and angle values shown in Table 3.2. The active 
site hydrogen bond network contains six bonds, two for each MTOB oxygen atom 
(Figure 3.7B,C). Bonds from the catalytic His321 and Arg272 NH1 anchor the MTOB 
carbonyl. The Arg272 NH2 and the amide backbone of Gly107 provide the bonds for the 
first MTOB carboxylate oxygen (MTOB O1), while the Ser106 amide and side chain 
provide both of the bonds to the second MTOB carboxylate oxygen (MTOB O3). The  
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Figure 3.6: Positioning MTOB in the CtBP2 active site. Monomers A, C, and H have 
high quality maps for ligand positioning. (A) An NCS average 2Fo-Fc (0.27 e-/Å3) map 
reveals that monomers A and C (cyan) fit well in the averaged density. The Arg272 
guanidinium in monomer H (orange) situates outside the average density, leading to 
omission of monomer H from ligand binding analysis. (B) MTOB occupies the 2Fo-Fc 
density at contour levels 1σ (blue, 0.27 e-/Å3) and 1.6σ (green, 0.43 e-/Å3), in monomers 
A and C. The sulfur is clearly visible at the higher contour level. (B) An omit map (Fo-Fc) 
generated by repeating the final round of refinement without MTOB or waters present, 
was contoured to 2.4σ (0.19 e-/Å3; blue mesh) and 3.5σ (0.27 e-/Å3; green surface). 
MTOB placements show good agreement with the omit map, including monomers A and 
C. The maps confirm the MTOB C9 in CtBP2 exists in the alternate conformation 
observed in CtBP1. The MTOB C9 atom does not clash with Arg97 in CtBP2 due to 
differences in side chain position. 
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bond length from the Ser106 side chain, equivalent to the maximum allowable distance, 
suggests this bond is the weakest of the conserved bonds. The D2-HDH family lacks 
conservation of a side chain possessing a hydrogen bond donor at this position, 
suggesting a weak hydrogen bond to Ser106 Oγ may contribute only minimally. 
In monomer A, Arg272 NH2 donates a non-conserved hydrogen bond to the 
MTOB carbonyl (Figure 3.7B). The geometry of this bond indicates it is weak, providing 
a rationale for its inconsistent appearance in all CtBP2 subunits. The length and angles of 
the bond exist at the criteria limits in monomer A, and just beyond the limits in monomer 
C. Therefore, a network of six fully conserved hydrogen bonds, with a potential, weaker 
seventh bond, anchors MTOB in the active site in CtBP2.  
The CtBP1 hydrogen bonding network is distinct from CtBP2 
The network of hydrogen bonds in CtBP1 is distinct compared to CtBP2 (Figure 
3.7D). The differences arise from an unexpected twist in the MTOB carboxylate and the 
position of Arg97. The MTOB carboxylate group rotates relative to the plane of the O5 
carbonyl, as evidenced by a shift in the MTOB O5 carbonyl – O1 carboxylate dihedral 
angle relative to CtBP2 monomers A and C by 72° and 44° respectively. The side chain 
of Arg97 situates further into the active site in the CtBP1 ternary complex than in either 
the CtBP1 binary complex or any of the MTOB bound CtBP2 monomers (Figure 3.8). 
This new position allows for formation of a unique hydrogen bond and increased 
coulombic interaction to the MTOB carboxylate.  
 Only four of the six hydrogen bonds conserved in the CtBP2 complex are found 
in the CtBP1 structure. The two strong hydrogen bonds anchoring the MTOB carbonyl 
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Figure 3.7: Substrate hydrogen bond network. (A) The hydrogen bond network of D-
glycerate in the GRHPR active site (24). Catalytic residues Arg245 and His293 from the 
coenzyme binding domain, and residues Val83 and Gly84 from the substrate binding 
domain hydrogen bond to the D-glycerate carboxylate and 2’ hydroxyl group (green 
dashes). Ser296 and a water molecule (red) donate two final hydrogen bonds to the 3’ 
hydroxyl. (B) The MTOB hydrogen bond network of CtBP2 Monomer A. Six conserved 
hydrogen bonds in Monomer A (orange dashes) and one Monomer A specific bond 
(yellow dashes) comprise the MTOB hydrogen bond network. (C) The hydrogen bond 
network of Monomer C contains only conserved bonds. (D) The network of hydrogen 
bonds in CtBP1 is distinct from CtBP2. MTOB’s conformation in CtBP1 allows for 
formation of only four of the six conserved bonds (orange dashes). Arg97 forms a unique 
hydrogen bond with MTOB in CtBP1 (blue dashes). 
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are present in the CtBP1 structure. The bonds from His315 and Arg266 NH1 are the most 
ideal hydrogen bonds of the CtBP1 network. Despite its rotation relative to the CtBP2 
structure, the MTOB carboxylate still forms the conserved hydrogen bonds with the 
amide backbone of S100/106 and Gly101/107, albeit with less ideal bond geometry, 
suggesting these bonds are weaker in the CtBP1 complex. A slight improvement in 
geometry would form a CtBP1 unique hydrogen bond between Gly101 and alternate 
carboxylate oxygen, MTOB O3. However, as it is modeled, the geometry lies just outside 
the bond criteria. The CtBP1 complex lacks the conserved bonds donated from the CtBP2 
Ser106 side chain and Arg272 NH2 to the MTOB O3 and O1 respectively.  
The mobility of the Arg97 side chain evident from human and rat CtBP1 
structures, permits formation of a hydrogen bond with CtBP1 MTOB not observed in the 
CtBP2 complex. In each CtBP1 structure, the Arg97 guanidinium group situates to 
interact with a molecule bound in the active site.  This includes formate or acetate in the 
human and rat CtBP1 structures, and MTOB in the ternary structure (Figure 3.8A,B). 
The same mobility is not observed in the CtBP2 structures (Figure 3.8C,D). In the 
CtBP1 ternary structure, Arg97 protrusion into the active site allows the formation of a 
weak hydrogen bond between a guanidinium nitrogen and MTOB carboxylate oxygen 
O3. The bond distance and DHA angle exist at the limits of hydrogen bonding criteria, 
suggesting the hydrogen bond is weak. 
The conformation of MTOB in CTBP1 results in a distinct, albeit weaker, 
hydrogen bond network. Only four of six hydrogen bonds conserved in CtBP2 also exist 
in CtBP1. Gaining the weak hydrogen bond between CtBP1 Arg97 and MTOB O3 does 
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not account for the loss of the other hydrogen bonds or for the reduction of quality in 
bond geometry between the MTOB carboxylate and the amide backbone. However, the 
movement of Arg97 into the active site cavity, coupled with the rotation of the MTOB 
carboxylate, suggests an increase in coulombic interaction may offset the energetic 
penalty incurred by the CtBP1 specific MTOB conformation. 
Unique Substrate Contacts and MTOB Specificity  
Van der Waals analysis of the CtBP-MTOB complexes specifies details of 
contacts between MTOB and active site residues, providing insight into substrate 
specificity. Utilizing a program created by Ozen et al. (193), the energetics of each 
contact was calculated utilizing a Leonard-Jones potential. Only attractive forces were 
considered in the current analysis to avoid skewing of the binding profile by short 
hydrogen bonds (Figure 3.9A). For details on the attractive and repulsive forces 
observed, see Appendix Figure A.4.  
The MTOB α-keto group contacts CtBP similarly to other liganded D2-DHDs as 
discussed above. The major contacts include the coenzyme binding domain catalytic 
Arg266/272 (CtBP1/CtBP2) and His315/321 residues and the substrate binding domain 
active site loop, Gly99/105, Ser100/106, Gly101/107. CtBP however lacks a contact 
present in other D2-DHD, such as bacterial D-LDH, human GRHPR, and human 
PHGDH. The substrate α-keto acid moiety of other D2-HDHs contacts a large residue 
opposite from the catalytic arginine. The bulky residues originate from one of two 
equivalent CtBP positions, Ala123/129 and Ser124/Ala130 (Figure 3.1), neither of which  
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Figure 3.8: The mobility of the CtBP1 Arg97 guanidinium group. In all panels, Arg97 
and MTOB in the CtBP1 ternary complex are shown with cyan carbon atoms. (A) Arg97 
of the human CtBP1 binary complex (1MX3, orange) (10) situates 2.8 Å and 3.1 Å 
(green dashes) from an acetate ion and water molecule (red sphere), respectively. Arg97 
of the CtBP1 ternary complex (cyan) moves further into the active site, positioning 3.2 Å 
from the MTOB carboxylate. A new CtBP1 unique hydrogen bond is formed (cyan 
dashes) between the ternary complex Arg97 and MTOB. (B) The rat CtBP1 Arg97 
(1HKU, purple) (39) pushes even further into the active site, creating a 3.2 Å contact 
(purple dashes) with a formate ion. The CtBP1 ternary complex R97 situates 4.0 Å from 
the same formate oxygen. (C, D) All eight CtBP2 binary complex (yellow) and ternary 
complex (green) Arg103 residues fail to shift into the active site, even when MTOB 
(monomer A) is present, suggesting the mobility of the arginine is unique to CtBP1. 
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contacts MTOB. In bacterial enzymes, this residue is typically a tyrosine, whereas in the 
human GRHPR and PHGDH, it is a leucine (Leu107) and asparagine (Asn106), 
respectively. 
The MTOB atoms outside the α-keto acid moiety contact residues previously 
implicated in substrate specificity of other D2-DHDs. CtBP1 residues Tyr76/82, 
His77/83, and Met327/333, as well as Val159’/165’ from the neighboring dimeric 
subunit, contact the terminal atoms on of MTOB, sterically preventing larger molecules 
from binding. Tyr76/82 and Met327/333 match residues implicated in substrate 
specificity and binding in bacterial D2-HDHs (19). CtBP unique residue His77/83 
situates in an identical position as a leucine directly linked with substrate specificity in 
human protein GRHPR (24). These residues prevent α-keto acids larger than MTOB from 
binding. Variations exist in the level of contact between the MTOB terminal atoms across 
the CtBP complexes, due to the difference in C9 position between the CtBP complexes. 
CtBP1 Trp318 (CtBP2 Trp324) dominates the active site and is within van der 
Waals distance of all MTOB atoms outside the α-keto acid moiety (Figure 3.12A). 
Trp318/324 occupies a homologous position (Figure 1) to a phenylalanine in L. 
bulgaricus D-LDH, tyrosine of A. aeolicus D-LDH, and tyrosine of D-HicDH, all 
residues implicated in substrate specificity (19-21). Human PHGDH lacks an aromatic 
residue in this position, with an alanine instead permitting additional arginine residues 
that stabilize the substrate’s negatively charged phosphate. Human GRHPR residues 
Ser296, Arg302, and a crystallographic water molecule occupy a position roughly 
equivalent to CtBP Trp318/324, serving as specificity determinants that contact the 
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terminal hydroxyl group of the hydroxypyruvate substrate (24). The water molecule 
situates between the Ser296 and Trp141’ donated by the neighboring dimeric GRHPR 
subunit. When aligned to CtBP1, this tryptophan positions between CtBP1 residues 
Trp318/324 and His77/83, helping to coordinate the GRHPR water, and making contact 
with the substrate. Alignment the CtBP structures with the GRHPR structure indicates 
MTOB, or any α-keto acids larger than hydroxypyruvate, would severely clash with the 
GRHPR Trp141’. Thus, CtBP Trp318/324 is a unique feature among human D2-HDH 
proteins that provides an extensive binding surface lining the active site.  
Interestingly, the MTOB S8 atom centers over the CtBP Trp318/324 indole, 
rather than orienting its lone pair of electrons towards the positively charged Arg97/103 
guanidinium (Figure 3.9B). The positional preference suggests a sulfur-pi interaction 
commonly observed in the protein data bank between methionine and cysteine residues 
stacking over aromatic rings, plays a role in substrate specificity (194-196). The finding 
that replacing the MTOB sulfur with a methylene carbon decreased enzymatic efficiency 
8 fold (63), suggests a sulfur-pi interaction with active site Trp318/324 contributes to 
substrate specificity of CtBP. 
Only a single large magnitude difference exists in MTOB contacts between 
CtBP1 and CtBP2. CtBP1 Arg97 contacts MTOB more extensively in the CtBP1 
complex than the homologous Arg103 in the CtBP2 complex due to the shift of the 
MTOB carboxylate, as discussed above in relation to hydrogen bonding. Not only does 
the CtBP1 carboxylate conformation create a unique hydrogen bond, but it also increases  
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Figure 3.9: MTOB van der Waals interactions. (A) The calculated van der Waals 
contacts with MTOB in CtBP1, CtBP2 monomer A, and CtBP2 monomer C. The largest 
magnitude difference between the CtBP1 and CtBP2 occurs with increased contacts of 
CtBP1 at Arg97/103. CtBP2 monomers possess greater contacts at His77/83, with 
offsetting lower contacts at Trp318/324 due to MTOB C9 conformational differences 
between structures. Trp318/324 forms the most extensive contacts with MTOB in all 
three structures. (B) The active site of CtBP1 (green) and CtBP2 Monomer A (cyan). The 
shift in CtBP1 MTOB carboxylate, and corresponding movement of Arg97 increase van 
der Waals contacts relative to CtBP2. Trp318/324 contacts all MTOB atoms outside the 
α-keto acid moiety in both structures.  
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favorable van der Waals interactions and intensifies the coulombic interaction between 
MTOB and the Arg97 guanidinium (Figure 3.9B). However, in terms of overall impact 
on binding, the shift of MTOB in CtBP1 does not greatly affect the total van der Waals 
interaction profile. 
The unique hydrophilic cavity of the CtBP active site 
A unique aspect of the CtBP active site, not shared by other members of the D2-
HDH family, is a hydrophilic cavity between the MTOB binding site and NAD+. Four 
ordered water molecules fill this cavity in the CtBP1 ternary structure, linking MTOB 
with the nicotinamide phosphate group of NAD+. Other D2-HDH family members 
possess residues with bulky side chains that interact with the substrate, sealing the 
binding site and preventing formation of the water network. CtBP lacks a bulky residue at 
this position (see Unique Contacts and Specificity above) allowing the existence of the 
water network. This unique hydrophilic cavity may be exploited for future small 
molecule affinity and specificity.  
CtBP water network 
The active site cavity in CtBP contains a network of waters observed in multiple 
structures. The network of waters, designated as waters A, B, C and D, fills a cavity that 
may provide useful, CtBP specific, contacts for future inhibitor development (Figure 
3.10A). Two other CtBP1 structures, the human CtBP1 binary complex (pdb code 
1MX3) (10) and a rat CtBP1 binary complex (pdb code 1HKU) (39) display the full 
network of four water molecules, while a lower resolution rat CtBP1 (pdb code 2HU2) 
(44) retains only waters A and B (Figure 3.10B). Individual monomers in the binary 
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CtBP2 structure (pdb code 2OME) (90) contain some of the conserved waters despite the 
low resolution relative to the CtBP1 structures (Figure 3.10C). Finally, the CtBP2 
ternary complex contains no active site waters as attempts to model these waters resulted 
in low quality 2Fo-Fc maps. However, the Fo-Fc omit map utilized for MTOB placement 
indicates positive density occurs at some positions of the water network providing 
evidence that water molecules bind at these positions (Figure 3.10D).  
The positions of water molecules that fill the active site cavity are very similar, 
with the exception of Water A (Figure 3.10B,C). The precise binding location for water 
A depends on the occupants of the active site in various structures, with binding of ions 
(acetate or formate), MTOB, or other water molecules dictating the location of water A 
binding. Interestingly, the CtBP2 MTOB carboxylate sterically clashes with a water 
molecule at position A, which accounts for the lack of Fo-Fc density at this position 
(Figure 3.10D). It appears therefore that the CtBP1 MTOB carboxylate shift towards 
Arg97 is required for water binding at position A. Water molecules in positions B-D 
show much less variation in position. 
In addition to contacting NAD+, the water network contacts protein residues that 
comprise the hinge region between the substrate binding domain and coenzyme binding 
domain, and a single active site loop residue. The CtBP1 residues involved in binding 
include 120-125 (VPAASV), and the equivalent CtBP2 residues 126-130 (IPSAAV). 
Despite the three amino acid variations between CtBP1 and CtBP2 in this loop, only the 
Ser124/Ala130 difference affects contacts within the water network. The side chains of 
the other amino acids orient outside of the cavity and do not affect the peptide backbone 
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Figure 3.10: Comparing other CtBP water networks to the CtBP1 ternary complex. 
(A) The water filled cavity in the CtBP1 ternary complex. Shown are the protein surface 
(grey), NAD (yellow), MTOB (CtBP1, cyan), and the water network (red spheres) 
labeled A to D. The water molecules form a network (blue dashes) between the MTOB 
carboxylate and an NAD+ phosphate. (B) The CtBP1 ternary complex, network was 
compared to human CtBP1 binary complex (1MX3, blue spheres) (10), and two rat 
CtBP1 structures (1HKU, green spheres; 2HU2, yellow sphere) (39, 44). 1MX3 has a 
fifth water (labeled with “X”), which is highly mobile, or incorrectly modeled (B factor = 
97.1Å2). MTOB, bound ions, or other waters dictate water A position across different 
structures. (C) CtBP2 binary complex (pdb 2OME) (90) monomers C (purple), F 
(orange), and G (dark green) contain partial water networks. (D) MTOB (green) from the 
CtBP2 ternary complex clashes with the CtBP1 water A position. CtBP2 ternary complex 
Fo-Fc map (0.24 e-/Å3) indicates positive density at water positions for monomers A 
(green mesh), G (purple mesh), and H (blue mesh). The low resolution of the CtBP2 
ternary complex does not permit confident modeling of these water molecules. 
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contacts. The substrate binding domain active site loop provides the final residue, CtBP 
Ser100/106, contributing to binding with waters at positions A and D, in addition to 
MTOB. An NAD+ phosphate group oxygen hydrogen bonds with the final water in the 
network at position D. 
The cavity exists because CtBP lacks a bulky residue at a key position 
The observed active site cavity is present because CtBP lacks a residue typically 
involved in substrate binding in other D2-HDHs. In other family members a residue with 
a large side chain typically occupies the homologous position to CtBP Ala123/129 or 
Ser124/Ala130 in the hinge region just outside the coenzyme binding domain. These side 
chains interact with the substrate, as evidenced by the van der Waals analysis, but appear 
not to contribute to differentiation between different α–keto acids as the residues only 
contact the α-keto acid moiety (19). A tyrosine residue occupies the Ala123/129 position 
in three bacterial homologs, using its hydroxyl group for hydrogen bonding with the 
substrate carboxylate of A. aeolicus D-LDH and D-HicDH , or the sulfate ion oxygen in 
the case of L. bulgaricus D-LDH (19-21). In human D2-HDHs, PHGDH and GRHPR, 
similar bulky residue contact occurs with substrate. In GRHPR, Leu107 substitutes for 
CtBP Ser124/Ala130, providing van der Waals contacts to the carboxylate of the 
enzymatic product, D-Glycerate (24). Similarly, in PHGDH Asn106 substitutes for CtBP 
Ser124/Ala130, creating an interaction between the carboxamide nitrogen and a 
carboxylate belonging to a bound malate, an ion utilized in crystallization (25). The 
smaller CtBP residues in this position fail to contact MTOB in both the CtBP1 and 
CtBP2 ternary structures. The CtBP1 Ser124 hydroxyl oxygen and CtBP2 Ala130 methyl 
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group lay 5.7 and 5.6 Å from the MTOB carboxylate respectively. The lack of interaction 
between CtBP Ser124/Ala130 with MTOB may contribute to the 2x102 slower kcat of 
CtBP1 for MTOB compared to rat PHGDH with its endogenous substrate (63, 67).  
The effect of the bulkier residues of GRHPR and PHGDH is to close the active 
site around the substrate, whereas the smaller CtBP residues leave a gap, allowing 
formation of the water network (Figure 3.11A). Both PHGDH Asn106 and GRHPR 
Leu107 side chain approach the active site loop at the residue equivalent to CtBP 
Ser100/106, closing the cavity observed in CtBP. When aligning structures based on the 
well- conserved coenzyme binding domain, the GRHPR Leu107 side chain severely 
clashes with the water network, displacing waters in positions A-C (Figure 3.11B). 
Similarly, the PHGDH Asn106 carboxamide nitrogen situates about 1.5 Å from the water 
A position in CtBP1 (Figure 3.11C). These large residues do not completely destroy the 
water network; rather they restrict the substrate to the active site volume adjacent to the 
catalytic residues (Figure 3.11B,C). Remaining waters are unable to form a complete 
network connecting coenzyme and substrate, instead situating equivalent to water 
positions C or D. 
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Figure 3.11: A small CtBP residue side chain allows formation of the water network.         
(A) Active site cavity surface maps of human D2-DHDs were generated in the absence of 
substrate atoms and aligned to CtBP1 (grey). The CtBP1 cavity surface map (blue 
surface) encapsulates MTOB (cyan) and the water network (red spheres) in one 
contiguous volume. CtBP1 hinge residue S124 fails to contact both MTOB and the active 
site loop, allowing water to fill the gap. (B) Leu107 of human GRHPR (green) closes the 
gap between the hinge and active site loop, closing off the active site volume, indicated 
by the termination of the green volume surface map. Leu107 contacts D-glycerate (red 
dashes) and displaces water positions A-C. One water molecule remains (green sphere) 
roughly equivalent to CtBP1 water position D. (C) PHGDH Asn101 (orange) also closes 
the gap between the hinge and active site loop, capping the active site volume (orange 
surface). The carboxamide nitrogen contacts a malate ion (red dashes), which situates 
approximately where substrate binds. Asn101 displaces waters at positions A and B, but 
leaves room for binding of waters at positions C and D adjacent. 
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DISCUSSION 
Substantial evidence implicates CtBP in the pathogenesis of multiple forms of 
cancer (8, 72, 75, 81, 83, 182). A putative substrate for CtBP’s dehydrogenase activity, 
MTOB, has been shown in two different cancer models to effectively interfere with CtBP 
transcriptional regulation (72, 81). Although high concentrations (mM) of MTOB are 
required, these studies validate CtBP as a therapeutic target. In the colon cancer model, 
MTOB evicted CtBP from its DNA-bound complex, reversing CtBP mediated repression 
of pro-apoptotic factors, thus inducing apoptosis in transformed cells (81). In the breast 
cancer model, CtBP mediated de-differentiation from epithelial to mesenchymal 
phenotype, a metabolic change observed specifically in transformed cells, was reversed 
in MTOB treated cells (72). These studies suggest that pharmacologically targeting CtBP 
would potentially have great benefits in treatment of various malignancies.  
The effects of MTOB in these cancer models provided incentive to initiate the 
drug design process. MTOB was co-crystallized with CtBP1 and CtBP2 to ascertain how 
binding impacts the overall CtBP structure, and to determine the stereochemical features 
of the active site that could be exploited for drug design. Binding of MTOB failed to 
induce a significant overall tertiary or quaternary change in either CtBP1 or CtBP2, thus 
arguing against ligand-linked conformational changes as driving transcriptional 
modulation. Although the mechanism of inhibition remains undetermined, these 
structures provide the groundwork to begin rationally developing new small molecule 
inhibitors, which in turn should aid in understanding modulation of CtBP activity. 
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 Our crystal structures of ternary complexes of MTOB and NAD+ with CtBP1 and 
CtBP2 reveal minor differences in the active sites of the two enzymes that do not appear 
to preclude development of a single inhibitor for both enzymes. The observed differences 
in MTOB binding between the structures derive primarily from the flexibility of CtBP1 
Arg97 relative to the homologous CtBP2 Arg103 residue. The MTOB α-keto acid group 
in CtBP2 forms hydrogen bonds and van der Waals contacts similar to other D2-DHDs, 
where as the CtBP1 network has distinctions. CtBP2 Arg103, whose conformation is 
similar in the binary and ternary complexes, remains outside of hydrogen bonding 
distance of the MTOB carboxylate, leaving space for the MTOB C9 atom to orient 
towards the Arg 103 guanidinium. In contrast, CtBP1 Arg97 attains distinct 
conformations in different crystal structures, exhibiting plasticity to interact with the 
specific ion or substrate occupying the active site. Movement of the Arg97 guanidinium 
group in the CtBP1 MTOB complex increases contact with the MTOB, apparently 
stabilizing the distinct carboxylate orientation relative to MTOB bound CtBP2. The 
change in carboxylate orientation disrupts some of the hydrogen bonds observed in 
CtBP2, but compensates through an additional hydrogen bond, van der Waals, and 
coulombic interactions with Arg97. Simultaneously, CtBP1 Arg97 movement causes 
minor clashes with MTOB C9, resulting in possible multiple conformations (Figure 
3.5C,D). Overall, the plasticity of Arg97 in CtBP1 relative to Arg103 in CtBP2 is not 
likely to preclude future inhibitors from binding both enzymes, as conformation of Arg97 
in the binary complex closely resembles the CtBP2 position. Thus, small molecules 
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binding the CtBP2 active site may simply induce Arg97 in CtBP1 to assume the CtBP2 
conformation.  
Although the various CtBP structures fail to provide definitive reasons for the 
mobility of Arg97 in CtBP1, the plasticity is not expected to drastically affect drug 
design. The main difference between the CtBP1 and CtBP2 structures that may influence 
Arg97 mobility originates from sequence variation at a residue, CtBP1 Ile105 (CtBP2 
Val111), which packs on the interior of the protein adjacent to the Arg97 (Arg103) side 
chain. The substitution of Val111 in CtBP2 diminishes contact with the Arg97/103 side 
chain. The change in packing with the larger CtBP1 isoleucine residue however, does not 
force Arg97 to shift relative to CtBP2, as evidenced by the ability of Arg97 in the CtBP1 
binary complex to assume a similar position to the CtBP2 Arg103 (Figure 3.8A, C). The 
similarity of the CtBP1 binary Arg97 and CtBP2 ternary structure, suggests other ligands 
and small molecules designed to bind the active site will simply induce CtBP1 Arg97 to 
adopt a conformation nearly identical to CtBP2 Arg103, thereby making binding 
conformation identical between the proteins. 
 CtBP1 Trp318 and CtBP2 Trp324, which line the active site, provide an extensive 
surface in each active site that is capable of accommodating a large moiety attached to an 
α-keto acid. In the ternary complexes, extensive interactions with Trp318/324 appear to 
contribute to the preference for MTOB over other substrates. These interactions include 
the packing of the MTOB sulfur atom (S8) against Trp318/324, which is reminiscent of 
sulfur-aromatic interactions identified through studies of protein and small molecule 
structures (194-196). The significant decrease in enzymatic efficiency when replacing the 
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sulfur with a methylene carbon (63) argues that the observed sulfur-aromatic interaction 
contributes to the specificity of CtBP for MTOB.   The extensive aromatic surface 
formed by Trp318/324 represents an opportunity for inhibitor design.  This surface is a 
characteristic not shared by other D2-HDH family members (Figure 3.1) and, thus, could 
be exploited for designing high affinity and specificity inhibitors to bind into the active 
site of CtBP.  
A second important CtBP active site characteristic, a unique water filled cavity, 
would impart specificity on inhibitors designed fill the cavity. Other D2-HDHs have a 
bulky residue that forms stabilizing contacts with the substrate, isolating the active site. 
CtBP1 and CtBP2 however, possess a Ser (124) and Ala (130) at the homologous 
position, respectively, which do not contact the substrate and leave a gap in the active site 
wall that spills into another cavity. The water network that fills this extra cavity in CtBP1 
(and presumably CtBP2) provides an opportunity to develop small molecules that bind 
with higher affinity and specificity. By displacing the water network with inhibitor atoms, 
additional contacts with CtBP will increase affinity while simultaneously reducing cross 
reactivity with other D2-HDHs that lack this cavity. Of course, increasing inhibitor 
affinity is contingent on the sum of new inhibitor interaction energies and entropic gains 
of water release being sufficient to offset the penalty of breaking the water network 
hydrogen bonds. If the water network can be displaced, the potential exists to eventually 
synthesize molecules that bind not only in the MTOB binding site and adjoining cavity, 
but also connects to moieties that take advantage at the NAD(H) binding site, greatly 
increasing inhibitor affinity, while maintaining CtBP specificity.   
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 The goal of our ternary MTOB/NAD+/CtBP structure determination was to obtain 
insights into the mechanism of inhibition and to determine detailed interactions that may 
facilitate inhibitor design. Given the lack of structural changes upon MTOB binding, 
mechanisms other than quaternary and tertiary rearrangements must underlie inhibition, 
perhaps involving substrate turnover and NAD+ release, or altered coenzyme affinity. 
Any mechanism affecting coenzyme binding may effectively inhibit CtBP transcriptional 
modulation by disrupting dimerization. The detailed active site interactions described 
here provide a framework for inhibitor design. Two key features, the extensive 
interactions with Trp318/324 and a hydrophilic active site channel, may be particularly 
useful to exploit for inhibitor design, as they are unique to CtBP. Thus, the results 
presented here provide a first step guide design of highly specific inhibitors of CtBP that 
could become therapeutically valuable.  
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CHAPTER IV 
Structure-Guided Design of CtBP Inhibitors 
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INTRODUCTION 
CtBP represses transcription of a variety of genes involved in prevention of 
cancer formation. CtBP targeting of pro-apoptotic factors (81), cellular adhesion 
molecules (66), and tumor suppressors (71) facilitates progression from normal cellular 
function to malignancy. More broadly, CtBP appears to target thousands of genes for 
repression or activation, allowing epigenetic modulation of the metabolic state of a cell, 
including the epithelial to mesenchymal transition, a hallmark of cancer progression and 
invasiveness (72).  
Two recent independent studies have demonstrated the potential, to 
pharmacologically target the role of CtBP in specific malignancies. These studies 
identified the role of CtBP in colon and breast cancer, and the ability of high levels of 
substrate, MTOB, to repress CtBP function (72, 81). However, MTOB treatment alone 
would be infeasible, due to the millimolar concentration required to abrogate CtBP 
function.  
The impetus provided by the link between MTOB and CtBP inhibition, and the 
prospect of pharmacologically targeting CtBP to treat cancer, drove us to determine the 
structure of both CtBP1 and CtBP2 in complex with MTOB and cofactor NAD+. These 
structures revealed unique characteristics of the CtBP active site, including a hydrated 
cavity not present in other related human proteins. By utilizing specific residue contacts, 
and the unique active site cavity, inhibitors that would improve on MTOB mediated CtBP 
inhibition may be identified or designed. 
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This chapter focuses on attempts to identify and characterize small molecule 
inhibitors of CtBP that will provide the groundwork for future structure based drug 
design. First, readily available α-keto acid compounds that would replicate and enhance 
the critical contacts observed in the CtBP structure were identified. These compounds 
were then screened by in silico docking to the CtBP1 active site to narrow down the 
number of compounds to test experimentally. Compounds that were predicted to bind 
similarly to MTOB were then subjected to co-crystallization trials with CtBP1 and 
binding affinity measurements with CtBP2. This approach allowed us to overcome the 
weak affinity of MTOB and identify substantially tighter binding compounds through 
structure-guided design combined with a bit of serendipity. Our best inhibitor, the tightest 
binder identified to date, will prove essential to the future progress in targeting CtBP for 
inhibition to treat cancer. 
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MATERIALS AND METHODS 
CtBP constructs, expression, and purification 
The constructs, expression, and purification were identical to those methods 
employed in Chapter III with the exception of the CtBP1 construct. A CtBP1 Q301A 
mutation was introduced to optimize lattice contacts. 
Crystallization: CtBP1 
Protein was thawed, and spin filtered in a Spin-X (Corning) column for 5 min at 
4°C. Ligands were dissolved in stock solutions, neutralized by 20 mM Tris pH 7.5. 
Inhibitor was added at a 50 molar excess to protein. The solution was then mixed 1:1 
with crystallization buffer. Previous CtBP1 crystals were frequently damaged during 
cryoprotection. New screening resulted in successful crystallization in buffers containing 
75-300 mM magnesium chloride or calcium chloride, 100 mM Hepes pH 7.5, 2.5 mM 
NAD+, and 10-40% PEG 400. Crystals grown in buffer containing greater than 20% PEG 
400 were harvested and immediately flash frozen. Crystals grown in lower PEG 400 
concentrations were transferred to higher PEG 400 concentrations for cryoprotection. 
Data collection and structure solution 
The CtBP1/NADH/Mandelic Acid complex diffraction data were collected on 
GM/CA CAT 23-ID-B beamline, at the Advanced Photon Source. Data for the 
CtBP1/NADH/2-hydroxyimino-3-phenyl propanoic acid complex were collected on a 
home source MicroMax007-HF/Saturn 944 CCD detector X-ray diffraction system. 
Model building and refinement were performed as in Chapter 2, utilizing Coot and the 
PHENIX software suite (187, 188). 
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Distance difference matrix plots 
Distance difference matrix plots were constructed as described in Chapter III. 
Docking 
 Docking experiments were performed using the Schrödinger Suite Glide program. 
Briefly, hydrogens were added, atom charges and protonation were calculated, and 
minimization was performed on the CtBP1-MTOB complex using the Protein Prepwizard 
(189, 190). MTOB was removed, and a docking grid was created around the CtBP1 
active site. Ligand charges and stereochemistries were processed in LigPrep (197). 
Ligands were then docked into the rigid receptor using Glide (198-201). Docked ligands 
were minimized and scored. 
Hydrogen bond determination 
 Hydrogen bonds were calculated as described in Chapter III. 
Isothermal titration calorimetry 
 ITC experiments were performed on the ITC200 (GE). Purified CtBP2 was 
concentrated to 40-60 µM, and dialyzed overnight into 300 mM sodium chloride, 50 mM 
glycylglycine pH 8.5, 2 mM TCEP, with or without 1.5 mM NAD+. Ligand stocks were 
diluted in dialysate. Experiments were performed at 20°C using twenty 2µL injections 
spaced by 180s. Data were processed in Origin. 
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RESULTS 
Exploiting CtBP - MTOB contacts to identify new inhibitors 
 The stereochemistry and contacts formed by MTOB in the co-crystal structures of 
CtBP1 and 2 aided in identifying new compounds to test for CtBP inhibition. Compounds 
from the Chemical Abstracts Service (CAS) registry chemically similar to MTOB were 
selected and tested in silico for their ability to dock into the CtBP1 active site. Initial 
compounds were selected to include an α-keto or α-hydroxy moiety to maintain favorable 
contacts observed with MTOB and other substrates across the D2-HDH family, with 
catalytic residues Arg266 and His315 and the backbone amides of the substrate binding 
domain active site loop (Figure 3.7). Compounds varied in size and chemical properties 
outside the α-keto acid moiety (Figure 4.1). 
The variable region of the selected molecules contained different moieties 
designed to exploit the largest per residue interaction between MTOB and CtBP at 
Trp318, which dominates MTOB binding (Figure 3.9A). Trp318 is unique among similar 
human D2-HDH family members, thereby conferring specificity for substrate and 
inhibitors. The MTOB sulfur atom (S8) contact with Trp318 appears to ascribe 
specificity over a methylene group, perhaps through a specific sulfur-pi interaction 
commonly observed in protein structures (63, 194, 195). Sulfur atoms were therefore 
incorporated into many of the initial docking candidates. Branched chain compounds 
were also tested for potential interactions and fit of various length and size compounds. 
Finally, compounds containing pi electron systems, including aromatic rings, were also 
tested in an attempt to induce pi interactions. Different length carbon linkers separated 
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Figure 4.1: Compounds docked into the CtBP1 active site. Compounds were chosen to 
mimic the conformation of the MTOB (red box) α-keto acid moiety while enhancing 
interactions with Trp318. Different chemical groups were tested to determine which 
compounds would assume the intended conformation. Sulfur containing compounds were 
chosen to exploit the MTOB sulfur-pi interaction. Branched chain compounds were 
selected for van der Waals/hydrophobic contacts. Alkene and alkyne compounds were 
chosen to induce pi-pi interactions. Finally, aromatic ring compounds were selected to 
maximize pi stacking with Trp318. Compounds with aromatic rings on the terminal 
carbon of two or three carbon chain length α-keto acids consistently had the highest 
docking scores (best predicted energies) and assumed a conformation similar to MTOB. 
Biochemical data indicated phenylpyruvate and a racemic mixture of ± vanillylmandelic 
acid bind the CtBP active site.  Thus phenylpyruvate and D-mandelic acid (D-isomer 
product mimic) were selected for further biochemical and structural characterization. 
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the α-keto moiety core and the pi systems. Although cation-pi interactions were 
considered, the CtBP active site contains two arginine residues and the protonated 
catalytic histidine, suggesting the repulsive forces of an additional cation would likely 
lower affinity of those compounds. See Figure 4.1 for a full list of the initial compounds 
docked into the CtBP1 active site. 
Interpreting docking results 
 The in silico docking of compounds into the CtBP1 active site resulted in 
selection of candidates for further biochemical and structural analysis. MTOB was 
docked into the CtBP1 active site to provide a control for identification of more tightly 
binding compounds. However, in silico docked MTOB failed to adopt the observed 
conformation present in the CtBP1 and 2 crystal structures. Rather, docking orients the 
sulfur atom towards Arg97 instead of positioning it adjacent to Trp318, potentially due to 
poor characterization of the energetic forces involved in sulfur-pi interactions. In this 
conformation, docking favors placement of the MTOB sulfur partial negative charge and 
hydrogen bond accepting lone pair in proximity to the positively charged, hydrogen bond 
donor guanidinium group (Figure 4.2). Docking was able to accurately predict the 
conformation of the MTOB α-keto moiety, providing confidence in the ability to 
accurately dock other compounds despite the inability of the force fields to appropriately 
represent sulfur-pi interactions. Candidate molecules with strong predicted docking 
energies were aligned to the MTOB co-crystal structures to compare the position of the 
α-keto acid moieties. Sulfur containing candidate molecules, similarly to MTOB, were 
biased towards interaction with Arg97. These compounds therefore were allotted more 
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Figure 4.2: Docking software incorrectly docks MTOB. Panels (A) and (B) show the 
conformation and hydrogen bond network (cyan dashes) of MTOB in CtBP1 and CtBP2, 
respectively. The distance of the MTOB sulfur to the Trp318/324 Cε2 and Arg97/103 
NH2 atoms is labeled (yellow dashes).  (C) Docked MTOB has a similar hydrogen bond 
network as the crystal structures, but the sulfur atom is incorrectly positioned. The Glide 
docking software positions the MTOB sulfur atom within hydrogen bonding distance of 
Arg97/103.  Additional docking suggests even when outside the maximum hydrogen 
bond distance, the partial negative character of the sulfur is still oriented towards 
Arg97/103. Because sulfur atoms were preferentially oriented towards Arg97/103 over 
Trp318/324, sulfur-containing compounds were allocated extra docking poses in an 
attempt capture conformations that interacted with Trp318/324.  
Although docking of candidate compounds lacked an MTOB control with which to 
compare binding scores, the conformation of docked molecules still provided useful 
information regarding contacts with Trp318/324 and an overall fit within the active site.  
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final docked conformations to capture those interacting with Trp318, in addition to the 
conformation interacting with Arg97. Molecules with both proper α-keto orientation and 
interaction with Trp318 were selected for co-crystallization and binding analysis. 
Stacking aromatic rings with Trp318 
Compounds with phenyl rings linked to an α-keto (2-oxoacid) moiety assumed a 
conformation in docking simulations similar to that in the MTOB co-crystal structures 
while also stacking the aromatic group with the Trp318 indole. Docking suggested two 
such compounds would have the highest probability of assuming a conformation similar 
to MTOB while stacking with Trp318. These compounds include 2-oxo-2-phenylethanoic 
acid (phenyl ring attached to the smallest possible α-keto acid) and 2-oxo-3-
phenylpropanoic acid (phenylpyruvate; α-keto acid linked to phenyl ring with a single 
methylene carbon) (Figure 4.1). Docking indicated the potential for clashes between 
active site residues and the ligand aromatic ring when two methylene carbons linked the 
phenyl ring to the α-keto acid moiety, as observed in 2-oxo-4-phenylbutanoic acid or 
larger compounds.  
Biochemical data provided the final evidence necessary to choose compounds for 
co-crystallization and binding assays. Phenylpyruvate had previously been established as 
a CtBP1 substrate (63), indicating the compound could bind the active site. A co-crystal 
structure would determine if the ligand’s aromatic ring stacked with the Trp318 indole as 
predicted by docking. Small molecule library screening for CtBP enzymatic inhibition by 
Grossman et al. (results not published) revealed D/L vanillylmandelic acid (VMA), a 
racemic mixture of an α-hydroxy acid similar to 2-oxo-2-phenylethanoic acid, inhibited 
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CtBP, presumably by binding the active site (Figure 4.1). Based on the chemical 
screening results the VMA D-isomer and the D-2-hydroxy-2-phenylethanoic acid (D-
mandelic acid) were docked with CtBP1 (Figure 4.3). The results suggested that even 
with one less methylene carbon separating the α-keto/α-hydroxy group and the phenyl 
ring than phenylpyruvate, stacking may still occur with D-VMA or D-mandelic acid and 
the Trp318 indole. Although a racemic mixture of VMA is commercially available, the 
high cost and lack of enantiomer separation prohibited co-crystallization and binding 
assay development. A single enantiomer of an α-hydroxy acid enzymatic product mimic, 
D-mandelic acid, and phenylpyruvate were both reasonably priced, and therefore 
procured for co-crystallization and binding assays.  
Small molecule CtBP1 co-crystallization and structure 
  Attempts were made to co-crystallize phenylpyruvate and D-mandelic acid with 
CtBP1 due to the typically higher resolution diffraction of this CtBP family member. The 
datasets collected from phenylpyruvate co-crystals failed to process beyond 3.5 Å 
resolution. The electron density in the CtBP1 active site was ambiguous and 
uninformative at this resolution. However, the D-mandelic acid co-crystals diffracted to 
2.5 Å resolution. The active site was clearly bound by D-mandelic acid, with the phenyl 
ring positioned adjacent to Trp318 (Figure 4.4). 
 D-mandelic acid was present in the active site, but the co-crystal structure 
contained serious flaws. Similarly to MTOB, D-mandelic acid failed to fully bind the 
CtBP1 active site, evidenced by the occupancy refining to 68%. The refined 2Fo-Fc maps 
fail to completely encompass D-mandelic acid around a small portion of the phenyl ring  
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Figure 4.3: Candidates chosen for structural and biochemical characterization. 
Docking conformations and hydrogen bond networks (dashes) of candidate molecules are 
shown. (A) and (B) Separate docking conformations of phenylpyruvate (orange) into the 
CtBP1 active site. Docking predicted the α-keto acid moiety would assume a 
conformation similar to MTOB with the phenyl ring would stacking against Trp318. 
Very few conformational differences were observed under different docking conditions. 
(C) and (D) The α-hydroxy moiety of the D-isomer of VMA assumes the expected 
conformation. The aromatic ring interacts with Trp318, although different conformations 
are predicted.  (E) and (F) D-mandelic acid (yellow) is predicted to bind similarly to D-
VMA. Phenylpyruvate and D-mandelic acid were selected for structural and biochemical 
characterization. 
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and carboxylate group (Figure 4.4A-C). The electron density suggests the phenyl ring 
position is correct. However, the same is not true for the accuracy of the carboxylate 
position. Similar to MTOB in the CtBP1 structure, the density around the carboxylate is 
incomplete. Unlike MTOB, every conformation tested contained steric clashes with 
Arg97, Arg266, or an active site water molecule when utilizing the existing density and 
refined B factors (Figure 4.4B). The overall moderate to poor ligand density combined 
with the uncertainty of the carboxylate position prevents detailed analysis of the binding. 
 The position of the D-mandelic acid phenyl ring closely matches the in silico 
docking results, but D-mandelic acid does not appear to strongly bind the CtBP1 active 
site (Figure 4.4C). The plane of the D-mandelic acid phenyl ring positions slightly 
further from the Trp318 indole than the MTOB sulfur atom (Figure 4.4D), but well 
within distances for pi-pi interactions. Despite achieving the intended conformation and 
interaction with Trp318, the occupancy (68%) and poor density suggest D-Mandelic acid 
binding is weak. These results did not lead us to abandon characterization of D-Mandelic 
acid binding, but our priorities shifted to characterization of phenylpyruvate. Docking 
indicates that the additional methylene carbon in phenylpyruvate permits the aromatic 
ring to assume a distinct conformation relative to D-mandelic acid, altering and 
potentially strengthening contacts between the aromatic groups (Figure 4.4E).  
2-Hydroxyimino-3-phenyl propanoic acid 
 While attempting to measure phenylpyruvate binding, and continuing to generate 
new crystals for co-crystal structures, our collaborator Dr. Keith Ellis suggested utilizing 
2-hydroxyimino-3-phenylpropanoic acid (HIPP) to mimic the transition state of  
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Figure 4.4: The 2.5 Å D-mandelic Acid / CtBP1 complex. (A) D-mandelic acid is 
positioned into the 2Fo-Fc density contoured to 1 σ (0.17 e-/Å3) in the CtBP1 active site. 
The density is not high quality, but it is readily apparent that the D-mandelic acid 
aromatic ring interacts with Trp318. (B) The ligand carboxylate cannot be accurately 
modeled. As modeled currently the carboxylate clashes with Arg97 (red disks). Rotation 
of the carboxylate away from Arg97 induces clashes with Arg266 or a crystallographic 
water. Occupancy refined to only 68%. (C) Comparing docked D-mandelic acid (yellow) 
with the crystal structure demonstrates their similarity. However, the docked 
conformation does not satisfy the electron density. (D) The co-structure reveals that the 
aromatic ring stacks with Trp318, similarly to the MTOB sulfur (dark blue, 
MTOB/CtBP2; cyan, MTOB/CtBP1). (E) Docking predicts the additional methylene 
carbon in phenylpyruvate causes a distinct, and potentially stronger interaction with 
Trp318 relative to D-mandelic acid. 
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phenylpyruvate conversion to D-phenyllactate. As previously mentioned, CtBP1 
catalyzes the reduction of phenylpyruvate, but at a lower efficiency than MTOB (63). A 
compound mimicking the transition state could maintain the beneficial contacts between 
the chemical intermediate and CtBP without catalytic turnover and subsequent release of 
the product. HIPP substitutes the reactive α-keto acid carbonyl with a hydroxyimino 
group, preventing catalysis. Co-crystallization and binding affinity studies revealed HIPP 
binds CtBP with high affinity relative to MTOB, but assumes an unexpected 
conformation in the active site. 
CtBP1 HIPP co-crystal structure 
Structure determination 
 Human CtBP1 Q301A (28-353) was crystallized in complex with HIPP and 
NAD+ (Table 4.1). Unlike the active site electron densities for phenylpyruvate and D-
mandelic acid, the HIPP electron density was immediately apparent despite the low 
resolution of the data. The MTOB bound CtBP1 complex served as a search model for 
molecular replacement, providing the initial phases. Identical to the other existing CtBP1 
structures, the HIPP bound CtBP1 complex crystallized in space group P6422, with a 
monomer in the asymmetric unit, with physiological dimers formed across a two fold 
crystallographic axis. The Q301A mutation, introduced to improve a crystal lattice 
contact, did not alter the crystallization or conformation of CtBP1. 
HIPP Quaternary Structure 
 Distance difference matrix plot analysis indicates only small Cα variations exist in 
the HIPP-CtBP1 complex relative to both the binary CtBP1 complex (pdb 1MX3) (10) 
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and MTOB bound CtBP1 (Figure 4.5A,B). The small magnitude suggests these 
differences arise from artifacts of crystallization and the lower resolution of the HIPP 
structure, not from ligand induced changes. HIPP binding, similar to MTOB binding, 
does not induce any significant tertiary or quaternary changes in CtBP1. 
HIPP placement and conformation 
 Difference maps guided the placement of HIPP into the CtBP1 active site, 
revealing an unexpected HIPP conformation. The active site of the initial model 
contained strong Fobs-Fcalc (Fo-Fc) density. The prominence of the HIPP phenyl ring 
density made it immediately apparent that it stacks with Trp318 as intended. However, 
refining the HIPP carboxylate in a position analogous to the MTOB conformation 
resulted in positive and negative Fo-Fc density at different positions in the active site 
(Figure 4.6A). In this conformation, the hydroxyimino group oriented towards His315, 
analogous to the carbonyl of MTOB. However, the HIPP hydroxyimino group (atom O6) 
and carboxylate oxygen (atom O1) sterically clashed with Arg266 and S100 respectively 
(Figure 4.6B). Model building and subsequent refinement never relieved both the steric 
clashes and Fo-Fc peaks. The clashes and difference map peaks therefore suggested HIPP 
assumed a novel conformation, distinct from MTOB. Reorienting both the HIPP 
carboxylate oxygens towards the Arg266 guanidinium, and the hydroxyimino group 
towards the active site loop, satisfied the Fo-Fc peaks and relieved the steric clashes, 
while maintaining the aromatic stacking with Trp318 (Figure 4.6C, D). Importantly, the 
maps and refinement indicate HIPP assumes full occupancy of the active site unlike all 
other liganded CtBP structures. 
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Figure 4.5: The Conformation of the HIPP structure matches the binary and MTOB 
bound CtBP1 structures. Distance difference plot matrix analysis indicates only small 
changes occur upon HIPP binding relative to the CtBP1 binary complex (pdb code 
1MX3) (10). As before, generating symmetry mates created CtBP1dimers. Comparison 
of analogous monomers (subunit 1 and 1’) reveals small changes in the substrate binding 
domain (discontinuous 28-120 and 319-353) relative to the dimerization loop (148-178) 
and a region (205-230) involved in lattice contacts. The same lattice contact showed 
variability when comparing binary and MTOB bound CtBP2 (Figure A.3 purple boxes) 
and when comparing MTOB bound CtBP1 and CtBP2 (Figure A.5 Group 1). When 
viewing the position of subunit 1 to 2’ (or 1’ to 2) the highest positional variation occurs 
in the substrate binding, specifically residues 55-90, relative to one another (red boxes). 
(B) Analysis with the MTOB bound dimer shows the smaller magnitude movements in 
the same regions, suggesting ligand binding alone does not induce this shift.  Likely, the 
differences in crystallization conditions combined with the lower resolution result in the 
movement of substrate binding domains relative to one another.  A higher resolution 
HIPP structure would definitively demonstrate if a significant shift is occurring. 
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Figure 4.6 Positioning HIPP in the CtBP1 active site. (A) The initial HIPP 
conformation (Conf-1, purple) modeled orienting the hydroxyimino group analogous to 
the MTOB carbonyl. The phenyl ring position was immediately clear, as shown in the 
2Fo-Fc density (blue mesh) contoured to 1 σ (0.16 e-/Å3). A water molecule (red sphere) 
was apparent in this active site density. The Fo-Fc map (3 σ; 0.21 e-/Å3) showed both 
positive (green surface) and negative (red surface) density, indicating a need for more and 
less electron density, respectively. (B) Additionally, HIPP carboxylate oxygen O1 and 
hydroxyimino oxygen O6 sterically clash (red disks) with Ser100 and Arg266, 
respectively. (C, D) A new conformation of HIPP was chosen (Conf-2, teal) and placed 
into the Conf-1 active site maps. Conf-2 appeared to satisfy the difference map peaks and  
not possess clashes with active site residue. (E) Refinement of Conf-2 shows a good fit 
into the  2Fo-Fc density, contoured to 0.16 e-/Å3 (blue mesh) and 0.28 e-/Å3 (purple 
surface). (F) As panel C suggests, the Conf-1 Fo-Fc peaks disappear when HIPP is refined 
in the Conf-2 orientation. The remaining peak (present in both structures but omitted 
from panel A) is positive density near Arg97. This density belongs to a water molecule 
that may partially occupy this position, as observed in the binary structure (1MX3) (10).    
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The only remaining active site Fo-Fc peak occurs away from HIPP, adjacent to the 
Arg97 guanidinium (Figure 4.6E). The variability of Arg97 across CtBP1 structures 
suggests small movement of the guanidinium away from the active site, which would 
allow a water molecule or ion binding in the positive Fo-Fc peak, interacting with Arg97 
and His77, but not clashing with HIPP. A water molecule is present at this position in the 
CtBP1 binary complex (pdb code 1MX3), where Arg97 has assumed a conformation 
further outside the active site. Movement of the CtBP1-HIPP complex Arg97 side-chain 
further into the active site to fill the Fo-Fc density would cause collisions with either 
His77 or HIPP.  
After further refinement, an omit map confirmed the novel HIPP conformation. 
The novel HIPP conformation matches very well with the omit map Fo-Fc density, unlike 
the initial HIPP conformation based on MTOB binding (Figure 4.7). Replacing the single 
oxygen atom of the MTOB carbonyl with the two atoms of the hydroxyimino group 
results in a compound that cannot physically situate in the active site analogous to D2-
HDH substrate conformation, and instead adopts an unexpected conformation. HIPP in 
silico docking also results in this novel conformation instead of mimicking substrate or 
product binding, in agreement with the crystallographic finding (Figure 4.8A). 
HIPP interactions and affinity 
HIPP aromatic and coulombic interactions 
 After verifying that HIPP adopts a novel confirmation, computational 
analysis was performed to investigate the changes associated with the new confirmation. 
The HIPP carboxylate orients to maximize coulombic interactions (Figure 4.8B, C). 
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Figure 4.7: The HIPP omit map confirms the novel conformation. An Fo-Fc omit map 
contoured to 0.21 e-/Å3 (green mesh) and 0.30 e-/Å3 (blue surface). (A) Conf-2 (teal) fits 
well within the difference map density.  (B) Conf-1 (purple) does not fit as well, with a 
carboxylate oxygen protruding out of the density. This carboxylate position is the same 
location in Figure 4.6A where the Conf-1 Fo-Fc map indicated the need for less electron 
density. (C) Rotating the view 90° shows how well Conf-2 fits within the density, 
especially at the higher contour level (blue surface). (D) Again, Conf-1 fails to fit as well.  
The omit map helps confirms Conf-2, the novel conformation different from that of 
MTOB, is in fact the actual conformation of HIPP in the CtBP1 active site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 155 
 
 156 
Both carboxylate oxygens align with the Arg266 guanidinium nitrogens. The carboxylate 
oxygens interact with two additional charged active site residues, positioning carboxylate 
oxygen O1 2.7Å from the Arg97 guanidinium and carboxylate oxygen O3 2.9Å from the 
protonated catalytic His315. Beyond the coulombic contacts, HIPP orients its phenyl ring 
to stack with Trp318, capturing the intended pi-stacking interactions despite the alternate 
conformation (Figure 4.8B, D). Thus, the structure suggests very favorable interactions 
with CtBP1 across the entire HIPP molecule.  
HIPP hydrogen bonding 
 The unique conformation of HIPP results in a hydrogen bond network distinct 
from MTOB that utilizes the same active site hydrogen bond donors (Figure 4.9A). 
Catalytic residues His315 and Arg266, as well as substrate binding domain residue G101 
form a network of four bonds with the HIPP carboxylate (O1 and O3). The distinctive 
HIPP conformation positions the imine nitrogen (N5) adjacent to S100, whereas the 
equivalent MTOB O5 carbonyl atom instead hydrogen bonds with His315. S100 can 
form two hydrogen bonds, either from the backbone amide or side chain Oγ, with the 
HIPP imino lone pair. A final hydrogen bond is formed between the HIPP hydroxyl 
group oxygen (O6) and a crystallographic water. Hydrogen bonds in an MTOB-like 
conformation would be weaker, supporting the observed novel confirmation (Figure 
4.9B). 
Water network 
 Larger CtBP inhibitors may displace crystallographically observed active site 
water molecules when they bind CtBP. CtBP contains a unique network of four 
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Figure 4.8: HIPP interactions in the CtBP1 active site. (A) The HIPP co-crystal 
structure (grey protein, teal HIPP) compared to the Glide docking results (magenta). 
HIPP assumes a very similar conformation in both structures, verifying the unexpected 
conformation in the crystal structure. (B) The HIPP phenyl ring closely interacts with the 
Trp318 indole (teal dashes). The negatively charged HIPP carboxylate positions adjacent 
to Arg97, Arg266, and His315, maximizing coulombic interactions (yellow dashes). (C) 
A closer view of the coulombic interactions with the distances between atoms listed (Å). 
(D) A similar view for the aromatic ring interaction with Trp318. A portion of the HIPP 
phenyl ring positions at the minimum van der Waal distance from the Trp318 pyrrole 
group.  The remaining portion of the ring positions slightly further away from the Trp318 
benzene ring. 
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Figure 4.9: The HIPP – CtBP1 hydrogen bond network. (A) The hydrogen bond 
network of HIPP Conf-2 (teal). Hydrogen bonds were calculated as described in the 
Materials and Methods (Chapter III). HIPP forms six hydrogen bonds with CtBP1 
residues, and a seventh hydrogen bond with a crystallographic water. (B) HIPP Conf-1 
(purple) has a less ideal hydrogen bond network. There are four hydrogen bonds to 
CtBP1, and a fifth hydrogen bond with the crystallographic water. The somewhat weaker 
hydrogen bond network for HIPP Conf-1 again suggests HIPP assumes the novel 
conformation (Conf-2).   
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crystallographic water molecules (positions lettered A-D, as discussed in Chapter III). In 
the CtBP1-MTOB complex the waters form a chain connecting the MTOB carboxylate 
(water molecule position A) to the coenzyme nicotinamide phosphate oxygen (water 
molecule position D), threading through a cavity unique to CtBP. This cavity presents a 
unique opportunity for fitting larger, higher affinity, CtBP specific inhibitors at the 
energetic cost of displacing the water network. Previous studies with inhibitors of p38 
alpha MAP kinase (202) and the fungal enzyme scytalone dehydratase (203) successfully 
displaced ordered water molecules to improve inhibitor binding and activity. However, 
other attempts to displace waters resulted in decreasing the inhibitor affinity, as observed 
with an EGFR kinase inhibitor (204), providing an important caveat with this approach.  
HIPP binding alters the CtBP1 water network relative to the binary (10)and 
MTOB bound CtBP1 structures, suggesting water displacement may be a practical 
approach to future inhibitor design. Importantly, the HIPP hydroxyimino group 
completely displaces water from position A (Figure 4.10C). Furthermore, alignment with 
the CtBP2 binary structure monomer G (pdb code 2OME), CtBP1 binary (pdb code 
1MX3), rat CtBP1 (pdb codes 1HKU and 2HU2), and CtBP1-MTOB complexes 
indicates the position of water B has shifted about 1 Å (new position referred to as B’), 
moving the water molecule to a location 2.6 Å from the HIPP hydroxyimino oxygen 
(atom O6). The movement alters the contacts between water at position B’ and the 
protein, relative to position B. Although the water B’ position is unambiguous (Figure 
4.10A, B), even at the low resolution of the HIPP structure, water molecules are not 
observed at positions C and D, similar to the comparably low resolution rat CtBP1 
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structure (205) (pdb code 2HU2). Interestingly, water molecules in the B’ position may 
interfere with water molecule binding at position C. Alignment of the HIPP structure to 
the CtBP1 structures containing full water networks indicates the distance between water 
positions B and C decreases from 2.9 Å to 2.4-2.6 Å upon shifting the water molecule to 
the B’ position (Figure 4.10C, D). Hence, HIPP binding displaced water at position A, 
and shifted the water molecule B into a position where it would displace or modify the 
position of water molecule C. These results imply the CtBP water network, or portions of 
the network, may be displaced by inhibitor moieties without an excessive energetic 
penalty. Successful displacement by newer inhibitors will require the sum of gaining new 
inhibitor contacts and entropically favored release of the waters offsetting the hydrogen 
bonds lost by the waters.  
Experimental analysis of MTOB, phenylpyruvate, and HIPP binding affinity 
 Binding experiments were conducted first with MTOB and phenylpyruvate and 
finally with HIPP to determine their affinity for CtBP.  The CtBP2 construct utilized for 
co-crystallization with MTOB possessed higher solubility than the CtBP1 construct and, 
thus, was used for isothermal titration calorimetry (ITC) experiments. An extensive 
survey of conditions for an ITC compatible buffer in which CtBP2 was stable eventually 
led to some success in determining the binding affinity for each small molecule tested. 
 The weak affinity of MTOB for CtBP2 caused difficulties in the experimental 
design. Typical successful ITC experiments require high affinity and solubility of 
reactants, which result in a sigmoidal binding isotherm when kcal/mol of injectant 
(ligand) is plotted versus the molar ratio of ligand to total protein concentration. The  
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Figure 4.10: The effect of HIPP on the CtBP water network. (A) The 2Fo-Fc density 
contoured to 1 σ (0.16 e-/Å3) shows a water molecule forming hydrogen bonds (teal 
dashes; distances in Å) with the backbone carbonyl of Val120, and the HIPP. (B) The Fo-
Fc omit map contoured to 3 σ (0.21 e-/Å3) confirms the presence of a water molecule. (C) 
Shown are full CtBP1 water networks (positions A through D) in MTOB – CtBP1 
(white), binary CtBP1 (blue, pdb 1MX3) (10), and rat CtBP1 (orange, pdb 1HKU) (39) 
against the surface of CtBP1 (grey). The partial network (molecules A and B) is included 
from another rat CtBP1 structure (yellow, pdb 2HU2) (44). CtBP2 waters were omitted 
for clarity. The HIPP – CtBP1 hydroxyimino group displaces the water at position A, and 
shifts water molecule B (teal) into a new position, labeled B’. (D) A closer view of the 
MTOB – CtBP1 network (white) and the HIPP – CtBP1 water (distances indicated in Å). 
Position B’ shifted about 1 Å from position B (yellow line), forming a short hydrogen 
bond with the HIPP. The proximity of position B’ to C may shift or displace water 
molecule C.  HIPP – CtBP1 water molecules C and D were not modeled due to their 
absence or the structure’s low resolution. 
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c value, defined as c = n[M](1/Kd) where n is the number of binding sites or binding 
stoichiometry, [M] is the total protein concentration, and Kd is the dissociation constant, 
helps define the quality of the sigmoidal isotherm. Typically a value of 10 ≤ c ≤ 500 
results in a curve where one can accurately fit ΔH, Kd, and n (206). However, in the case 
of low affinity binding (c < 1), the three parameters cannot be fit as the curve appears 
nearly flat in the typical window of zero to two or three molar equivalents of ligand 
relative to protein. Extending the molar ratio window, by injecting higher concentrations 
of ligand (molar ratio window increased to ~30 equivalents), results in a hyperbolic curve 
where ΔH and the Kd can be fit, but only when n is fixed (206, 207). However, if n is 
known, and the protein and ligand concentrations are accurate, the binding affinity can be 
confidently determined. MTOB affinity, due to the low signal upon binding, was 
measured through the low-c value approach, fixing n = 1 during curve fitting. The 
resulting Kd was calculated to be 2.38 ± 0.09 mM, confirming that MTOB only weakly 
binds CtBP (Figure 4.11).   
 Binding affinity of phenylpyruvate with CtBP2 was stronger than MTOB, but still 
relatively weak. Typical experimental ITC setup and processing resulted in a Kd of 
approximately 80 µM (Figure 4.11). Only an approximation is used here because this 
value was calculated from a single experiment with buffer conditions distinct from 
MTOB, and without having a proper ligand heat of dilution control. These experiments 
have not yet been successful due to low active protein concentration in the most recent 
attempts. The low c value (c = 1.8) indicates the curve is outside the optimal binding 
range. However, the obvious stronger binding signal relative to MTOB suggests phenyl 
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group resulted in a significant gain of affinity demonstrating our approach of aromatic 
ring stacking with Trp318 would be successful.  
With full HIPP occupancy in the CtBP1 active site, not observed with either 
MTOB or D-mandelic acid, we expected a high HIPP affinity for CtBP2. ITC trials 
immediately yielded results showing HIPP indeed binds much more tightly to CtBP2 than 
MTOB or phenylpyruvate. In buffer containing 1.5 mM NAD+, where CtBP2 is 
presumed to be dimeric, the HIPP Kd was measured at 1.12 ± 0.13 µM. In buffer without 
NAD+ the Kd was determined to be 0.93 ± 0.05 µM (Figure 4.11). These values denote 
an improvement in affinity of greater than three orders of magnitude over MTOB 
(identical conditions to the NAD+ free binding experiment), and an approximately 80-
fold increase in affinity relative to phenylpyruvate. MTOB binding appears enthalpically 
driven, with an unfavorable entropic contribution to the free energy. Favorable enthalpic 
and entropic interactions contribute to HIPP binding free energy, although entropic 
interactions dominate binding. The shift towards entropic binding suggests the release of 
ordered water molecules from the hydrophobic surfaces of HIPP, as well as release of 
solvent molecules from the CtBP active site. 
Despite the tight binding of HIPP, the oligomeric state of CtBP2 in these 
conditions needs to be verified in future trials. The protein used in these experiments was 
either largely inactive, or substantial negative cooperativity is present, as indicated by a 
molar ratio close to n = 0.5 before adjusting it to n = 1 (1:1 binding). The low molar ratio 
was observed in every trial, even those without NAD+ where CtBP2 should be 
monomeric and, therefore, unlikely to exhibit any cooperativity, negative or positive. 
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Figure 4.11: HIPP affinity for CtBP2 is higher than phenylpyruvate or MTOB. 
Isotherms from ITC experiments performed with MTOB, phenylpyruvate, and HIPP. The 
weak binding of MTOB (low c value) necessitated using a large molar excess of ligand. 
The molar ratio was fixed to n = 1 during curve fitting. The phenylpyruvate experiment 
was performed in different buffer conditions than the other experiments. The experiment 
lacked a heat of dilution control for the phenylpyruvate. Three separate experiments were 
performed with HIPP, without NAD+ in the buffer. Protein and buffer were supplemented 
with NAD+ during dialysis, and binding of HIPP was measured in four separate trials. 
The low molar ratio of the MTOB and HIPP experiments was treated as a result of 
inactive protein. Active protein concentrations were recalculated in the HIPP experiments 
so that n = 1.  
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Assuming negative cooperativity is not occurring, the low molar ratio would simply 
indicate the protein sample, which had previously been subjected to freeze thaw cycles 
and dialysis into multiple conditions, was roughly 50% inactive. This is the likely 
explanation given the following: (1) HIPP fully occupied the active site in the CtBP1 
crystal structure, demonstrating both sites on a dimer can simultaneously be loaded with 
ligand; (2) A second binding event was never observed with different concentrations of 
HIPP; (3) The phenylpyruvate binding experiment, conducted with a different batch of 
purified protein, had a molar ratio of close to n = 1. Although a reduced activity of the 
protein is the likely explanation, the possibility exists that if a significant population of 
CtBP2 was able to dimerize in the absence of NAD+, and negative cooperativity was 
occurring, then the molar ratio would be n = 0.5. Residual NADH from purification, or 
concentration dependent oligomerization could account for an unexpected oligomeric 
state. However, CtBP is incubated with pyruvate during purification to convert NADH to 
the weaker binding NAD+. When done properly, this protocol removes NADH from 
CtBP (26). Regardless of the explanation for the low molar ratio, the measured affinity 
constant should remain virtually unchanged. The Kd does not change whether the curve is 
fit to n = 0.5 with fully active protein, or the protein concentration is adjusted so n = 1.  
Even if only half of the protein were active, this would be enough to accurately measure 
the Kd. Repeating binding will therefore only serve to rule out cooperativity.  
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DISCUSSION 
 The co-crystal structures of MTOB bound CtBP1 and CtBP2 proved instrumental 
for identifying higher affinity molecules that target the CtBP active site. We identified 
compounds predicted to interact with active site residue Trp318/324 while maintaining 
the contacts observed between the MTOB α-keto acid moiety and CtBP. The interaction 
with Trp318/324 would also confer specificity to any inhibitor minimizing cross 
reactivity with related human D2-HDH family members, GRHPR and PHGDH. Residues 
homologous to Trp318/324 in GRHPR and PHGDH are hydrophilic and positively 
charged, respectively, which contribute to substrate specificity. GRHPR hydrophilic 
residues would likely deter binding with hydrophobic/aromatic groups chosen to interact 
with Trp318/324. Although GRHPR residues could potentially form favorable cation-pi 
interactions, the multiple arginine residues designed to stabilize the natural substrate’s 
phosphate group would likely cause some repulsion with an aromatic group if positioned 
near the edge of the ring. 
The two molecules that seemed to best fit the desired criteria were phenylpyruvate 
and D-mandelic acid. Phenylpyruvate, a proven substrate (63), and D-mandelic acid, an 
enzymatic product mimic identified through a small molecule library screen, would 
potentially stack their aromatic rings with the Trp318/324 indole. The differing length 
between their α-keto/α-hydroxy acid “core” and the phenyl ring would help identify the 
ideal compound for further development. Co-crystallization with D-mandelic acid 
demonstrated the phenyl ring did indeed interact with Trp318/324 as predicted. However, 
D-mandelic acid failed to fully occupy the active site, and the electron density was too 
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poor to confidently model the carboxylate group, suggesting weaker than desired binding. 
The docked phenylpyruvate structure implied the aromatic ring would likely assume a 
distinct conformation relative to D-mandelic acid, possibly strengthening the interaction 
with Trp318/324. 
 While attempts continued to structurally and biochemically characterize 
phenylpyruvate binding, we began examining binding of 2-hydroxyimino-3-
phenylpropionic acid (HIPP); a molecule that would mimic the transition state of 
catalytic conversion from phenylpyruvate to D-phenyllactate. Although this molecule 
was intended to mimic the conformation of the transition state within the CtBP active 
site, the additional volume of the HIPP hydroxyimino group, relative to the typical 
substrate carbonyl, forced HIPP to adopt an unexpected conformation distinct from any 
bound substrate in the D2-HDH family. Despite the unexpected conformation of the 
carboxylate and hydroxyimino group, the HIPP aromatic ring remained in a position to 
interact with Trp318 indole. 
 Experimental measures of the affinity of MTOB, phenylpyruvate, and HIPP 
proved that increasing interactions with Trp318/324 drastically increased ligand affinity. 
Phenylpyruvate affinity improved roughly 30-fold relative to the millimolar dissociation 
constant of MTOB. HIPP binding increased more considerably, with an affinity roughly 
2000-fold stronger than MTOB. The Kd values correspond very well with unpublished 
enzymatic CtBP-HIPP KI data measured by Grossman et al. Although the unique 
conformation of HIPP relative to phenylpyruvate most likely drives the difference in 
affinity, it is unclear why MTOB, D-mandelic acid, or any other substrate would not 
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assume the alternative confirmation as well. Utilizing ITC displacement assays (208), a 
more accurate affinity and thermodynamic profile will be measured for MTOB, 
phenylpyruvate, and D-mandelic acid. 
 HIPP binding also altered the CtBP water network, suggesting that displacing the 
water molecules with inhibitor moieties could improve future inhibitor binding. The 
HIPP hydroxyimino group completely displaces a water molecule (position A) found in 
other CtBP structures. The hydroxyimino group also shifts the position of the second 
water molecule in the network (position B), forming a hydrogen bond with HIPP.  
Movement of water molecule B away from the position observed in the other CtBP 
structures implies future inhibitor moieties may be able to displace it completely without 
an excessive energetic penalty. Water molecules at positions C and D were not observed 
in the HIPP structure, possibly due to the low resolution of the crystallographic analysis. 
The shift in water molecule B position places it in a position that would likely cause a 
shift or complete displacement of a water molecule at position C. If the water network 
can be displaced, new inhibitors can be produced that not only bind in the MTOB binding 
site and adjoining cavity, but also connect to moieties that take advantage at the NAD(H) 
binding site. This strategy would increase inhibitor affinity and maintain CtBP 
specificity, while competing for NADH binding, thus disrupting CtBP dimerization.  
As the process of identifying and designing tighter binding, CtBP specific 
molecules continues, many questions still remain with regards to the mechanism behind 
MTOB mediated CtBP inhibition. Ligand binding to CtBP, including MTOB, fails to 
induce any large conformational changes, ruling it out as a mechanism of inhibition. A 
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full discussion regarding the possible mechanism of MTOB mediated inhibition and its 
impact on future inhibitor design is presented in Chapter V.  
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Chapter V 
Discussion 
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Implications from CtBP co-crystal structures 
The results reported in this dissertation provide the framework for the structure 
based design and development of potent inhibitors to pharmacologically target CtBP 
function in cancer. The first goal along the path to improving CtBP inhibition was to 
structurally characterize substrate MTOB binding to CtBP in order to gain insights into 
the mechanism of inhibition, as well as analyze specific contacts that may be exploited in 
inhibitor design. As described in Chapter III, we succeeded in co-crystallizing MTOB 
with both CtBP family members. Our original hypothesis of MTOB induced 
conformational change proved to be incorrect as there was no significant difference in 
conformation between the MTOB bound and unbound structures (Figure 3.2C and Figure 
A.3).  
Our current hypothesis regarding the inhibition mechanism of MTOB is that 
enzymatic turnover of MTOB, which oxidizes NADH to NAD+, drives inhibition of CtBP 
transcriptional regulation. Coenzyme binding induces dimerization (27), a change in 
oligomeric state necessary for most of CtBP’s transcriptional regulation functions (15, 
29). By preferentially binding NADH over NAD+ (26) CtBP acts as a redox sensor, 
activating transcriptional regulatory functions when changes in a cell’s metabolic state 
perturbs the NADH/NAD+ ratio (28, 30). Catalysis oxidizes NADH, converting it to 
NAD+, potentially leading to dissociation as coenzyme affinity decreases 100 fold upon 
oxidation (26). Upon coenzyme dissociation, the CtBP dimer would also dissociate, 
disrupting CtBP transcriptional regulatory function. MTOB may therefore sabotage CtBP 
redox sensing ability, inhibiting CtBP oligomerization and blocking complex formation. 
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The interactions of MTOB with CtBP highlight important features of the active 
site. The α-keto acid moiety assumed a conformation similar to other D2-HDH family 
member substrates (20, 21, 24). The remaining MTOB atoms, which confer an 80-fold 
increase in substrate turnover relative to pyruvate (63), contact a number of active site 
residues, with the largest interaction occurring with Trp318/324. This side chain is unique 
among human D2-HDH family members, suggesting that targeting the active site 
tryptophan may confer specificity to CtBP. 
A second key structural feature of CtBP is a water filled cavity adjoining the 
active site. Previous CtBP structures (10, 39, 44, 90) contain a portion or full network of 
four water molecules filling this cavity. It was not until co-crystallization with MTOB 
that we realized that this cavity and water network was exclusive to CtBP. Other D2-
HDH family members possess a large amino acid that severs the continuity of the cavity 
volume by capping the active site and contacting the substrate (Figure 5.1). In the MTOB 
– CtBP1 complex the four water molecules form a network that bridges MTOB with an 
NAD+ phosphate. This observation spawned the idea of incorporating the cavity and, 
eventually, NAD(H) moieties into inhibitor design.  
 After achieving our first goal, we utilized the CtBP co-structures to identify and 
design new molecules that would more strongly bind the CtBP active site, forming the 
intended critical contacts observed in MTOB. As described in Chapter IV, our focus 
quickly led to α-keto/α-hydroxy acid compounds with aromatic rings, selected to 
maximize the interaction with Trp318/324. The critical variable in these initial 
compounds was the length of the carbon linker between the carbonyl/hydroxyl C2 carbon 
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Figure 5.1: The unique cavity in the CtBP active site will provide specificity for 
inhibitors. (A) The active site cavity and NAD(H) binding site represented by a surface 
map (blue) generated by the Sitemap program (209-211). MTOB (cyan), NAD+ (yellow), 
and the water network (red spheres) are shown within the cavity. Panels (B) and (C) show 
alignment with the GRHPR and PHGDH active sites and coenzyme binding pockets 
(green and orange surface respectively). The CtBP water network cavity does not exist in 
the either protein (discussed in Chapter III), providing specificity for inhibitors designed 
to fill this volume. 
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and the aromatic group. Our first co-structure, with D-mandelic acid achieved the 
intended interaction with Trp318/324 but with less occupancy and less than ideal 
aromatic packing. Our focus continued with phenylpyruvate, a compound with an 
additional methylene carbon linking the aromatic group to the C2 carbon. Because 
phenylpyruvate is an established CtBP substrate (63), we tested a transition state mimic, 
2-hydroxyimino-3-phenylpropionic acid (HIPP), which substitutes a hydroxyimino group 
for the carbonyl. 
Co-crystallization with CtBP1 and binding affinity studies with CtBP2 revealed that 
HIPP not only binds in an unanticipated conformation (Figure 5.2A, B), but also shows 
vastly increased affinity relative to MTOB (Figure 4.11). The flexibility introduced by 
the extra methylene carbon, relative to D-mandelic acid, allowed the HIPP phenyl ring to 
maintain contact with Trp318 despite the new contacts with other active site residues. 
Initial ITC studies measured the HIPP dissociation constant at about 1 µM. The HIPP 
affinity represents an 80-fold increase over phenylpyruvate binding, and more than three 
orders of magnitude improvement relative to MTOB. Our findings reveal that the phenyl 
ring increases affinity in both phenylpyruvate and HIPP, and that the novel conformation 
of HIPP further strengthens interactions relative to phenylpyruvate. Additionally, HIPP 
appears to have altered the CtBP1 water network, displacing at least one water molecule, 
and shifting the position of a second. These results support our proposed strategy of water 
displacement by inhibitor moieties as a feasible approach to enhance potency and 
specificity in CtBP inhibitor design. 
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Figure 5.2: MTOB and HIPP fill only a small portion of the active site. MTOB and 
HIPP are shown in the CtBP1 active site and water network volume (blue surface) with 
waters (red) and NAD+ (yellow). (A) MTOB from the CtBP1 structure (cyan) and CtBP2 
structure monomer A (orange) positioned in the active site. (B) HIPP (green) compared 
with CtBP1 MTOB (cyan) shows the novel conformation of HIPP. The hydroxyimino 
group positions towards the water network, displacing the first water in the network. 
Future inhibitors will contain additional chemical groups, further occupying the water 
network cavity. Displacing the entire water network would position inhibitor atoms 
adjacent to an NAD+ phosphate. 
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Future directions 
 Next steps in this project involve improving existing data on the HIPP –co-crystal 
structure and re-measuring affinity of weaker binding molecules via ITC. The relatively 
low resolution (3.06 Å) of the initial HIPP – CtBP1 crystal structure limits detailed 
analysis of the binding interactions. Although we have confidence in the placement of 
HIPP in the active site, a higher resolution structure would provide greater accuracy for 
specific contacts and determine the full extent of the changes observed in the HIPP water 
network. Understanding the full impact of HIPP binding on the network will help future 
inhibitor design. Since far fewer crystals were screened to obtain the HIPP-CtBP1 crystal 
structure than those used for the MTOB crystal structures, it is likely that a higher 
resolution diffraction data set can be obtained. Furthermore, despite CtBP2 structures 
typically crystallizing at lower resolution, an HIPP – CtBP2 molecule would determine if 
the HIPP conformation is identical between the CtBP family members.  
 The initial attempts to measure MTOB and phenylpyruvate affinity with ITC were 
deterred by the low affinity. However, the very recent success with HIPP binding 
provides a means to accurately measure binding affinity of MTOB, phenylpyruvate, D-
mandelic acid, and any other low affinity compound. By measuring the change in HIPP 
affinity in the presence of the weaker binding compound (competitive inhibitor), we can 
accurately calculate the affinity and thermodynamics of binding (208). Performing the 
HIPP binding experiments again with fresh protein will have the added benefit of 
recalculating the molar ratio, which was low in the first round of experiments. Although 
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CtBP2 tends to be more soluble, future ITC experiments should be conducted with both 
CtBP1 and CtBP2 to determine any differences between the CtBP proteins. 
Future inhibitor design 
 Our analysis of CtBP with substrates and inhibitors has provided a framework for 
the development of tighter binding inhibitors. In order for such inhibitors to become lead 
compounds for therapeutic agents, these compounds must also interfere with CtBP co-
transcriptional activity. If the hypothesis regarding enzymatic turnover as the mechanism 
for MTOB mediated CtBP inhibition is correct, then only enzymatic substrates can utilize 
this mechanism to inhibit transcriptional regulation. Our inhibitors, which will likely not 
be substrates, would need to act through an inhibitory mechanism distinct from MTOB.  
Given the importance of dimerization in CtBP activity, we surmise that targeting 
dimerization will effectively inhibit CtBP transcriptional activity. Dimerization, which is 
induced by NADH binding (27), is required for CtBP transcriptional regulatory function 
(15, 29). Mutational studies have shown that impeding CtBP dimerization through 
disruption of the dimer interface or NAD(H) binding motif effectively reduces or 
eliminates CtBP transcriptional regulation (10, 18, 212). Small molecule targeting 
NAD(H) binding also inhibited CtBP transcriptional function (213). Therefore, we intend 
to target dimerization with inhibitors designed to compete for NAD(H) binding, 
effectively replicating the mutagenesis and NAD(H) inhibitor studies. 
 Using the HIPP – CtBP1 complex as a guide, the next generation of inhibitors 
will extend into the unique CtBP active site cavity, displacing the water network in the 
hinge region between CtBP domains to gain affinity and specificity. The energy required 
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to displace the water network, and the chemical characteristics of the inhibitor moiety 
will determine if the thermodynamics of new inhibitor binding becomes more or less 
favorable. Currently, we are docking molecules with different chemistry at the imine 
position of HIPP. This includes substitutions with an amine, ether, β-amino acid, or β-
hydroxy acid to maintain the hydrogen bond observed in the HIPP structure between the 
imine lone pair and Ser100. We will also explore removing the hydrogen bond donor 
from this site by replacing it with a methylene carbon (Figure 5.3). All of the different 
chemistries at the HIPP imine position will be linked to various chemical groups 
designed to fill the active site cavity. Among different groups considered, five-atom 
aromatic heterocycles are particularly appealing as their large surface fits snuggly within 
cavity making a number of contacts without creating collisions. Additional groups added 
onto the heterocycles fill the entire water network cavity, positioning near the NAD(H) 
nicotinamide phosphate. Recent computational experiments tested the ability of 
molecules containing different combinations of the above groups to dock into CtBP1 
(Figure 5.3). Many of the resulting compounds had a higher docking score than HIPP 
while maintaining critical contacts at Arg266 and Trp318. The water network cavity 
appears to accommodate these large heterocycles, suggesting various sized chemical 
groups could be synthesized to fit the cavity (Figure 5.4). After exploring the ability of 
these molecules to displace the water network, we will begin addition of chemical groups 
to compete for NAD(H) binding moieties. Before discussing NAD(H) moieties in 
inhibitor design, we consider the effects of NAD(H) binding on domain arrangement and 
CtBP activity. Movement of the CtBP substrate binding domain and coenzyme binding 
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domain relative to one another may have a role in forming transcriptional regulatory 
complexes. The implications of domain movement in CtBP function must be factored 
into inhibitor design strategies to avoid causing activation rather than inhibition by small 
molecules designed to bind the active site and NAD(H) binding pocket. 
The implications of domain movement on inhibitor design 
 Understanding the structural role of coenzyme binding to CtBP activation is 
paramount to the inhibitor design process, as this will impact the ability to develop 
inhibitors capable of disrupting dimerization and co-transcriptional activity. The 
structures of other D2-HDH family members exhibit movement of the substrate and 
coenzyme binding domains relative to one another, representing open and closed forms 
of the enzymes (19, 21, 24). To date, all structures of CtBP are in the closed form (10, 39, 
44, 90, 214). Coenzyme binding has been linked to domain closure, a process that brings 
the substrate and coenzyme binding domains in proximity to form the active site (19, 22). 
Even ligands, or bound ions in the active site may contribute to domain closure and 
stability of the complex (19, 22). The energy barrier between open and closed 
conformation appears small as low energy crystal lattice contacts force some D2-HDH 
structure subunits into open conformations, reducing the ability of coenzyme and 
substrate to bind (19, 21, 22, 24). The current model of binding therefore begins with 
coenzyme and substrate binding to the coenzyme binding domain only of a D2-HDH 
protein in the open conformation. Equilibrium then favors domain closure, stabilized by 
weak electrostatic forces (19, 21). It remains unclear if domain closure is necessary for 
formation of active dimers since roughly 90 % of dimer interface forms between the  
 186 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Recent docking with new compounds. In order to extend the inhibitors into 
the water network cavity, we have begun docking compounds with different chemistries 
into the CtBP active site. This figure serves as an example of the most recent docking 
experiment. Different R groups are attached to the C2 carbon of 3-phenylpropionic acid. 
Many of the new groups introduce chiral centers, allowing sampling of various 
stereochemistries during docking. 
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Figure 5.4: Docked compounds that would displace the water network. Three 
examples of compounds that dock well into the CtBP1 active site. The compounds fill the 
entire water network cavity. Future inhibitors could be expanded to include groups to 
compete with NAD(H) for binding. 
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coenzyme binding domains of dimer subunits (10, 21, 24, 39, 62). However, the role of 
NAD(H) binding in dimerization and domain closure suggests a link between the two, 
such that domain closure may contribute to the stability of the dimer or otherwise impact 
transcriptional regulatory activity.  
Although details of domain movement in CtBP are not yet well understood, 
information from other D2-HDH family members implies that domain movement must 
be factored into future inhibitor designs to avoid making favorable contacts that induce 
domain closure, as this could possibly increase CtBP transcriptional activity. One 
strategy would therefore be to design molecules that solely bind the coenzyme binding 
domain, avoiding formation of any inter-domain contacts. As an alternative strategy, 
inhibitors could be designed to force the domain equilibrium towards the open state, 
taking advantage of the low energy barrier between the open and closed states. The latter 
strategy would actively target known inter-domain contacts for disruption. Maintaining 
CtBP in an open conformation may turn out not to affect transcriptional regulatory 
functions, but we must be aware of the potential for complications caused by domain 
movement to modify inhibitor designs accordingly. Moreover, creating inhibitors that 
favor an open CtBP conformation will provide useful experimental tools for investigating 
the role of domain conformation in cell function and also possibly for structural studies 
with a stabilized open conformation of CtBP. 
To investigate inhibitors that impact dimerization and domain orientation, we will 
add chemical groups to occupy the position of the NAD(H) phosphates. The NAD(H) 
atoms from the phosphates and the adenine moiety only contact the coenzyme binding 
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domain. Building inhibitor groups into the adenine-binding motif should significantly 
increase inhibitor affinity without inducing domain closure. Greater care must be taken 
when designing compounds that situate near the nicotinamide ribose ring, as this region 
contains the NAD(H) contacts bridging the substrate binding domain and coenzyme 
binding domain. Structures of open and closed D-LDH from L. Bulgaricus demonstrate a 
key inter-domain contact is made by coordination of a water by the NAD(H) 
nicotinamide ribose, a conserved substrate binding domain Asp residue, and the amide 
backbone of a coenzyme binding domain residue (19). A similar water coordination is 
present in CtBP. Inhibitors can be designed to avoid or disrupt this coordination, thus 
altering inter-domain contacts.  
The other primary inter-domain contacts involve substrate binding in D2-HDH 
family members. MTOB binds the coenzyme binding domain of CtBP1/CtBP2 through 
catalytic Arg266/272 and His315/321, as well as specificity determinant Trp318/324. 
However, the substrate binding domain residues Gly99/105 and Ser100/106 form 
hydrogen bonds with the MTOB carboxylate, closing the active site (Figure 3.7). 
S100/S106 also forms a single hydrogen bond with the HIPP imine lone pair. Thus the 
substrate bridges the two domains. Future inhibitor designs should minimize contacts 
with the active site loop to avoid facilitating domain closure, while exploiting contacts 
with the coenzyme binding domain residues in the active site. Fortunately, losing 
interaction with the active site loop does not appear to preclude ligand binding to 
coenzyme domain residues (21). Thus a strategy of focusing on coenzyme binding 
domain contacts while avoiding substrate binding domain contacts appears feasible. 
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Conformational change in the CtBP hinge region between domains may affect 
inhibitor binding in the open state. The water network in the unique CtBP active site 
cavity forms contacts with a section of the hinge region (CtBP1 residues 120-125). Our 
proposed strategy involves designing inhibitors to occupy this cavity in order to gain 
specificity for CtBP over other D2-HDH family members. A portion of the hinge region 
changes conformation in D-LDH proteins to create the movement of substrate binding 
domain relative to coenzyme binding domain (19, 21, 24). Inhibitors designed based on 
the closed conformation in the crystal structure may lose some contacts, particularly at 
CtBP 1/CtBP2 Val120/Ile126 and Pro121/127, upon domain opening. In D-LDH, 
movement of these residues affects water molecule coordination between the proline 
residue and an NAD(H) phosphate, equivalent to CtBP water position D (19). As the N-
terminal portion of the hinge shifts, the CtBP cavity would become larger near water 
molecule positions C and D. Fortunately the conformational changes within the hinge are 
smaller in magnitude compared to the movements of the entire substrate binding domain. 
The hinge does not appear to have a large conformational change at key residues that 
convey specificity for CtBP (Ala123/129, Ser124/Ala130). Therefore inhibitors designed 
to bind CtBP would still be unable to bind other D2-HDH family members, even if the 
enzyme is in the open conformation. In summary, some inhibitor contacts may be lost in 
the hinge region upon opening, but moieties in this position should still convey 
specificity. 
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Determining the potency of new inhibitors 
New inhibitors will be designed to enhance affinity by including binding in the 
NAD(H) binding motif, with the eventual goal of disrupting NAD(H) binding and 
dimerization. Improvements in newly designed inhibitors can be monitored in vitro by 
measuring dissociation constants with ITC, changes in CtBP oligomerization, and 
weakening of NAD(H) affinity. As with HIPP, ITC will measure the affinity of an new 
inhibitors for CtBP. Monitoring CtBP oligomerization through size exclusion 
chromatography (27, 215) will measure the efficacy of these newly designed inhibitors to 
block oligomerization in the presence of coenzyme. This assay will determine the 
ultimate effects of inhibitor binding regardless of whether domain movements have an 
effect on CtBP activity. Measuring changes in NAD(H) affinity will provide details on 
the competition between the inhibitor and coenzyme binding to CtBP. To date, we have 
been unable to measure NAD(H) affinity through ITC experiments or replicate NAD(H) 
binding data through Trp318 – NAD(H) FRET experiments (26). Although not critical, 
being able to measure affinity changes of NAD(H) for CtBP would help quantitate the 
effects of inhibitors on NAD(H) binding. 
Concluding remarks 
 The results in this dissertation provide the foundation for developing inhibitors 
designed to pharmacologically target CtBP transcriptional regulatory functions in cancer. 
The benefit of targeting CtBP has become more apparent with each new study linking 
CtBP transcriptional regulatory activity to different types of cancer. Through structural 
studies we have elucidated the stereochemical basis for binding and important features of 
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the active site, facilitating the design of other potential inhibitors. New inhibitor designs 
will undoubtedly advance our understanding of the mechanism of CtBP inhibition on the 
pathway to creating an effective anti-cancer drug. 
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The effects of MTOB binding on CtBP conformation  
As discussed in Chapter III, MTOB binding fails to induce a conformational 
change upon binding CtBP1 or CtBP2. Using distance difference matrix plots we 
carefully compared the MTOB bound CtBP1 and CtBP2 ternary complexes 
(CtBP/NAD+/MTOB) to their respective binary (CtBP/NAD+) structures. Our analysis 
concluded MTOB did not induce significant conformational changes. The first 
comparison between the MTOB bound CtBP1 dimer to the MTOB free (binary) dimer 
(10) revealed no significant differences (Figure 3.2C). The equivalent CtBP2 analysis, 
discussed below, is more involved due to the eight monomers in the asymmetric unit. 
In order to perform a similar analysis for CtBP2, we began by comparing all eight 
chains of the CtBP2 asymmetric unit between the MTOB bound (ternary) and MTOB 
free (binary) (90) complexes. This analysis provided a comparison between equivalent 
chains (A vs. A, etc.), equivalent dimers (AB vs. AB, etc.), and helped gauge the packing 
of the dimers relative to one another (AB position vs. GH position, etc.). The results 
show that the backbone of the individual monomers and dimer pairs does not exhibit any 
large changes (Figure A.1). However, the packing between the four dimer pairs slightly 
changes, resulting in the movement of the entire GH dimer 1-3 Å relative to AB dimer. 
These movements reflect a small reduction of the asymmetric unit volume in the MTOB 
bound CtBP2 structure relative to the binary structure. These packing changes and 
asymmetric unit dimensions may result from sequence differences in the remaining 
unstructured N-terminal tag sequence, or variation of the crystallization conditions 
between binary and ternary complexes. 
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Figure A.1: Comparing the asymmetric unit of the binary CtBP2 structure to the 
ternary structure. For clarity a grid separates individual monomers in the distance 
difference matrix plot. Equivalent monomer comparisons (Binary A vs. Ternary A, etc.) 
follow the diagonal from the origin. Equivalent dimers (AB vs. AB, etc.) are outlined by 
red dashes. Equivalent individual monomers and dimers do not exhibit large variations. 
However, comparing the positions of dimers relative to one another reveals changes in 
positions that culminate with a 1-3 Å shift of dimer GH relative to AB between the binary 
and ternary structures. The slight change in dimeric packing is reflected in a reduction of 
the unit cell dimensions differences of a = -1.6 Å, b = -1.0 Å, and c = -3.1 Å in the 
ternary structure. These packing differences may result from additional remaining N-
terminal tag residues in the ternary complex relative to the binary complex. 
 198 
 
 199 
  After comparing the entire CtBP2 asymmetric unit, we focused on ternary and 
binary CtBP2 dimer pairs to closely examine tertiary and quaternary structure 
differences. Analysis of the four dimers within the binary CtBP2 structure reveals almost 
no changes in Cα position, probably due to strong non-crystallographic symmetry (NCS) 
restraints used during refinement (Figure A.2). Since all binary complex monomers and 
dimer pairs were identical to one another, only the binary complex dimer composed of 
monomers A and B was used for comparison with each of the four MTOB-bound CtBP2 
dimers. The binary to ternary dimer comparisons verify significant Cα variation does not 
occur upon MTOB binding in CtBP2, although Small variations are observed when 
comparing the binary CtBP2 dimer AB with the ternary AB dimer (Figure A.3). The 
dimerization loop (148-178) of the ternary structure has shifted position in both 
monomers A and B relative to the binary structure. Monomer B displays additional small 
variations of coenzyme binding domain residues involved in an interface with monomer 
C (210-230) relative to a portion of substrate binding domain residues. These small 
variations sum to show a slight difference in domain packing of the binary CtBP2 AB 
dimer relative to the ternary AB dimer. MTOB binding however does not appear to be 
responsible for these differences as the remaining ternary dimers (CD, EF, GH) show 
only minute differences to the binary structure (Figure A.3). As there are no consistent 
structural variations across dimers MTOB does not appear to induce changes upon 
binding CtBP2. 
 The individual monomers of the CtBP2 ternary complex were then compared 
against one another to examine conformational differences of the MTOB bound subunits.  
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Figure A.2: The CtBP2 binary complex subunits are identical. Distance difference 
matrix plots show that there are no differences between the individual monomers or 
dimers of the CtBP2 structure. Therefore, CtBP2 binary complex dimer composed of 
monomers A and B was used for comparisons with CtBP2 ternary complex dimers.  
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Figure A.3: MTOB does not induce conformational changes in CtBP2 dimers. 
CtBP2 binary and ternary dimer conformations were compared for Cα differences. The 
individual CtBP2 AB monomeric subunits and dimer display a small variation of Cα 
position. Monomers A and B show differences in the dimerization loop position (blue 
boxes). Monomer B displays additional variation at a crystal interface (purple boxes). 
Comparing Monomer A position relative to Monomer B, the quaternary structure exhibits 
a small shifts in portions of the Monomer B Substrate Binding Domain (orange dashes) 
and Monomer A Coenzyme Binding Domain (green dashes) between binary and ternary 
complexes. The differences in Cα position do not appear to be MTOB induced, as the 
remaining three dimer pairs do not exhibit any of the same shifts. The differences 
observed in monomer C are described in Figure A.4B. 
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The differences observed between individual monomers within the ternary structure 
correspond to the small variation previously observed between binary and ternary CtBP2 
dimers. Hence, there were no new significant changes within the ternary complex 
subunits to report. For the ternary complex analysis, monomer A Cα positions were 
compared directly to all other CtBP2 ternary complex monomers. Although most regions 
of the protein show little variation (Figure A.4A) two regions exhibit variances, with the 
most notable differences occurring at residues 63-66 in monomer C (Figure A.4B) and 
the dimerization loop in multiple monomers (Figure A.4C). The backbone variation at  
residues 63-66 in monomer C, previously observed during comparisons of the binary and 
ternary dimers (dimer CD, Figure A.3), results from a unique ternary structure crystal 
lattice contact between monomer C and monomer H’ of an adjacent asymmetric unit. The 
variability of the dimerization loop also mirrors a difference previously observed between 
binary and ternary (AB) dimers. The magnitude of the loop variation is not a consistent 
value between different monomers with the maximum difference observed between 
monomer A and E. These changes in magnitude suggest inherent dimerization loop 
flexibility causes it to assume a small array of conformations across the ternary structure 
asymmetric unit. Therefore, the observed changes in Cα positions are the result of altered 
crystal packing (monomer C), or flexibility of the dimerization loop conformation 
observed across different monomers. Other than these two regions, no single CtBP2 
ternary complex monomer differs greatly from another, permitting accurate structural 
analysis across MTOB bound monomers. 
 205 
 Our final analysis of conformational differences was compared MTOB bound 
CtBP1 and MTOB bound CtBP2. Consistent with the very high degree of homology of 
the recombinant constructs, limited differences exist between MTOB bound CtBP1 and 
CtBP2 monomers. The first small differences observed occur at CtBP2 Gln214 (CtBP1 
Ser208) where sequence variation in the dehydrogenase domain impacts lattice contacts 
(Figure A.5A, B). Sequence variation at the C-terminus, CtBP2 Arg354  (CtBP1 
Lys348), alters the side chain packing of the complementary surface of the 
Gln214/Ser208 lattice contact, facilitating the observed Cα shift. A second difference, 
observed at CtBP2 residues 48 and 54-55 results from similar sequence variation and 
crystal packing (Figure A.5A, B). Although the sequence varies (CtBP2 Leu54; CtBP1 
Val48), the greater impact on Cα position arises from a unique CtBP1 lattice contact 
involving these residues, for which there is no equivalent contact in the CtBP2 lattice. A 
third difference, limited to comparisons with monomer C, arises from a unique lattice 
contact conformation found only with ternary complex monomer C, and an adjacent 
asymmetric unit monomer H’. This is the same unique CtBP2 monomer C lattice contact 
responsible for the differences between CtBP2 structures in Figure A.3 and A.4B. 
Finally, because the dimerization loop changes position across different CtBP2 
monomers (see Figure A.3), the same difference appears in comparisons of those CtBP2 
monomers with CtBP1 (Figure A.5C).  
The distance difference matrix plot comparisons demonstrate that all the CtBP 
structures, regardless of the presence of MTOB, are essentially equivalent. The 
differences that are observed are the result of lattice contacts, sequence variation, and 
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backbone flexibility unrelated to MTOB binding. With no apparent conformational 
change upon MTOB binding, the mechanism of MTOB mediated CtBP inhibition 
remains unclear.  
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Figure A.4: The range of small differences between individual CtBP2 ternary 
structure monomers. (A) CtBP2 monomer A Cα position plotted against CtBP2 
monomer H reveals no large variations occur between some of the subunits. (B) 
monomer A compared to monomer C reveals residues 63-66 show a sharp change in Cα 
position. A unique crystal lattice contact between monomer C and monomer H’ of an 
adjacent asymmetric unit causes this variation compared to any other CtBP1 or CtBP2 
monomer. (C) Variation between monomer A and monomer E shows the maximum 
differences observed in the “dimerization loop” (148-178) between subunits. Other 
CtBP2 monomers display varying patterns of dimerization loop movement relative to 
Monomers A and E, indicating the loop is flexible. 
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Figure A.5: Comparing MTOB bound CtBP1 and CtBP2 structures. For consistency, 
the same CtBP2 monomers in Figure A.4 are also used here. (A) The variance between 
CtBP2 Monomer C Cα position compared to CtBP1 (CtBP2 residue numbering) occurs at 
residue 214 and the extreme C-terminus (Group 1), residues 48 and 54-55 (Group 2), and 
residues involved a unique Monomer C lattice contact at residues 63-66 (Group 3). 
Sequence variation between CtBP1 and 2 (Q214S and R354K) results in Group 1 
variation at a common lattice contact. Sequence variation (L54V) and a CtBP1 specific 
lattice contact causes Group 2 differences. See Figure 3.4 for an explanation of variation 
at Group 3. (B) The magnitude of Group 1 and 2 variation differs across CtBP2 
monomers, seen here by a reduction in variation observed between CtBP1 and CtBP2 
Monomer E. (C) In addition to Groups 1 and 2, CtBP 2 monomers show variation at the 
dimerization loop, residues 148-178 (Group 4), as observed here in Monomer A. MTOB 
bound CtBP1 and 2 exhibit only small differences, verifying the overall structures can be 
treated as equivalent. 
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MTOB Placement in the CtBP2 Active Site 
 Chapter III details the methods used to place MTOB in the CtBP2 active site, 
describing the criteria used to select monomers A and C for evaluation of MTOB 
binding. This section displays the quality of the data of the other six subunits in the 
asymmetric unit.  Specifically the 2Fo-Fc density after refinement (Figure A.6) and the 
omit map Fo-Fc density (Figure A.7) are shown for monomers B, D, E, F, G, and H. 
Although the accuracy of placement in monomers A and C was superior, it is clear 
MTOB binds the active site of the other six monomers in a similar conformation. 
However, the accuracy of individual atoms in the most other monomers was 
questionable, and hence they were omitted from MTOB binding analysis. Monomer H is 
the exception, showing high quality density maps for MTOB equivalent to that observed 
in monomers A and C.  Monomer H catalytic residue Arg272 assumes a conformation 
distinct from the other subunits (Figure 3.6A), and was therefore omitted from binding 
analysis as well. Overall, monomers A and C the only two monomers that possessed high 
quality density maps for MTOB, and contained active site residues that fit within an NCS 
averaged map. As such, only these two monomers were selected for MTOB binding 
analysis.  
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Figure A.6: MTOB 2Fo-Fc density in the CtBP2 active site. The 2Fo-Fc density for the 
remaining six monomers not shown in Figure 3.6B. Maps are contoured to 1σ (blue 
mesh, 0.27 e-/Å3) and 1.6σ (green surface, 0.43 e-/Å3). All monomers display electron 
density around the sulfur atom. Monomer H has high quality density for MTOB, but 
active site residue Arg272 was not in accord with the non-crystallographic (NCS) 
averaged map (Figure 3.6A) leading to omission of monomer H from ligand analysis. 
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Figure A.7: MTOB omit map Fo-Fc density in the CtBP2 active site. The omit map 
Fo-Fc density for the remaining six monomers not shown in Figure 3.6C. Maps are 
contoured to 2.4σ (0.19 e-/Å3; blue mesh) and 3.5σ (0.27 e-/Å3; green surface). Ligand 
placement is generally in good agreement with the map density, with the poorest fit 
apparent in monomer G. Every other monomer displays density for the MTOB sulfur and 
α-keto acid group. 
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MTOB van der Waal analysis with repulsive terms 
 The van der Waal analysis of MTOB in the CtBP active site employed a Lennard-
Jones potential to calculate the energy of interactions between individual atoms: 
Vr = 4ε [ (σ/r)12 – (σ/r)6 ] 
The Lennard-Jones potential, Vr, was calculated using the interatomic distance (r), depth 
of the well potential (ε), and the collision diameter (σ). The higher exponential term for 
the repulsive forces [ (σ/r)12 ] quickly dominates the lower exponential term for the 
attractive forces [ (σ/r)6 ] when the interatomic distance (r) becomes smaller than the 
collision diameter (σ). Hence, when atom pairs are equal to or just within the van der 
Waal radii, small variation across structures shows wide ranges of binding energies due 
to rapidly increase repulsive forces. 
When applying the van der Waals analysis to MTOB in the CtBP1 and CtBP2 
complexes most interactions are favorable (negative). Atoms involved in hydrogen bonds 
however, are typically closer together than the minimum van der Waal radii the program 
assigns for those atoms, thereby decreasing the favorable interactions. The van der Waal 
calculation is instead dominated by the repulsive term [ (σ/r)12 ]. When comparing 
hydrogen bonded atoms across different MTOB bound structures, slight atomic positional 
differences are amplified to large calculated differences in van der Waal potentials, 
making it appear that MTOB binding interactions vary greatly between structures. The 
positional variability inherent in moderate or low resolution structures exacerbates the 
problem, as the true positions of the atoms are less accurate. Very few clashes are 
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observed between non-hydrogen bonded atoms in the MTOB complexes suggesting the 
model is accurate.  
We approached the problem of varying forces at hydrogen bonds by recording 
just the attractive forces, as reported in Figure 3.9, and also as the summation of 
attractive and repulsive forces here, in the appendix (Figure A.8). By separating the 
attractive and repulsive values, we could identify where the repulsive terms were 
misleading due to tiny positional differences at hydrogen bonds. When repulsive terms 
were omitted, it became obvious that MTOB was in a similar position, with similar 
contacts in CtBP1 and CtBP2 monomers A and C. Including the repulsive terms, we see 
wildly varying values at the shortest hydrogen bonds, a trend observed when conducting 
similar analysis of other liganded D2-HDH family members (not shown). The repulsive 
terms at non-hydrogen bonded atom pairs however, was a good indicator of MTOB 
interactions, limited only by the accuracy of the crystal structure. 
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Figure A.8: Examining the repulsive van der Waals forces. The sum of attractive and 
repulsive terms is shown in red. Blue bars represent the final position of the binding 
energy calculated without the repulsive terms (values identical to Figure 3.9A). When no 
blue bars are apparent, there were no repulsive terms to remove. Repulsive (positive) 
values are occasionally obtained between atom pairs, usually involved in hydrogen 
bonds, which may place heavy atoms slightly within the van der Waals collision radius, 
such as the hydrogen bond at Gly101/107. Other smaller magnitude repulsions arise from 
model errors or dynamic atoms in these low to medium resolution CtBP complexes 
(I98/104). No large clashes ( > 1 kcal) were observed, suggesting MTOB is properly 
situated in the active site. 
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